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ABSTRACT 
 
Bicuspid aortic valve (BAV) is the most common congenital heart defect. It is a 
clinically heterogeneous disorder with valve dysfunction and related aortopathy 
being the major complications. Familial clustering and genetic studies have 
established that BAV is a highly heritable trait, indicating an underlying genetic 
basis. However, the underlying genetic basis of BAV disease in humans is 
mostly undetermined. The gene and molecular pathways that underlie the 
development of structural valve degeneration (SVD) and valvular dysfunction in 
BAV are also not well understood. Further, identification of patients with BAV 
who are at the highest risk for developing aortic complications presents a 
challenging task for most clinicians today.  Hence, the work carried out in this 
thesis aimed to address these gaps in our present knowledge of BAV disease.  
 
To investigate the genetics underlying BAV development, candidate gene 
approach and whole exome sequencing were performed on sporadic and 
familial cases of BAV, respectively. In the candidate gene study, the 
relationship between GATA5 and Nkx2-5 gene variations and BAV disease 
were investigated amongst 100 unrelated cases of BAV. Whilst screening of 
Nkx2-5 failed to identify disease-causing mutations in the study cohort, analysis 
of the GATA5 gene screening identified the presence of 4 rare non-
synonymous variants located in the transcriptional activator domains I and II of 
GATA5, of which 3 affected highly evolutionarily conserved amino acid 
residues, specifically Gln3Arg, Ser19Trp and Tyr142His. These non-
 
 
 x 
synonymous variants may alter the transcriptional activity of GATA5, and 
therefore may contribute to the development of BAV in humans. Meanwhile, 
exome sequencing approach was adopted to investigate the genetics 
underlying BAV development in 2 large Caucasian families with preponderance 
for BAV and the related aortopathy. Variants prioritisation and the subsequent 
co-segregation analyses revealed a completely different list of shared candidate 
gene variants between the 2 families. While the composition of the lists of 
shared candidate gene variants within the 2 families, apart from the causative 
variant itself, was mostly determined by chance, the fact that the lists were 
completely different between the 2 families, and assuming that the causative 
variant was present within the lists, implied that the causative variant 
responsible for BAV development in Family A and B would be different and 
unique to each family. Accordingly, this finding supported a previous 
observation that suggested the presence of mutations in diverse genes (i.e. 
genetic heterogeneity) to be responsible for the development of BAV in different 
families. Also, the study incidentally identified mutations in the GDNF-related 
pathway to be mutually occurring in both families, thus providing some clues 
toward its potential regulatory role in BAV development, which warranted further 
investigation. 
 
A genome-wide transcriptome profiling was performed using RNA sequencing 
to investigate the differential gene expression underlying SVD in human BAV 
compared to the normal trileaflet aortic valve (TAV). The study identified that 
differential gene expression profiles existed even within the BAV group, dividing 
them into those with calcification predominant disease and those with primarily 
 
 
 xi 
redundant leaflet degeneration. It also demonstrated the shared upregulation of 
inflammatory pathways and downregulation of NOTCH1 signalling within 
calcified human BAV and TAV leaflets, indicating a common mechanism of 
calcific leaflet degenerations in human aortic valve. Further, a unique pattern of 
dysregulation of foetal gene programs was also identified amongst the different 
study subgroups. Taken together, these findings indicated the presence of 
distinct gene expression signatures that marked the different type of SVD in 
BAV, compared to TAV, supporting an emerging theory that BAV is 
heterogeneous with respect to molecular events in disease progression. 
 
The project also investigated the role of CMR imaging in the evaluation of 
differential aortic wall mechanical properties between patients with BAV and 
TAV in response to exercise, in attempt to identify novel imaging biomarkers to 
predict those with a more aggressive BAV-related aortic disease phenotype. In 
this pilot study, free-breathing real-time CMR imaging was shown to provide the 
necessary spatial and temporal resolution to allow accurate dynamic structural 
assessment of the aorta. This study however failed to detect a statistically 
significant difference in aortic mechanical properties between patients with BAV 
and TAV during exercise, possibly related to the limitation created by a small 
sample size. An alternative explanation to this observation is that there is, in 
fact, no true difference between the 2 groups, i.e. the null hypothesis is correct. 
Interestingly, the study identified an immediate reduction of aortic elastic 
properties amongst patients with BAV in response to a brief period of resistance 
exercise, which may have important implications during exercise prescription 
amongst individuals with BAV. 
 
 
 xii 
 
In summary, the studies presented in this thesis have contributed to the present 
understanding of the underlying genetic and molecular basis of BAV disease in 
humans, and identified important questions that require continued 
investigations. The project also has laid an important foundation for future real-
time exercise CMR imaging-based work in efforts to identify novel imaging 
biomarkers that can be used to better risk stratify those with BAV-related 
aortopathy. Overall, the work in this thesis have provided an important step 
forward in our efforts to gain a greater understanding on the pathogenetic basis 
of BAV disease and one step closer towards our ultimate goal in reducing the 
overall health burden created by this complex, albeit common, human disease. 
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1.1. VALVULAR HEART DISEASE 
Worldwide, valvular heart disease (VHD) is a major cause of disability, 
diminished quality of life and premature death from cardiovascular disease 
(Mensah, 2009), making it an important clinical entity. Despite a dramatic 
decline in the incidence of rheumatic heart disease in industrialised countries, 
VHD remains highly prevalent and yet, is often under-diagnosed and its health 
burden underappreciated (Nkomo et al., 2006). It is estimated that significant 
VHD affects over 2.5% of the US population and its prevalence increases with 
age (Iung and Vahanian, 2011). Recent improvements in diagnostic imaging 
modalities and advancement in pharmacotherapies, interventional cardiology 
and surgical approaches have contributed to improved survival of patients with 
VHD, further increasing its prevalence and rendering it a growing public-health 
problem (Nkomo et al., 2006).  
 
While many VHDs are acquired during adult life, congenital forms present with 
abnormal valve structures at birth, yet may not manifest as valvular dysfunction 
and disease until later in life (Lincoln and Yutzey, 2011, Markwald et al., 2010). 
Furthermore, familial clustering and heritability have been noted for common 
heart valve defects, such as bicuspid aortic valve and myxomatous mitral valve 
prolapse, implying an underlying genetic basis (Garg et al., 2005, Hinton et al., 
2006, Lincoln and Yutzey, 2011). These familial VHDs can occur in isolation 
(non-syndromic) or present as part of a clinical genetic syndrome, such as 
Marfan, Turner and Noonan syndromes (Pierpont et al., 2007). 
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Traditionally, well-characterised multigeneration families have been invaluable 
for determining the genetic basis of disease, because they are amenable to 
marker-based genome-wide linkage analysis. However, the identification of 
causal genes in VHD has been hampered by complex genetic and phenotypic 
heterogeneity, incomplete penetrance, and the likely contribution of genetic 
modifier loci. Although in-vitro studies and transgenic animal models that 
recapitulate the human phenotype have provided insights into the genetic basis 
of VHD, these findings do not always translate to humans. Therefore, 
concurrent studies on the molecular pathways regulating valvulogenesis have 
sought to highlight gene networks relevant to VHD. 
 
The work presented in this thesis focuses on non-syndromic bicuspid aortic 
valve (BAV) disease (Figure 1.1), the commonest form of congenital heart 
disease, and specifically, it aims to investigate the underlying clinicopathological 
and genetic basis of this complex and highly heritable disorder.  
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Figure 1. 1. Internal view of the heart.  
Insets illustrate the superior view of a normal aortic valve (with three leaflets) 
versus a bicuspid aortic valve (with two leaflets). AV, aortic valve; Ao, aorta; LV, 
left ventricle; red arrow demonstrates direction of blood flow. Image adapted 
with modifications from The Mayo Foundation for Medical Education and 
Research (www.mayoclinic.org) and The Agnes Ginges Centre for Molecular 
Cardiology’s Familial Bicuspid Aortic Valve Patient Information Sheet. 
 
Given the developmental nature of BAV, which predisposes to premature 
calcification and adult aortic valve dysfunction, understanding of the molecular 
pathways and genetic factors that control normal heart valve development 
becomes important as they may give clues into the pathogenesis of BAV 
disease.  
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1.2. OVERVIEW OF DEVELOPMENT OF CARDIAC VALVES 
A key aspect of cardiac development is the formation and function of the 
cardiac valves. An overview of this process, specifically that relating to aortic 
valve development, is summarised in Figure 1.2. Cardiac valve development 
begins immediately following cardiac looping, at embryonic day 31-35 in 
humans, with the formation of endocardial cushions in the atrioventricular canal 
and outflow tract (Butcher and Markwald, 2007, Combs and Yutzey, 2009). 
Normal UDP-glucose dehydrogenase (UGDH) gene activity to synthesise 
glycosaminoglycan is critical for the early cell signalling events that establish 
the boundaries of these cushion-forming regions (Walsh and Stainier, 2001). 
Cardiac cushion formation involves the transformation of a subset of endothelial 
cells into mesenchymal cells in the cushion-forming area, which is induced by 
Bone Morphogenetic Protein-2 (BMP2) signals derived from adjacent 
myocardial cells (Combs and Yutzey, 2009). The mesenchymal progenitor cells 
migrate into the intervening cardiac jelly and proliferate to form swellings of 
valve primordial (Figure 1.2.A), which eventually give rise to valvuloseptal 
structures and adult valvular interstitial cells (Liu et al., 2007, Schoen, 2008, 
Combs and Yutzey, 2009, Hinton and Yutzey, 2011).  
 
The atrioventricular cushions contribute to atrioventricular (mitral and tricuspid) 
valve leaflets, whereas the outflow tract cushions contribute to semilunar (aortic 
and pulmonary) valve leaflets (Lincoln and Yutzey, 2011, Combs and Yutzey, 
2009). The outflow tract and semilunar valve development are complex and 
involve coordinated interactions between the endocardial-derived mesenchyme, 
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cardiac and smooth muscle progenitors from the anterior or secondary heart 
field and the cardiac neural crest (de la Pompa and Epstein, 2012). Whereas 
the secondary heart field progenitor cells contribute to the outflow tract 
myocardium, a population of neural crest-derived cells migrate into the distal 
(truncal) part of the outflow tract cushions, which subsequently divide the 
outflow tract into aortic and pulmonary trunks (Figure 1.2.B), and differentiate 
into the vascular smooth muscle layer of the aortic arch (Butcher and Markwald, 
2007, Niessen and Karsan, 2008, de la Pompa and Epstein, 2012). A number 
of signalling pathways including Wnt/β-catenin, NOTCH, TGF-β, BMP, VEGF, 
NFATc1 and MAPK, and transcription factors including Twist1, Tbx20, Msx1/2 
and Sox9 are active during this early stage of valvulogenesis (Figure 1.2.C). 
These pathways are collectively important in the regulation of cell migration, 
proliferation and extracellular matrix expression in the developing valves 
(Benson, 2008, Chakraborty et al., 2010, Combs and Yutzey, 2009, Hinton and 
Yutzey, 2011).  
 
Later in embryonic valve development, cell proliferation decreases and the 
fused endocardial cushions remodel and thin out to form mature valve leaflets, 
which are characterised by increasing complexity and organisation of the 
extracellular matrix, and compartmentalisation of valvular interstitial cells 
(Combs and Yutzey, 2009, Hinton and Yutzey, 2011). The molecular pathway 
which regulates this later stage of valvulogenesis is less well understood, but it 
involves periostin, a component of the extracellular matrix protein (Norris et al., 
2008). The periostin gene has been identified as a molecular switch that 
promotes endocardial cushion cells differentiation into a fibroblastic cell lineage, 
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rather than into myocardial or osteochondral cell lines, and regulates cushion 
remodelling, separation of the developing atrioventricular valve from the 
underlying myocardium, and its transformation into mature valve leaflet and the 
supporting apparatus (Butcher and Markwald, 2007, Norris et al., 2008).  
 
The mature valve leaflets are stratified into three layers with distinct mechanical 
properties arranged in orientation to the blood flow: a flexible elastin-rich atrialis 
/ ventricularis layer, a central shock-absorbing proteoglycan-rich spongiosa 
layer, and a tensile collagen-rich fibrosa layer (Lincoln et al., 2006). The 
process of valve compartmentalisation and remodelling occurs at late gestation 
and continues into postnatal life, suggesting that mechanisms of prenatal valve 
development persist during postnatal valve growth and maintenance (Hinton et 
al., 2006), (Liu et al., 2007). Furthermore, evidence suggests that 
developmental signalling pathways are shared between heart valves and the 
precursors of cartilage, tendon and bone, playing a critical role at this later 
stage of valve maturation / remodelling (Lincoln et al., 2006).  These pathways 
include BMP2-mediated induction of Sox9 and aggrecan, receptor activator of 
NFκB ligand (RANKL)-mediated induction of NFATc1, and FGF4-mediated 
induction of Scleraxis and tenascin (Lin et al., 2012b, Chakraborty et al., 2010, 
Lincoln et al., 2006).   
 
Cardiac valve development during embryogenesis is therefore complex, with an 
integrated mechanism of genetic factors, activation of signalling pathways, as 
well as external environmental factors, such as the physical forces of blood 
flow. Since many of the signalling pathways and transcription factors 
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responsible for valve development are reactivated in paediatric and adult valve 
diseases (Lincoln and Yutzey, 2011, Wirrig and Yutzey, 2011), the insights 
gained from understanding normal valvulogenesis have provided a platform to 
identify potential candidate genes involved in familial BAV. 
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1.3. BICUSPID AORTIC VALVE DISEASE 
1.3.1. Clinical significance of BAV disease 
BAV occurs when the aortic valve has two cusps, rather than three, and 
represents the most common form of congenital cardiac malformation, affecting 
approximately 1.3% of the general population (Michelena et al., 2011, Roger et 
al., 2012). BAV has a male predominance of approximately 3:1 (Siu and 
Silversides, 2010), and at least 35% of those affected develop serious 
complications including aortic stenosis and/or regurgitation requiring valve 
replacement, endocarditis, ascending aortic aneurysm and dissection (Vallely et 
al., 2008). BAV underlies 70-85% of stenotic aortic valve in children and at least 
50% of aortic stenosis in adults (Schoen, 2008, Cripe et al., 2004). Thoracic 
aortic enlargement is also common in BAV, reported in up to 50-60% of affected 
individuals (Tzemos et al., 2008, Nistri et al., 1999, Ward, 2000). Furthermore, 
BAV carries an 8-fold increased risk of aortic dissection and over a 25-year 
period, the risk of valve replacement is 53%, aneurysm formation is 26%, and 
aortic surgery is 25% (Michelena et al., 2011). As such, BAV represents a 
greater burden of disease than all other congenital heart diseases combined 
(Siu and Silversides, 2010, Ward, 2000).  
 
In up to 62.5% to 80% of cases, BAV reportedly occurs sporadically as an 
isolated birth defect (Cripe et al., 2004, Deshpande and Kinare, 1991, Garg, 
2006, Michelena et al., 2011). However, it can be familial and can occur as part 
of a syndrome with more global clinical manifestations, such as Turner, 
Williams-Beuren and Andersen syndromes. Furthermore, BAV is also 
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recognised to coexist with other congenital cardiovascular malformations, most 
commonly with coarctation of the aorta, but also with cardiac septal defects, 
aberrant coronary artery anatomy or the genetically-related hypoplastic left 
heart syndrome (Siu and Silversides, 2010, Hinton et al., 2009, Cripe et al., 
2004). This suggests that BAV is not only a disorder of valvulogenesis, but also 
represents a more complex coexistent genetic disease of the aorta and/or 
cardiac development (Cripe et al., 2004, Siu and Silversides, 2010).  
 
1.3.2. Anatomy and diagnosis of BAV 
Disorders of aortic valvulogenesis tend to be regarded in the context of a 
phenotypic continuum, ranging from aortic valves with a single leaflet to those 
with four leaflets (Vallely et al., 2008). Within this continuum, BAV exists and 
demonstrates a wide morphological variation (Figure 1.3), as seen in human 
cases of BAV (Figure 1.4) and observed in BAV of Syrian hamsters (Fernandez 
et al., 2009). BAV morphological phenotypes range from the typical form with 2 
unequal-sized leaflets and the larger leaflet having a central raphe due to 
commissural fusion (ie. functionally bicuspid), to the less common form with 2 
approximately symmetrical leaflets without a raphe (ie. anatomically bicuspid) 
(Sievers and Schmidtke, 2007, Siu and Silversides, 2010). Fusion of the right 
and left coronary (R-L) cusps is the most common pattern of BAV and is 
associated with coarctation of the aorta, whilst fusion of the right and 
noncoronary (R-N) cusps, the second commonest form, is associated with more 
cuspal pathology (Siu and Silversides, 2010). 
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Figure 1. 4. Different phenotypic spectrum of human BAV morphology.  
A) Tri-leaflet aortic valve with complete fusion of the right and left (R-L) 
coronary cusps; B) Tri-leaflet aortic valve with complete fusion of the R-L 
coronary cusps and partial fusion of the right and non coronary cusps; C) and 
D) Bi-leaflet aortic valve with extensive raphe in the fused leaflet; E) Bi-leaflet 
aortic valve with a vestigial raphe; F) True bicuspid aortic valve without raphe. 
Figure A and B are classified as functionally bicuspid and the remaining are 
classified as anatomically (“true”) bicuspid. 
 
While clinical auscultatory findings may suggest the presence of associated 
murmurs of aortic stenosis, incompetence or, when present, coarctation of the 
aorta, the mainstay of diagnosis of BAV is echocardiography (transthoracic or 
transoesophageal). When adequate echocardiographic images are obtained, 
figures of up to 92% sensitivity and 96% specificity have been reported for 
detecting BAV anatomy (Siu and Silversides, 2010). The presence of heavy 
leaflet calcification however can hamper echocardiographic diagnosis. Whilst 
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transoesophageal echocardiography can sometimes improve visualisation of 
the leaflets (Figure 1.5), it is not uncommon that the final diagnosis can only be 
made during direct inspection of the leaflets at time of valve surgery. In some 
instances, alternative cardiac imaging such as cardiac magnetic resonance 
(CMR) imaging or computer tomography (CT) can assist to confirm BAV 
anatomy, but usually, these modalities are used to evaluate the thoracic aorta 
for the presence of associated aortopathy or co-existent coarctation of the aorta 
(Figure 1.5). 
 
 
Figure 1. 5. Images of BAV and the aorta.  
A) Transoesophageal echocardiography short axis view of a BAV with a right 
and left cusps fusion. The image was taken during cardiac systole and the 
aortic valve orifice has a characteristic “fish mouthed” appearance. The red 
arrow points to the raphe, which was heavily calcified. B) Cine cardiac magnetic 
resonance (CMR) image of the thoracic aorta. The asterix denotes ascending 
aortic dilatation. C) 3D CMR reconstruction of the thoracic aorta. The red arrow 
points to the mild narrowing at the site of previous coarctation repair. 
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1.3.3. Pathogenesis of BAV 
Despite its high prevalence, the aetiology of BAV is largely undetermined, 
although gene mutations leading to alterations in cell migration and signal 
transduction, in conjunction with non-genetic factors such as blood flow during 
valvulogenesis may contribute to its formation prenatally (Lincoln and Yutzey, 
2011). Since the relationship of the individual valve cusps to specific 
endocardial cushion progenitors is not known (Combs and Yutzey, 2009), BAV 
could result from a failure of separation of primordial cusps (Lincoln and Yutzey, 
2011). Meanwhile, the pathogenesis of aortic valve dysfunction in BAV is 
thought to be the result of dysregulation in the complex molecular hierarchies 
controlling late valve development, which continues into postnatal life and 
results in the chronic process of valve tissue remodelling, leading to abnormal 
leaflet architecture, valvular thickening, and abnormal biomechanics (Figure 
1.6) (Hinton et al., 2006, Koullias et al., 2004, Martin et al., 2007). With 
increasing age, BAV leaflets are prone to develop premature fibrosis and 
calcification in response to hemodynamic shear stress (Fedak et al., 2002, 
Rajamannan, 2011), an active process that involves inflammation, endothelial 
dysfunction, lipoprotein and calcium deposition, and results in ossification of the 
leaflets and valvular stenosis (Siu and Silversides, 2010). Meanwhile, the 
aetiology of aortic regurgitation in BAV patients is more complex. It is often a 
consequence of an intrinsic leaflet(s) redundancy or prolapse of the larger of 
the unequally sized cusps; however, it can also occur secondary to other 
external factors, such as endocarditis, after balloon valvuloplasty, or 
concomitant dilatation of the aortic root (Siu and Silversides, 2010, Koullias et 
al., 2004, Fedak et al., 2002). 
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Histological examination of BAV tissue from paediatric patients revealed 
excessive extracellular matrix production and trilaminar matrix disorganisation, 
with fragmentation and reduction in elastin content, and accumulation of 
collagen and proteoglycan (Hinton et al., 2006). BAV leaflets also show valvular 
interstitial cell disarray and varying degrees of inflammatory cell infiltrates, 
which secrete proteolytic enzymes implicated in collagen and elastin 
degradation in abdominal aortic aneurysm, such as MMP-2 and MMP-9 
(Koullias et al., 2004). Supporting this, tissue microarray and 
immunohistochemical analysis of BAV leaflets demonstrated higher levels of 
MMP-2 and -9, and lower level of the MMP inhibitor, TIMP1 (Koullias et al., 
2004). The increased MMP activity extends to the aortic annulus and/or 
ascending aorta and may contribute to the related aortopathy (Tadros et al., 
2009).  
 
1.3.4. Genetic basis of BAV 
Familial clustering demonstrates that BAV is heritable, with 9% prevalence in 
first-degree relatives of patients with BAV, and up to 24% in families with more 
than 1 person affected (Siu and Silversides, 2010, Ward, 2000, Cripe et al., 
2004). While autosomal dominant transmission of BAV has been observed in 
several 3-generation pedigrees, there is however no single-gene model that can 
definitively explained BAV inheritance (Prakash et al., 2014). In fact, it is likely 
that mutations in diverse genes with dissimilar inheritance patterns to be 
responsible for the development of BAV in different families (Cripe et al., 2004). 
Table 1.1 summarises the key genetic findings in BAV identified to date. 
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Genetic heterogeneity in BAV is demonstrated by the involvement of mutations 
in diverse genes encoding transcription factors, extracellular matrix proteins and 
signalling pathways that regulate cell proliferation, differentiation, adhesion or 
apoptosis (Ward, 2000, Martin et al., 2007, Garg, 2006).  
 
Table 1. 1. Gene mutations in human and animal models of BAV. 
Human Mouse 
Non-syndromic (familial and sporadic) BAV Nos3 (eNOS) deficiency 
NOTCH1 missense and frame shift mutations  Nkx2.5 haploinsufficiency 
Linkage to locus on Chr 5q, 13q, 18q Targeted deletion of Gata5 
Syndromic BAV or BAV with other cardiovascular 
malformation: 
Endocardial cushion tissue-
specific deletion of Alk2 
Andersen syndrome - KCNJ2 mutation  (Chr 17q)   
Thoracic Aortic Aneurysm and Dissection syndrome (TAAD) 
- ACTA2 mutation (Chr 10q)  
 
Marfan syndrome - Fibrillin1 mutation (Chr 15q)   
William Beuren syndrome – Elastin mutation (Chr 7q)  
Turner syndrome (45XO karyotype)  
Chr = chromosome 
 
To date, only the transcriptional regulator NOTCH1 gene at chromosome 
9q34.3 has been linked to the development and calcific progression of non-
syndromic BAV in humans, in a limited number of familial cases and ~4% of 
sporadic cases (Garg et al., 2005, Mohamed et al., 2006). The Notch signalling 
pathway is highly conserved and plays a critical role in cell fate determination 
and differentiation during organogenesis (Garg, 2006). NOTCH1 transcripts are 
abundant in the mesenchyme of the outflow tract and the developing aortic 
valve leaflets, which probably underlie the role of Notch signalling in aortic valve 
development (Garg et al., 2005). NOTCH1 signalling represses BMP2 and the 
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downstream osteogenic gene, RUNX2, a central transcriptional regulator of 
osteoblast cell fate (Garg et al., 2005, Nigam and Srivastava, 2009). Recently, 
NOTCH1 signalling has been shown to regulate the expression of Sox9, a key 
chondrogenic transcription factor and regulator of extracellular matrix genes 
that is required for normal valve development and maintenance (Acharya et al., 
2011). While inhibition of NOTCH1 signalling downregulates Sox9 expression 
and promotes valvular calcification in-vitro, overexpression of Sox9 markedly 
attenuates the calcific process that occurs with NOTCH1 inhibition (Acharya et 
al., 2011). NOTCH1 mutations are therefore associated with both defective 
development of the aortic valve and, later, de-repression of an osteoblast gene 
program and dysregulation of valvular extracellular matrix genes, via a Sox9-
dependent mechanism, leading to accelerated aortic valve calcification.  
 
Further evidence of specific gene mutations as a cause of BAV has come from 
genome-wide marker-based linkage analyses. Families showing autosomal 
dominant inheritance of BAV and/or associated cardiovascular malformations 
have shown linkage to chromosomes 18q, 5q and 13q, whereas families with 
BAV and ascending aortic aneurysms have shown linkage to chromosome 
15q25-26 (Vallely et al., 2008, Martin et al., 2007). The causal gene(s) however 
are yet to be identified. Furthermore, mutations in the ACTA2 gene on 
chromosome 10q, which encodes smooth muscle alpha-actin (ACTA2), cause 
thoracic aortic aneurysm and, in some instances, BAV (Siu and Silversides, 
2010). It has been suggested that the different phenotypes of BAV-associated 
aortopathy may be caused by unique pathogenetic mechanisms (Girdauskas et 
al., 2011b). A missense mutation in the TGFBR2 gene, c.1159G>A, which 
  Chapter 1: Introduction 
 20 
 
destabilises the protein structure, was segregated in a family with non-
syndromic BAV with proximal aortic involvement (Girdauskas et al., 2011b), 
although the true incidence of TGFBR mutation in overall BAV populations is 
probably very low (Arrington et al., 2008). Associations have also been reported 
between aneurysm risks in BAV patients with polymorphisms in eNOS, ACE, 
MMP-9 and MMP-2 genes (Pisano et al., 2011, Foffa et al., 2012). Furthermore, 
downregulation of the ubiquitin fusion degradation 1-like gene (UFD1L), which 
is highly expressed in the cardiac outflow tract during embryogenesis, has also 
been noted in BAV, and may represent a candidate gene (Mohamed et al., 
2005). 
 
In addition to the above studies in humans, animal studies have shed light on 
the genetic basis of BAV. In mice, homozygous deletion of the endothelial nitric 
oxide synthase (Nos3) gene, and haploinsufficiency for the cardiac homeobox 
gene Nkx2-5, are associated with a higher incidence of BAV (Biben et al., 2000, 
Lee et al., 2000). Recently, tissue-specific deletion of Activin Receptor Type I 
gene (Alk2 or Acvr1) in the endocardial cushion mesenchyme of developing 
murine heart has been shown to result in formation of aortic valve defects, 
including BAV of R-N morphology (Thomas et al., 2012). However, none of 
these genes have been associated with BAV in humans (Laforest et al., 2011, 
Majumdar et al., 2006). Furthermore, targeted deletion of the transcription factor 
Gata5 in mice leads to partially penetrant BAV with fusion of the right and non-
coronary cusps (Laforest et al., 2011). An essential role of GATA5 in cardiac 
morphogenesis and aortic valve development has only recently been reported, 
whereby it regulates several pathways involved in endocardial cell 
  Chapter 1: Introduction 
 21 
 
differentiation, including those directed by Bmp4, Tbx20, and, notably, NOS3 
and NOTCH1 (Laforest et al., 2011). Downregulation of Nos3 expression and 
attenuation of the Notch pathway are observed in Gata5-/- mice (Laforest et al., 
2011), which may underlie the development of BAV as mutations in Nos3 and 
NOTCH1 are associated with BAV in mice and humans, respectively.  
 
Animal studies are also at the forefront of research into the hypothesis that the 
different BAV morphologies have a different etiological basis. Gata5-/- mice, 
eNOS knock-out mice and inbred Syrian hamsters each display a high 
incidence of BAV, but with different valve morphologies. BAV with fusion of the 
right coronary and non-coronary leaflets may result from morphogenetic defects 
that happen before outflow tract septation, which probably relies on an 
exacerbated nitric oxide-dependent endothelial-to-mesenchymal transformation. 
BAV with fusion of right and left coronary leaflets may result from the 
anomalous septation of the proximal portion of the outflow tract, due to distorted 
behaviour of neural crest cells (Fernandez et al., 2009). This anomalous 
behaviour of the cardiac neural crest is believed to explain the association of 
the right and left coronary leaflet fusion BAV morphology with coarctation of the 
aorta and the more pronounced aortic wall degeneration, compared to BAV with 
fusion of the right and non-coronary leaflets (Fernandez et al., 2009).  
 
Interestingly, Sans-Coma et al. recently demonstrated that BAV in Syrian 
hamsters are expressions of a quantitative trait, subject to polygenic 
inheritance, with reduced penetrance and variable expressivity (Sans-Coma et 
al., 2012). Furthermore, examination of aortic valve morphology in virtually 
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isogenic Syrian hamsters produced by systematic inbreeding through full-sib 
mating, with the probability of homozygosity being 0.999 or higher, 
demonstrated the presence of BAV in up to five-sixths of the hamsters studied, 
whilst the remaining one-sixth had a tri-leaflet aortic valve. This suggests that 
the same underlying genotype, which accounts for the whole range of valve 
morphology, including BAV, must be acting together with factors other than 
genetic ones during embryonic life, creating “developmental noise”, to influence 
the definitive anatomic configuration of the valve (Sans-Coma et al., 2012). 
Further, no significant association was noted between the valvular phenotype in 
the parents and the offspring produced by crossing genetically alike hamster, 
with the probability of homozygosity of at least 0.989. Taken together, these 
findings support a complex inheritance pattern, as seen in human BAV, and 
may explain the relatively low recurrence rate of BAV in first-degree relatives, 
despite its common prevalence within the general population (Sans-Coma et 
al., 2012). The findings also provide a potential explanation regarding aortic 
valve anatomy in monozygotic twins where BAV was present in one twin but 
tricuspid aortic valve in the other (Lewis and Henderson, 1990). 
 
While specific gene mutations can cause BAV in mice and humans, the 
variability in BAV morphology and its disease manifestations cannot be entirely 
explained. MicroRNAs (miRNAs) are a class of evolutionarily conserved small, 
non-coding RNAs that regulate gene expression in development and disease. 
Reduced expression of miR-26a, miR-30b and miR-195 in stenotic BAV 
associated with calcification, compared to a regurgitant phenotype, has been 
reported (Nigam et al., 2010). In-vitro transfection of each of these miRNAs into 
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human aortic valvular interstitial cells indirectly modulated the expression of 
several calcification-related genes, including RUNX2, BMP2, alkaline 
phosphatase (ALPL), SMAD1 and SMAD3 (Nigam et al., 2010). Patients with 
BAV-associated aortic stenosis have also been shown to have attenuated 
expression of miRNA-141, a repressor of BMP-2 (Yanagawa et al., 2012). 
Together, these studies suggest miRNA dysregulation contributes to aortic 
stenosis in BAV, and that miRNAs represent a potential new therapeutic target 
to limit progressive aortic valve calcification and dysfunction.  
 
Collectively, these findings support a genetic basis for BAV, although it remains 
undetermined in the majority of cases. Nevertheless, BAV pathogenesis is likely 
to involve a complex interplay between specific gene mutations, modifier loci, 
aberrant signalling pathways, abnormal neural crest migrations, environmental 
influences in-utero, and stochastic factors. The balance of this interaction is 
likely to have major influence on phenotypic heterogeneity, BAV disease 
progression and severity, including aortic valve dysfunction and aortic 
complications.  
 
1.3.5. BAV related aortopathy 
As mentioned previously, over 50% of individuals with BAV present with 
concurrent dilatation of the proximal aorta (Vallely et al., 2008, Fedak et al., 
2002). Significant phenotype heterogeneity of BAV related thoracic aortic 
enlargement has been described (Figure 1.7), which may occur independently 
of the underlying valvular morphology and function (Tzemos et al., 2008, Ward, 
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2000, Nistri et al., 1999, Jackson et al., 2011). This most commonly manifests 
as asymmetric ascending aortic dilatation beyond the sinotubular junction with 
variable arch involvement and/or varying degrees of annuloaortic ectasia, 
predisposing to aortic dissection or rupture, a feared complication.  
 
Figure 1. 7. Different morphologies of BAV-related aortopathy.  
The left panel depicts the different reference levels used in the assessment of 
thoracic aorta dimension. The panel on the right (adapted with modifications 
from (Mart, 2013)) demonstrates the different aortic dilatation pattern seen in 
patients with BAV: S1 – normal shape; S2 – ascending aorta dilatation; S3 – 
effacement of the sinotubular junction; S4 – enlargement of the aortic root, 
Marfan-like; S5 – enlarged sinus of Valsalva and ascending aorta; S6 – normal 
annulus and proximal sinus of Valsalva, enlarged distal sinus of Valsalva, 
sinotubular junction and ascending aorta. A, aortic annulus; AoR, aortic root; 
SoV, sinus of Valsalva; STJ, sinotubular junction; AsA, tubular portion of the 
ascending aorta; AoA, aortic arch; PrDA, proximal descending aorta; DisDA, 
distal descending aorta. 
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Presently, some controversies exist in the literature regarding the underlying 
pathogenesis of BAV related aortopathy (Girdauskas et al., 2011a), specifically 
whether it is genetic or hemodynamic in origin. This is of major clinical 
relevance because it will have an influence on the surgical management of the 
valve and the ascending aorta.  
 
1.3.5.1. Genetic underpinnings of BAV related aortopathy 
The developmental nature of BAV related aortopathy has been suggested by 
various studies, which indicates the presence of an underlying genetic defect 
causing inherent structural abnormality of the arterial wall. This is based on the 
observation that aortic root and ascending aortic dilatation have been 
documented in children with BAV (Gurvitz et al., 2004, Fernandes et al., 2012, 
Holmes et al., 2007), suggesting that BAV related aortopathy is a process that 
begins early in life. Progressive aortic dilatation can also occur in patients with 
normally functioning BAV and even following aortic valve replacement (Aicher 
et al., 2007, Gurvitz et al., 2004, Tadros et al., 2009, Michelena et al., 2008, 
Yasuda et al., 2003), implying the presence of an intrinsically ‘weaker’ aorta. In 
addition, the presence of valve dysfunction alone does not necessarily account 
for the degree or rate of progression of aortic dilatation in BAV patients (Keane 
et al., 2000, Nistri et al., 1999, Tadros et al., 2009), suggesting that factors, 
other than hemodynamic, are at play. Notably, an inherent structural alteration 
has been described in the ascending aorta of BAV patients, irrespective of the 
underlying valve haemodynamic (Fedak et al., 2003). Histological examination 
of dilated aortas of BAV patients demonstrate accelerated aortic media 
degeneration with focal matrix disruption, altered collagen content, greater 
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elastin fragmentation, accumulation of mucopolysaccharide ground substance 
and higher rates of vascular smooth muscle cell (VSMC) apoptosis (Figure 1.8) 
(Bonderman et al., 1999, Tadros et al., 2009). These findings are also present 
in the non-dilated aortas of BAV patients and similar to those observed in the 
aortas of Marfan syndrome patients with Fibrillin-1 gene mutation (Blunder et 
al., 2012, Bonderman et al., 1999, Tadros et al., 2009). In fact, deficiency of 
fibrillin-1, which occurs independently of aortic diameter, and increased matrix 
metalloproteinase-2 (MMP2) activity have been reported in BAV aortic tissue 
(Fedak et al., 2003).  
 
 
Figure 1. 8. Common histological findings in aneurysmal aortas of BAV 
patients.  
A) Extensive medial degenerative changes, with accumulation of basophilic 
mucopolysaccharide ground substance, as demonstrated using an alcian-blue 
stain. B) Significant reduction of elastin content with fragmentation, thinning and 
disarray of elastin fibres, particularly in areas of maximum aortic dilatation. C) In 
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contrast to Figure B, this image demonstrated a normal elastin content and 
organisation within the non-dilated aortic segment. These images are courtesy 
of Dr. Geoff Watson, Department of Anatomical Pathology, Royal Prince Alfred 
Hospital, Sydney, Australia. 
 
Further supporting the genetic basis of BAV related aortopathy is the 
observation that inherent abnormality of aortic elasticity is commonly seen in 
BAV patients, even at the non-dilated stage and irrespective of aortic size (Nistri 
et al., 2008). It has thereby been hypothesised that loss of fibrillin-1 microfibrils 
in BAV aortas, presumably from an underlying heritable microfibrillar gene 
defect, may cause detachment of VSMC from the elastic laminae, resulting in 
accelerated cell death and the release of pathological MMPs species with 
subsequent matrix degradation, weakening of aortic wall structural integrity, 
loss of aortic elasticity, progressive aortic dilatation, aneurysm and/or dissection 
(Figure 1.9) (Fedak et al., 2003, Verma and Siu, 2014). Interestingly, fibrillin-1 
deficiency is also observed in the pulmonary arteries of BAV patients and main 
pulmonary artery dilatation has been noted to occur in association with BAV in 
the absence of pulmonary valve abnormality (Fedak et al., 2003, Kutty et al., 
2010). It is therefore speculated that both aortic and main pulmonary artery 
dilatation in BAV may be the result of a common developmental abnormality as 
the great arteries originate from a common embryonic truncus (Fedak et al., 
2003). 
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Figure 1. 9. Pathophysiological features of Bicuspid Aortopathy.  
Structural support and elasticity are afforded to the aorta by means of 
alternating layers of elastic lamellae and smooth-muscle cells (SMCs). A) At the 
histologic level, the smooth-muscle cells in the aorta in persons with tricuspid 
valves are secured to the adjacent elastin and collagen matrix by fibrillin 1 
microfibrils. B) The aorta in persons with BAV may be deficient in fibrillin 1. This 
deficiency culminates in a disrupted architecture whereby SMCs detach, 
accompanied by a surge in local levels of matrix metalloproteinases (MMPs), 
leading to loss of integrity in the extracellular matrix and the accumulation of 
apoptotic cells. These events may lead to an aorta with weakened structural 
integrity and reduced elasticity. Adapted from (Verma and Siu, 2014). 
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Most recently, global gene expression levels have been compared in aortic 
tissue from patients with a bicuspid or tricuspid aortic valve, with and without 
thoracic aortic aneurysm (Folkersen et al., 2011). Only seven genes were 
differentially expressed between the non-dilated BAV and non-dilated tricuspid 
groups; the 4 upregulated genes were LEFTY2 (left-right determination factor 2; 
a TGF-β family member), FRAS1 (Fraser syndrome 1; a member of the 
extracellular matrix family of protein), SHC4 (Src homology 2 domain containing 
family, member 4) and DAPK3 (death-associated protein kinase 3; a 
proapoptotic gene), and the 3 downregulated genes were VEGFC (a member of 
the vascular endothelial growth factor family), NFASC (neurofascin homolog; a 
member of the L1 family of cell adhesion molecule), and LSP1 (lymphocyte-
specific protein 1). Given the possible shared genetic underpinnings of BAV and 
related aortopathy, an investigation of these genes in BAV is warranted. The 
study also showed immune responsive genes were upregulated in tricuspid 
valve patients with a dilated aorta, compared to those with a dilated aorta and 
BAV, suggesting that immune response genes are not directly involved in BAV 
related aneurysms. Rather, BAV patients with aortic dilation showed an almost 
exclusive expression of the TGF-β binding proteins LTBP3/4, ADAMTSL1 and 
an alternatively spliced isoform of Fibronectin-1 (FN1) (Folkersen et al., 2011). 
A common extracellular matrix component of the vessel wall, fibronectin is a 
glycoprotein that influences cell migration and proliferation, thus central to 
normal tissue repair / remodelling and maintenance of tissue integrity in 
response to injury. Patients with BAV-related aortopathy appear to have 
impaired TGF-β-mediated splicing mechanisms of fibronectin transcript, thereby 
leading to altered fibronectin expression in the aortic aneurysm tissue and 
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consequently contributing to the increased susceptibility to aortopathy 
development in BAV patients (Paloschi et al., 2011). Interestingly, a diverging 
alternative splicing fingerprint of the TGF-β pathways has been observed within 
ascending aortic dilatation in bicuspid versus tricuspid aortic valve patients 
(Kurtovic et al., 2011), resulting in differential downstream gene expression and 
signalling. Different epigenetic modification of the chromatin structure may be 
responsible for the observed differential splicing pattern of TGF-β (Kurtovic et 
al., 2011), which may play an important contributory role in modifying 
phenotypic heterogeneity of thoracic aneurysm pattern in BAV. Importantly, 
these findings highlight the central role of TGF-β as the key regulator of 
vascular matrix remodelling and VSMC activity, and that dysregulation of TGF-β 
signalling and its downstream pathways appears to be a common mechanism 
involved in aneurysm formation, including in BAV related aortopathy. Overall, 
these findings suggest an underlying genetic defect in the pathogenesis of 
aortic dilatation in BAV. 
 
1.3.5.2. Hemodynamic contributions in BAV related aortopathy  
There is emerging evidence to support the hypothesis that BAV-related 
aortopathy is a haemodynamic phenomenon, in which the structurally defective 
valve, or even a ‘normally’ functioning one, is in fact morphologically stenotic, 
as a result of restricted mobility / opening of the conjoined leaflet, producing a 
nonaxial transvalvular turbulent flow jet within the aortic root (Robicsek et al., 
2004, Girdauskas et al., 2012, Della Corte et al., 2012). This in turn creates 
abnormal biomechanics and helical flow alterations that propagate eccentrically 
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inside the proximal aorta, resulting uneven wall stress distribution and 
promoting aortic dilatation / aneurysm, which, in BAV, preferentially bulges 
asymmetrically toward the right-anterior aortic wall (i.e. aortic convexity) (Hope 
et al., 2011). A positive correlation has also been demonstrated between the 
degree of restriction in the conjoint cusp systolic motion (the so-called “conjoint 
cusp opening angle”), and the consequent eccentricity of the transvalvular 
systolic flow, with the severity and growth rate of the ascending aortic dilatation 
(Della Corte et al., 2012, den Reijer et al., 2010, Hope et al., 2012). 
Furthermore, in support of the hemodynamic theory, different aortic leaflet 
fusion patterns have been shown to generate specific jet orientations in the 
proximal aorta (Hope et al., 2011, Mahadevia et al., 2014), with distinct patterns 
of asymmetry in the aneurysms that develop, different rates of aortopathy 
progression, and unique MMPs and TIMPs (MMP inhibitors) signatures 
(Ikonomidis et al., 2012, Russo et al., 2008). Relatively recently, using 
sophisticated 4D flow cardiac MRI (Figure 1.10), fusion of the right and left 
coronary leaflets (R-L BAV), the most common type of BAV, has been shown to 
produce a right-anteriorly directed helical systolic flow jet with marked 
peripheral skewing towards the ascending aortic convexity (Hope et al., 2011, 
Mahadevia et al., 2014). This may explain the larger aortic root dimension and 
asymmetric dilatation of the mid-ascending aorta, commonly seen in these BAV 
patients, and the more severe degree of ascending aortic wall degeneration 
with enhanced proteolytic indices relative to the other BAV subtypes 
(Girdauskas et al., 2012, Ikonomidis et al., 2012, Russo et al., 2008). 
Meanwhile, fusion of the right and noncoronary leaflets (R-N BAV), the second 
commonest type of BAV, is associated with left-posteriorly directed eccentric 
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flow jet with propagation further towards the proximal aortic arch, which might 
explain its association with isolated ascending aortic dilatation (without aortic 
root involvement) and increased aortic arch dimensions seen in this subgroup 
of BAV patients (Girdauskas et al., 2012, Fazel et al., 2008). 
 
 
Figure 1. 10. Visualisation of peak systolic blood flow in patients with BAV 
(C (R-L BAV) and D (R-N BAV)) in comparison with an aorta sized-matched 
control subjects (B) and a healthy volunteer (A) using 4D flow CMR 
imaging.  
Adapted from (Mahadevia et al., 2014). Top panel, note the presence of 
distinctly different 3D outflow flow jet patterns (black dashed arrows) in the 
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ascending aorta (AAo) for patients B and C. Bottom panel, 3D flow patterns in 
the left ventricular outflow tract (LVOT) and AAo distal to the aortic valve. Note 
the different systolic aortic valve outflow flow jet patterns (red indicating high 
velocities > 1 m/s) and wall impingement zones that correspond to variable 
exertion of high wall shear forces between different valve groups (C and D) and 
aorta size–matched controls (B) and healthy volunteers (A). AV, aortic valve; 
DAo, descending aorta; m/s, metre per second. 
 
Further support for the importance of flow in BAV-related aortopathy 
pathogenesis has also arisen from in-vivo studies, which show that aberrant 
shear stress, such as that produced by BAV leaflets, is able to modulate 
expression of genes that regulate MMP production, matrix remodelling and 
VSMC apoptosis, thus predisposing to aneurysm formation (Dolan et al., 2011, 
Ruddy et al., 2010). This is substantiated by the increased expression of MMP2 
and a higher MMP2 to TIMP1 activity in tissue samples from aortic aneurysms 
in BAV patients (Tadros et al., 2009), as well as a higher apoptosis rate of 
cultured VSMC derived from the dilated aorta of BAV patients compared to 
controls (Bonderman et al., 1999). Furthermore, BAV aortic aneurysm tissues 
exhibit reduction of endothelial nitric oxide synthase (eNOS) protein expression, 
with site-dependent variability, which is probably triggered by variations in shear 
stress along the aortic wall (Aicher et al., 2007, Mohamed et al., 2012). 
Simulated reduction of eNOS expression in the cultured VSMCs of BAV-related 
aneurysm tissue, by treatment with NOS inhibitor L-NAME, results in cytosolic 
accumulation of HTRA2/Omi, a proapoptotic mitochondrial serine protease, 
which presumably mediates VSMC apoptosis in BAV aortas (Mohamed et al., 
2012), thereby conferring susceptibility to aneurysm formation. Moreover, 
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structural alteration of the extracellular matrix in itself can also result in 
transmission of proapoptotic cues to the VSMCs (Della Corte et al., 2008). 
Extracellular matrix remodelling occurs early in BAV, evident even in the 
nonaneurysmal BAV aortas, with maximum changes observed at the convexity, 
and is characterised by collagen and laminin reduction and increased in 
fibronectin and tenascin expression (Della Corte et al., 2008, Della Corte et al., 
2006). These changes are associated with enhanced VSMC apoptotic indices, 
also primarily at the convexity, even prior to overt aortic dilatation, and, 
interestingly, increased Bcl-2-modifying factor-Bcl-2 binding (Bmf-Bcl2), a 
known matrix-dependent proapoptotic signalling mechanism (Della Corte et al., 
2008). Therefore, it is speculated that stress-induced extracellular matrix 
changes within the aortic convexity of BAV patients may trigger cytoskeletal 
rearrangement of VSMCs that lead to early local apoptosis of these cells. This 
is presumably mediated by Bmf-Bcl2 binding, resulting in progressive, typically 
asymmetric aortic enlargement seen in BAV related aortopathy (Della Corte et 
al., 2008). These studies support the important role of haemodynamic in the 
initiation and progression of BAV-related aortopathy. 
 
1.3.5.3.Phenotype heterogeneity in BAV related aortopathy 
Not all patients with BAV will develop aortic dilatation over time, regardless of 
the underlying valvular function. There is also a highly heterogeneous 
expression of aortopathy in BAV disease even amongst patients with specific 
valve fusion pattern and similar levels of valve dysfunction (Barker et al., 2012). 
Furthermore, there is a small subset of BAV patients, mostly young males, who 
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present with predominantly symmetric dilatation of the aortic root at an early 
age. This is associated with annular dilatation and varying degrees of aortic 
insufficiency (Nistri et al., 1999) and may represent a predominantly genetic 
form of BAV disease less influenced by hemodynamic factors.  
 
Therefore, these studies suggest that BAV-related aortopathy is a product of 
the interaction between genetic and hemodynamic factors. BAV-related 
aortopathy could be associated with a congenital anomaly of some component 
of a matrix signalling pathway, thereby conferring inherent genetic susceptibility. 
Meanwhile, the hemodynamic disturbances, produced by the genetically 
determined, anatomically abnormal valve, then act after birth as a triggering and 
accelerating factor to the locally degenerative process within the aortic media, 
leading to progressive asymmetric aortic dilatation and aneurysm formation 
(Della Corte et al., 2008). Ultimately, the clinical heterogeneity seen in BAV-
related aortopathy may be explained by individual variable combinations of 
coexisting genetic susceptibilities, the severity of haemodynamic alteration and 
other yet-to-be-identified environmental factors in modifying the final phenotype 
manifestation of the aortopathy. 
 
Overall, current evidence points to BAV disease being a final common pathway 
for a wide variety of altered molecular and genetic defects. Determination of the 
genetic basis underlying BAV disease is complex. Not only that there are large 
number of genes involved in valvulogenesis (genetic heterogeneity) but 
epigenetic, haemodynamic, and stochastic factors are also important in 
modulating phenotype expression and thus contributing to the wide spectrum of 
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disease manifestations (clinical heterogeneity). Recent advances in the fields of 
valve development and BAV disease, combined with major developments in 
genetic analysis technologies, place the field at the precipice of accelerated 
discovery into the causative and pathogenetic mechanisms responsible for this 
common heart valve defect. Furthermore, the present limitation of 
pharmacological therapy in delaying or stopping disease progression has left 
surgical therapies as the most effective cure for many cases of BAV disease. 
Improved understanding of the genetic basis, molecular pathways, and cellular 
mediators involved in the pathogenesis of BAV disease will create great 
opportunities for the development of novel pharmacological treatment and pre-
vention strategies. This knowledge has the potential to also be used to stratify 
treatment modalities, time surgical intervention, and guide management of at-
risk family members, in terms of diagnostic, therapeutic, and prevention 
strategies, with the overall aim of reducing the health burden of BAV disease. 
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1.4. STRATEGIES TO IDENTIFY PATHOGENESIS OF BAV  
A common feature of nearly all types of genetic heart disease, including BAV, is 
the phenotype heterogeneity observed between affected individuals, even 
within the same family. This can largely be explained by the considerable 
genetic diversity and the heterogeneity of genetic modifiers that may influence 
the ultimate phenotypic manifestation of these conditions. Elucidating the 
genetic basis of diseases therefore becomes a fundamental starting point for 
studies of disease mechanisms, pathways and molecular targets for potential 
therapeutic interventions (McCarthy and Hirschhorn, 2008).  
 
Over the past few decades, many genetic techniques have been developed to 
assist with identification of causative mutation(s) for a Mendelian disease, as 
summarised in Table 1.2. Whilst traditional gene mapping approaches, such as 
karyotyping, linkage analysis, candidate gene, and copy number variation 
analysis, have lead to great insights into many Mendelian disorders, they are 
unable to detect all forms of genomic variation (Gilissen et al., 2011). 
Fortunately, researchers within genetic fields have received a boost over the 
past few years by the introduction of new technologies that enable DNA 
sequencing at much higher throughput and at much lower costs than previously 
possible (Gilissen et al., 2011), such as whole exome and whole genome 
sequencing.  
 
This project utilised a combination of candidate gene analysis and whole exome 
sequencing to investigate the underlying pathogenetic basis of BAV disease. 
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This project also employed RNA sequencing (transcriptome sequencing) 
technology to assess the effects of BAV disease states on gene expression 
within the aortic valve, which may give insights into disease mechanisms and 
pathways. These approaches will be briefly discussed in the following sections. 
 
Table 1. 2. Mendelian disease gene identification approaches. 
Approach Applies to Advantages Disadvantages 
Candidate 
gene 
Any disease Easy to perform for one or two 
genes; requires no mapping, can 
directly identify the causative 
variant/ mutation 
Relies heavily on current 
biological knowledge; success 
rate very low 
Genetic 
mapping by 
karyotyping 
Any disease Easy to perform; no familial 
cases required; can detect (large) 
balanced events 
Low resolution, only detects large 
chromosomal aberrations; 
mutation detection requires 
second step 
Genetic 
mapping by 
linkage 
analysis 
Inherited 
disease 
Easy to perform Requires large families, often 
identifies large loci; mutation 
detection requires second step 
Genetic 
mapping by 
homozygosity 
mapping 
Recessive 
monogenic 
diseases 
Small families can be used Most useful for consanguineous 
families; often identifies large loci; 
mutation detection requires 
second step 
Genetic 
mapping by 
CNV analysis 
Monogenic/ 
monolocus 
disease 
High resolution CNV screening; 
no familial cases required; can 
potentially identify small loci 
 
Only investigates CNVs; cannot 
detect balanced events, no base-
pair resolution; mutation 
detection requires second step 
Whole exome 
sequencing 
Any disease Base-pair resolution exome-wide; 
detects most types of genomic 
variation; can directly identify the 
causative variant/mutation 
Unable to detect non-coding 
variants; limited resolution for 
CNVs and other structural 
variation; coverage variability due 
to enrichment process; relatively 
expensive 
Whole 
genome 
sequencing 
Any disease Base-pair resolution genome-
wide; detects all types of genomic 
variation; can directly identify the 
causative variant/mutation 
Data analysis complex; even 
more expensive than exome 
sequencing  
Adapted from (Gilissen et al., 2011). Highlighted in grey are the techniques 
employed in this project.  
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1.4.1. Candidate gene approach 
Candidate gene studies have been at the forefront in the field of genetic 
epidemiology, where they have been used to identify genes with modest effect 
and the association of a genetic variant with a particular disease or clinical trait 
(Patnala et al., 2013). Candidate gene approach is relatively cheap and quick to 
perform, although it can be labour intensive and cost inefficient when genes 
with large number of exons are involved. It generally begins with selection of a 
putative candidate gene based on its relevance in the mechanism of disease 
being investigated. It is therefore dependent on a priori knowledge of the 
candidate gene’s biological function. 
 
Candidate gene approach is traditionally performed using Sanger sequencing 
(i.e. direct DNA sequencing). This is achieved by amplifying all exons along with 
intron/exon borders of the selected candidate gene of interests using PCR, 
followed by sequencing of the entire coding regions (Chapter 2.4.1). When DNA 
sequence variation is detected, the variation is then analysed for its functional 
significance and therefore the likely pathogenicity. The following are some of 
the criteria that can be used to support causality of the putative gene variants in 
the disease pathogenesis (Kuhlenbaumer et al., 2011): (1) variant co-
segregation with disease within the family; (2) gene variants lead to a non-
synonymous amino acid substitution, splicing aberration or protein truncation; 
(3) unknown or novel variants that are neither found in controls or public 
databases (e.g. dbSNP); (4) different mutations in the same gene are found in 
unrelated cohort with the same disease phenotype; and (5) functional evidence 
from animal or in-vitro models.  
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Whilst candidate gene approach has been used successfully in identifying a 
number of single gene defects, it is subject to a fundamental limitation. The 
major challenge with the candidate gene approach is how much is known of the 
biology of the disease being investigated and thus, the ability of the current 
knowledge to sufficiently predict causative genes. Since genetic heterogeneity 
is more the rule than the exception in many genetic disease, therefore, if only a 
small number of genes are considered, it is likely that only a subset of genes 
involved in a disease are identified (Tabor et al., 2002). This contributes to the 
generally low success rate of this approach. 
 
1.4.2. Whole exome sequencing 
With the advent of next-generation sequencing (NGS) technologies, 
fundamental limitations posed by candidate gene sequencing and other 
traditional approaches have been surmounted, assisting with the identification 
of causative genes at an accelerated rate. The NGS has the potential to identify 
all kinds of genetic variation at base-pair resolution throughout the human 
genome in a single experiment, hence a much faster and more cost efficient 
strategy compared to traditional techniques (Gilissen et al., 2011). There are 2 
unbiased sequencing approaches for detecting genetic variation within an 
individual, namely whole genome sequencing and whole exome sequencing. 
Whilst whole genome sequencing is the ultimate approach for detecting all 
genomic variation in a patient’s genome in a single experiment, it poses a 
significant bioinformatics analysis challenge and its regular application is 
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currently cost-prohibitive for many laboratories (Gilissen et al., 2011). 
Therefore, a more cost-efficient sequencing strategy is to study the 
approximately 1% of human genome that is protein-coding (the exome) by 
means of whole exome sequencing. This is supported by the fact that 
approximately 85% of mutations with large effects in Mendelian diseases reside 
within the exons (Choi et al., 2009), hence, making this a powerful strategy for 
identifying genes that underlie Mendelian disorders in circumstances in which 
conventional approaches have failed.  
 
The overall exome sequencing workflow is summarised in Figure 1.11 and 
Figure 1.12 further details the basic computational workflow and the online-tools 
or software used in the bioinformatics and single nucleotide variations (SNV) 
calling pipelines. The specifics of the process involved with this technique are 
described in greater details in Chapter 2.4.3. 
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Figure 1. 11. Whole exome sequencing workflow.  
Adapted from (Goh and Choi, 2012). 
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Figure 1. 12. Overview of bioinformatics and SNV calling pipelines.  
Adapted from (Altmann et al., 2012).  
 
Whilst many examples are available in the literature that provide proof-of-
concept of exome sequencing strategies for identification of disease-causing 
mutations for various recessive and dominant disorders, the technique is 
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subject to a number of technical and analytical limitations. These include the 
inability of exome sequencing to detect non-coding regulatory variants (i.e. 
promoters, enhancers and microRNAs), its limited resolution for analysis of 
copy number variations and other structural variation, and the variability of 
exome coverage depending on the enrichment process, which may lead to 
inadequate coverage of the region that contains a causal variant and even 
failure to accurately call a variant, due to the strict filtering process (Gilissen et 
al., 2011, Bamshad et al., 2011). Mismapped reads or errors in alignment, due 
to paralogous genes, pseudogenes or sequences that exhibit high sequence 
similarities in the genome, may also lead to false variants in a gene being 
called, leading to false positive findings. Meanwhile, false negative results can 
arise when part or the entire causative gene is not in the target definition 
(Bamshad et al., 2011); for example, it is not known to be a gene (i.e. 
unannotated exons) and thus not targeted in the current capture method. 
Additionally, some exonic regions with high GC content or repetitive sequences 
(up to 10-15% of the exome) can also be very difficult to target with the current 
exome sequencing approach (Ware et al., 2012). Therefore, presently Sanger 
sequencing will continue to be used as a complementary strategy to cover 
these poorly covered target regions and to validate exome sequencing findings. 
Nonetheless, despite these limitations, exome sequencing is well justified as a 
valuable strategy to search for causative alleles underlying Mendelian disorders 
(Ng et al., 2010). 
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1.4.3. RNA sequencing (Transcriptome sequencing) 
A transcriptome is a collection of all the transcripts or messenger RNA (mRNA) 
present in a given cell or tissue of an organism. Therefore, RNA sequencing or 
transcriptome sequencing is very useful in providing a snapshot of the current 
state of a cell or tissue and the possible effects of disease states on gene 
expressions (transcriptome) (Churko et al., 2013). RNA sequencing also 
provides information on the differences between the transcriptome and the 
exome as a result of RNA editing (Churko et al., 2013). Whilst hybridisation-
based microarray profiling has revolutionised the study of transcriptomics and 
proved useful in determining gene expression profiles, transcriptome analysis 
using RNA sequencing is becoming the preferred method of choice (Kogenaru 
et al., 2012). This is because RNA sequencing is more sensitive, provides 
absolute quantity levels, offers a large dynamic range of expression that is not 
affected by on-chip sequence biases, and gives additional information on gene 
expression levels and splice junction variants (Churko et al., 2013). 
Furthermore, RNA sequencing requires a relatively small amount of total RNA 
compared to microarray for quantification (Kogenaru et al., 2012), making it a 
more attractive technique to employ. Figure 1.13 illustrates the overall RNA 
sequencing workflow for transcriptome quantification and functional analysis. 
The specific process involved in RNA sequencing is detailed on Chapter 2.4.4.    
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Figure 1. 13. RNA sequencing workflow.   
Figure adapted with modification from http://www.bioinfo.mc.vanderbilt.edu/ 
NGS/rna-seq.html.  
 
Evaluation of transcriptome using RNA sequencing plays a valuable role in 
cardiovascular medicine because transcriptome changes can identify how 
cardiovascular diseases changes with time (Churko et al., 2013). Thus, RNA 
sequencing provides a means for understanding the genetic and epigenetic 
consequences that produce and influence the actual disease phenotype 
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(Schnabel et al., 2012), highlighting molecular pathways that are important in 
disease pathogenesis. In turn, it provides us with a better understanding of 
disease mechanisms and an opportunity to develop targets for potential 
therapeutic interventions. 
 
1.4.4. Cardiac Magnetic Resonance (CMR) imaging in BAV-related 
aortopathy 
Whilst echocardiography (transthoracic and/or transoesophageal when 
indicated) remains the first-line diagnostic imaging modality for the detection of 
BAV, evaluation of its morphological feature and assessment of related valvular 
and aortic complications in the majority of patients, its use can be challenging in 
those with poor acoustic windows or extensive leaflets calcifications. Further, 
adequate echocardiographic views of the mid and distal ascending aorta and 
aortic arch, the usual sites of maximum dilatation in BAV disease, can be 
difficult to assess (Ko et al., 2012) and therefore, clinically important aortic 
dilatation can potentially be missed.  
 
In the last decade, CMR imaging has emerged as a powerful adjunctive 
modality in the assessment of BAV patients (Shenoy et al., 2014), especially in 
those with suboptimal echocardiography images and when 
conflicting/ambiguous echo measurements are obtained, which can critically 
impact on clinical management and interventional planning. In BAV, CMR 
imaging can be used for comprehensive assessment of aortic valve structure, 
left ventricular volume and function, accurate quantification of aortic 
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regurgitation, and detection of other coexistent congenital cardiac malformation. 
Further, CMR imaging provides a complete assessment of the entire thoracic 
aorta, allowing anatomical, morphological and dynamic/functional evaluation of 
BAV-related aortic abnormalities (Evangelista, 2014), including aneurysm, 
dissection and aortic coarctation. Given the need for life-long routine aortic 
imaging surveillance in these patients and the lack of radiation exposure that is 
associated with CT angiography (CTA), CMR imaging appears to be the 
imaging modality of choice in the long-term follow-up of aortic pathologies in 
BAV patients. However, the major limitations of CMR imaging are limited 
availability, lack of portability, relatively long acquisition time, high cost and 
contraindications to use in certain patients, i.e. those with implanted cardiac 
pacemakers/defibrillators or claustrophobia. Table 1.3 summarised comparative 
strengths and limitations between the different imaging modalities that are 
currently available for the assessment of various aortic pathologies, including 
echocardiography, CTA, and CMR imaging.  
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Table 1. 3. Comparative advantages of imaging modalities for aortic 
diseases assessment. 
Advantages of modality TTE TOE CTA CMR 
Readily available +++ + +++ + 
Quickly performed +++ ++ ++ + 
Non-invasive +++ + +++ +++ 
No iodinated contrast +++ +++ - +++^ 
No radiation +++ +++ - +++ 
Overall aorta segment assessment +* ++$ +++ +++ 
3D multiplanar and high resolution - - +++ +++ 
Dynamic and functional information ++ ++ - +++ 
Measurement accuracy +* +* +++ ++ 
Branch vessel involvement + + +++ +++ 
Presence of AR and mechanisms +++ +++ - ++ 
Assessment of LV function +++ +++ + +++ 
* good in ascending aorta; $ good in thoracic aorta; ^using gadolinium (Gd)-
based contrast medium; +++, excellent; ++, good; + limited; -,  bad; CTA, CT 
angiography; CMR, cardiac magnetic resonance imaging; TOE, 
transoesophageal echocardiography; TTE, transthoracic echocardiography; AR, 
aortic regurgitation; LV, left ventricle. Adapted from (Evangelista, 2014).  
 
Typically, a comprehensive CMR examination of the aorta includes the 
following imaging sequences (Evangelista, 2014): (1) basic black-blood imaging 
using spin-echo sequences, which provide significant morphological information 
on the aortic wall and adjacent structures; (2) cine-MR images or non-contrast 
white-blood imaging with high temporal resolution to obtain images of multiple 
phases and visualise blood flow during systole and diastole; (3) MR imaging 
contrast-enhanced angiography (MRA) with intravenous gadolinium, which 
provides accurate information on aortic diameter, aneurysm extent and its 
relationship with the main arterial branches; (4) the phase-contrast imaging 
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technique, which can provide functional data, including quantification of forward 
and reverse aortic flow in case of aortic regurgitation; and (5) 3D isotropic 
whole-heart imaging, using FIESTA (fast imaging employing steady state 
acquisition)-based sequence, to provide complementary evaluation of the great 
vessels and intracardiac anatomy. These imaging sequences are 
conventionally acquired with ECG-gating and breath-holding, in order to obtain 
CMR images with high temporal and spatial resolutions, as data are acquired 
over a number of cardiac cycles. Thus, regular heart rhythm and consistent 
cardiac position are important during CMR image acquisition.  Figure 1.14 
illustrates an example of a recommended CMR protocol for the overall 
assessment of BAV and BAV-related aortic abnormalities (Shenoy et al., 2014). 
Recently, advancement in CMR imaging technique has resulted in the 
development of a free-breathing real-time phase contrast CMR sequence with 
good spatiotemporal resolution, which allows instantaneous assessments of 
physiological blood flow and cardiac dynamics (Lin et al., 2012c, Sohns et al., 
2013). 
 
This project utilised state-of-the-art real time exercise CMR imaging techniques 
to evaluate the differential aortic wall mechanical properties between patients 
with BAV and TAV and ultimately, to identify novel imaging biomarker(s) that 
can potentially be used to predict for the development of adverse aortic 
outcome in those with BAV disease. The specifics of the process involved with 
this technique are described briefly in Chapter 2.5 and in greater details in 
Chapter 6.2. 
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Figure 1. 14. Outline of CMR protocol for the assessment of BAV 
syndrome.  
Adapted from (Shenoy et al., 2014). *As part of our institutional protocol, a 3D 
isotropic whole-heart image acquisition is routinely performed following the 3D 
contrast-enhanced MRA imaging. The entire study is typically performed in 
under an hour. SSFP, steady-state free precession; HASTE, half-Fourier 
acquisition single-shot turbo spin-echo; ECG, electrocardiogram. 
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1.5. HYPOTHESES AND AIMS 
Despite being the commonest form of congenital cardiac disorder with 
significant clinical implications and health burden, the underlying genetic basis 
of BAV disease is mostly undetermined.  
 
1.5.1. Hypotheses 
There are two hypotheses being addressed in this thesis. 
 
Hypothesis 1: In a significant proportion of patients with BAV disease, there is 
an underlying genetic cause of the disorder. Identification of the genetic and 
molecular basis of BAV disease has major implications in our understanding of 
disease pathogenesis as well as in creating great opportunities for the 
development of novel pharmacological treatment and prevention strategies.  
 
Hypothesis 2: There is an inherent structural abnormality within the ascending 
aortic wall of patients with BAV, which predispose them to develop ascending 
aortic dilatation in response to life-long haemodynamic stress. This structural 
abnormality can be detected clinically using non-invasive exercise CMR 
imaging by evaluating various measures of aortic stiffness or elasticity.  
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1.5.2. Aims of the project  
Based on the above hypotheses, there are two main aims: 
 
1. To perform genetic studies to identify causative and modifier genes as well 
as molecular pathways responsible for BAV disease development and 
progression.  
• Specifically, a candidate gene approach will be used in sporadic cases 
of BAV and a whole-exome sequencing approach in familial cases of 
BAV. Furthermore, transcriptome analysis of aortic valve tissues will 
be performed to evaluate the differential pattern of gene expression 
underlying structural valve degeneration in BAV versus TAV. 
• When a positive genetic study is obtained, a genotype-phenotype 
correlation study is to be performed. 
 
2. To evaluate the differential aortic wall mechanical properties between those 
with BAV and TAV, using real-time exercise CMR imaging, in order to 
identify predictors of adverse clinical outcome in those with BAV-related 
aortopathy. 
 
 
A summary of the research plan is shown in Figure 1.15. 
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2.1. MATERIALS 
Table 2. 1. General materials, chemicals and molecular biology reagents. 
Reagent Source / Supplier 
DNA extraction procedure 
QIAamp DNA Blood Mini Kit Qiagen (Germantown, MD, USA) 
PCR reagents 
GoTaq® Flexi Buffer Promega (Maddison, WI, USA) 
MgCl2 Promega (Maddison, WI, USA) 
GoTaq® Flexi DNA polymerase Promega (Maddison, WI, USA) 
dNTPs Roche Diagnostics GmbH (Mannheim, Germany) 
Dimethly sulfoxide (DMSO) Sigma-Aldrich (St. Louis, MO, USA) 
Primers Geneworks (Hindmarsh, SA, Australia) 
PCR product purification 
Exonuclease I Amersham Biosciences (Piscataway, NJ, USA) 
Antarctic phosphatase New England BioLabs (Ipswich, MA, USA) 
Agarose gel electrophoresis 
Agarose Amresco (Solon, OH, USA) 
EDTA Sigma Aldrich (St. Louis, MO, USA) 
Tris base Sigma Aldrich (St. Louis, MO, USA) 
Glacial acetic acid Crown Scientific (Moorebank, NSW, Australia) 
TAE, 25x Ready-Pack Amresco (Solon, OH, USA) 
Orange G Sodium salt Sigma Aldrich (St. Louis, MO, USA) 
Gel red Biotium (Hayward, CA, USA) 
DNA Molecular Weight Marker IX Roche Diagnostics GmbH (Mannheim, Germany) 
RNA preservation 
RNAlater® Ambion, Life Technologies (CA, USA) 
RNA extraction 
100% ethanol Chem-Supply (Gillman, SA, Australia) 
Isopropyl alcohol Sigma Aldrich (St. Louis, MO, USA) 
Triple distilled water (TDW) Centenary Institute (Sydney, NSW, Australia) 
TRIzol® Reagent Invitrogen, Life Technologies (CA, USA) 
Chloroform Chem-Supply (Gillman, SA, Australia) 
DEPC-treated water Ambion, Life Technologies (CA, USA) 
cDNA synthesis and reverse transcription quantitative PCR (RT-qPCR) 
SuperScript® VILO Invitrogen, Life Technologies (CA, USA) 
Express SYBR® GreenER qPCR 
SuperMix Universal 
Invitrogen, Life Technologies (CA, USA) 
  Chapter 2: Materials and Methods 
 
 57 
 
2.2. ONLINE TOOLS AND DATABASES 
Table 2. 2. Online tools, software and databases used in the project. 
Tool or Database Website 
1000 Genomes Project http://www.1000genomes.org/home  
Bowtie http://bowtie-bio.sourceforge.net/index.shtml 
Burrows-Wheeler Aligner (BWA)  http://bio-bwa.sourceforge.net/ 
dbSNP (build 137) http://www.ncbi.nlm.nih.gov/projects/SNP/ 
Database for Annotation, 
Visualisation and Integrated 
Discovery (DAVID) version 6.7 
http://david.abcc.ncifcrf.gov 
Ensembl http://www.ensembl.org/index.html 
Genome Analysis Toolkit (GATK, 
version 2.7.2) 
http://www.broadinstitute.org/gsa/wiki/index.php
/The_Genome_Analysis_Toolkit 
Human genome reference 
(GRCh37/hg19) 
http://genome.ucsc.edu 
Integrative Genome Viewer (IGV) http://broadinstitute.org/igv/ 
Ingenuity Pathway Analysis (IPA) http://www.ingenuity.com/products/ipa 
National Centre for Biotechnology 
Information (NCBI) 
http://www.ncbi.nlm.nih.gov/guide/ 
NetPrimer (Premier Biosoft) http://www.premierbiosoft.com/NetPrimer/Analy
zePrimer.jsp 
NHLBI Exome variant server (EVS) http://evs.gs.washington.edu/EVS/ 
PANTHER Classification System http://www.pantherdb.org 
Primer3 version 0.4.0 http://bioinfo.ut.ee/primer3-0.4.0/ 
Primer3Plus©  http://www.bioinformatics.nl/cgi-bin/primer3plus/  
primer3plus.cgi 
Primer-BLAST http://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
Polyphen2 http://genetics.bwh.harvard.edu/pph2/ 
SamTools version 0.1.19 http://samtools.sourceforge.net/ 
Seattle Seq Annotation tool http://snp.gs.washington.edu/SeattleSeqAnnotat
ion131/index.jsp 
TopHat2 version 2.0.6 http://tophat.cbcb.umd.edu 
OligoEvaluator DNA calculator http://www.sigmaaldrich.com/life-
science/custom-oligos.html 
SeqMonk (Babraham 
Bioinformatics) 
http://www.bioinformatics.babraham.ac.uk/proje
cts/seqmonk/ 
Uniprot http://www.uniprot.org/ 
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2.3. STUDY POPULATIONS AND TISSUE BANK 
Patient recruitment and all human sample collection were done following 
informed consent. The study protocol was approved by the Sydney South West 
Area Health Service Ethics Committee. 
 
2.3.1.  BAV populations 
Patients attending specialised cardiology clinics and those who were scheduled 
to have aortic valve replacement (AVR) surgery at the Royal Prince Alfred 
Hospital (RPAH), Sydney, Australia, were prospectively recruited from February 
2011 to January 2013. Following informed consent, clinical information and 
20mls of peripheral blood were collected from each patient. All patients 
underwent clinical evaluation that included family history, physical examination, 
and 2D-echocardiography. In each case, aortic valve morphology was 
confirmed by imaging and/or during cardiac surgery and their functional state 
was determined according to the American Heart Association and the American 
College of Cardiology guidelines (Bonow et al., 2008). 
 
Aortic valve was categorised as structurally normal when the valve had 3 
completely separate leaflets, i.e. tricuspid/tri-leaflet aortic valve (TAV), and was 
bicuspid when it had only 2 leaflets. BAV morphology was classified as 
anatomically bicuspid when there were 2 approximately symmetrical leaflets 
without a raphe; functionally bicuspid when the 2 leaflets were unequal in size 
with the larger leaflet having a central raphe due to commissural fusion; or 
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indeterminate when the morphology was unrecognisable, e.g. due to heavy 
calcification.  
 
2.3.2. Control population 
The control DNA population used in the candidate gene study consisted of 160 
predominantly Caucasian individuals, 51% females, from Sydney, Australia, 
who did not suffer from any cardiac-related health problems at the time of blood 
collection. Routine clinical and/or formal echocardiographic evaluations 
however were not performed amongst the majority of the control subjects at the 
time of recruitment. 
 
2.3.3. Tissue banking 
Aortic valve tissue of BAV or TAV morphology were prospectively collected 
from all consenting participants undergoing aortic valve or aortic root surgery at 
the RPAH between February 2011 to December 2013. The valve tissues 
obtained between February 2011 to February 2012 were immediately snap-
frozen in dry ice upon surgical removal and stored at -80°C fridge until genetic 
materials were extracted.  Since March 2012, all harvested leaflet tissues were 
immersed in RNAlater solution (Ambion Inc, Austin, TX) overnight and stored at 
-80°C to allow better RNA preservation, prior to extraction. 
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2.4. MOLECULAR GENETIC METHODS 
2.4.1. Methods of DNA analysis 
2.4.1.1.%DNA%extraction%
Genomic DNA was extracted from the peripheral blood leukocytes of all adult 
cohorts using the QIAamp DNA Blood Mini Kit according to the standard 
manufacturer’s protocol. For young cohorts, aged 12 or below, the Oragene 
DNA Self-Collection Kit (either OG-300 or OG-250; DNA Genotek Inc, Kanata, 
Ontario, Canada) was used to collect and extract participants’ genomic DNA 
from their saliva, in accordance to the manufacturer’s instructions. The 
concentration and purity of all stock genomic DNA samples were assessed 
using the Nanodrop 2000 spectrophotometer (Thermo Scientific, MA, USA). 
Aliquots of stock genomic DNA samples were diluted with TDW to 15ng/µL 
working concentration and stored at 4°C until their use in subsequent 
downstream applications.   
 
2.4.1.2. Standard DNA Polymerase Chain Reaction amplification 
Polymerase chain reaction (PCR) was used to amplify DNA sequences of 
interest. Primers were designed with Primer3Plus software, using reference 
sequences obtained from the Ensembl Genome Browsers. Specific primer 
sequences and their optimal reaction conditions used in the different sections of 
this project are listed in Appendix I. 
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The PCR mixture consisted of 2.5µL of template DNA (15ng/µL), 5µL of 5x 
GoTaq® Flexi Buffer (pH 8.5), 1.2µL of dNTPs (0.4mM), 1.2µL of MgCl2 
(2.0mM), 1µL of each forward and reverse primer (0.6µM), and 0.08µL of 
GoTaq Flexi DNA polymerase (5U/µL), with or without DMSO (2.5µL), made up 
to a final volume of 25µL per reaction with TDW. A negative control of DNA 
replaced by TDW was used to verify the absence of DNA contaminations in 
reactions. The PCR was carried out in a PTC-100 or the PTC-200 Peltier 
Thermal Cycler (MJ Research Inc., Waltham, MA, USA). Thermal cycling was 
performed at 95°C for 2 minutes, followed by 35 cycles of 95°C for 30 seconds, 
primer specific annealing temperature (Ta) for 30 seconds and 72°C for 1 
minute, followed by a final extension of 72°C for 5 minutes. PCR products were 
stored at 4°C. 
 
2.4.1.3. Agarose gel electrophoresis 
The size of PCR products, RNA and DNA were resolved using agarose gel 
electrophoresis. Five µL of samples were mixed with 5µL Orange G loading dye 
and electrophoresed in either a 1% (for PCR products or DNA) or 2% (for RNA) 
agarose gel containing 1:10,000 parts of Gel Red. DNA molecular weight 
marker (Marker IX, in a 1 in 5 dilution with Orange G loading dye) was run 
simultaneously next to samples to determine approximate size of nucleic acid. 
Electrophoresis was performed in 1x TAE buffer (100 mM Tris base, 50 mM 
glacial acetic acid, 3 mM EDTA, pH 8.0) at 190 Volts for 50-60 minutes. The gel 
was then visualised under UV light using Syngene Image Analyser G:Box.  
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2.4.1.4. PCR product purification 
PCR products were purified prior to sequencing to remove excess PCR primers 
and dNTPs, which may interfere with DNA sequencing. Five U/µL Exonuclease 
I and 1 U/µL Antarctic Phosphatase, made up to 4 µL with 0.1 mM Tris buffer, 
was added to 20 µL PCR product and incubated at 37°C for 30 minutes, 
followed by 80°C for 30 minutes to heat inactivate the enzymes. 
 
2.4.1.5. Direct sequencing of PCR products 
Sanger sequencing of the PCR products was performed in the forward and/or 
reverse direction at the Macrogen Ltd Facility (Gasan-Dong, Geumchun-Gu, 
Seoul, Korea). Sequencing data were analysed for variants using Sequencher 
Version 4.8 (Gene Codes Corporation, Ann Arbor, MI, USA). This method is 
used during candidate gene screening. 
 
2.4.2. Methods of RNA analysis 
2.4.2.1. RNA extraction 
Total RNA was isolated from approximately 75-100mg of leaflet tissue following 
immediate homogenisation directly in the TRIzol Reagent with Polytron 
sonication (Polytron pt-MR2100 homogenizer, Kinematica AG, Lucerne, 
Switzerland). The RNA extraction procedure was performed using a modified 
TRIzol protocol that includes two RNA-DNA-protein phase separations to 
maximise RNA yield while minimising degradation and contamination. A similar 
two-phase separation method had recently been validated as an effective 
method for RNA extraction from cartilaginous tissue (Ali and Alman, 2012), 
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which had low cellularity and high proteoglycan content as seen in human aortic 
valve. Briefly and specific to our protocol, following the addition of isopropyl 
alcohol, incubation and centrifugation, a thin transparent layer of RNA will 
collect at the bottom half of the tube. The upper aqueous isopropyl alcohol 
phase was carefully removed, without disrupting the RNA layer, and discarded. 
One ml of TRIzol was then added to the residual solution containing the RNA 
layer and the extraction procedure was continued as per the standard protocol. 
The precipitated RNA was later re-suspended in DEPC-treated water and 
stored at the -80°C freezer until further use. 
 
RNA quality was assessed for integrity (lack of degradation) and purity 
(absence of contaminants). The RNA purity and concentration was measured 
with a Nanodrop 2000 spectrophotometer (Thermo Scientific, MA, USA). The 
RNA integrity was assessed by 2% gel electrophoresis (as outlined in Chapter 
2.4.1.3) and/or the Agilent 2100 Bioanalyzer (RNA6000 Nano LabChip, Agilent 
Technologies, Santa Clara, CA, USA). RNA samples with clear 28S and 18S 
rRNA bands on gel electrophoresis, where the intensity of the 28S band was 
approximately twice that of the 18S band, indicate good quality RNA. An RNA 
integrity number (RIN) of ≥ 7 on the Bioanalyzer indicates acceptable RNA 
quality for transcriptome analysis. 
 
2.4.2.2. Reverse Transcription quantitative PCR (RT-qPCR) 
RT-qPCR was used to quantitatively study gene expression levels in specific 
tissue or organ of interest through the creation of complementary DNA (cDNA) 
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transcripts. Here, two-step RT-qPCR was used, as previously described in our 
group (Bagnall et al., 2012). The RNA template is first converted into a cDNA 
using a reverse transcriptase. The cDNA is then used as a template for 
exponential amplification using PCR. 
 
2.4.2.2.1. cDNA synthesis  
RNA was reverse transcribed in duplicate using SuperScript® VILO cDNA 
synthesis kit and master mix to make cDNA. The reaction mixture includes 2 µL 
of 5x VILO buffer (containing random primers, MgCl2 and dNTPs), 1 µL of 10x 
SuperScript® III RT Enzyme Mix (containing SuperScript® III RT, RNase OUT 
Recombinant Ribonuclease Inhibitor and a proprietary helper protein), 3µL of 
RNA (at 100 ng/µL) and 4 µL of DEPC-treated water. Two negative controls, 
without reverse transcriptase and without RNA template, were included to 
evaluate for the presence of contamination with DNA and contamination with 
RNA or cDNA, respectively. The final reaction mixture was incubated in the 
PTC-100 or the PTC-200 Peltier Thermal Cycler under the following conditions: 
25°C for 10 minutes, 42°C for 60 minutes, followed by 85°C for 5 minutes. The 
resultant cDNA sample was diluted with DEPC-treated water to a concentration 
of 1.5 ng/µL and stored at -80°C until PCR can be performed. 
 
2.4.2.2.2. RT-qPCR preparation and analysis 
Primers were designed with Primer3 (version 0.4.0) software, using reference 
sequences obtained from the Ensembl Genome Browser. The quality and 
specificity of each set of primers were then assessed using NetPrimer, NCBI 
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Primer-BLAST and OligoEvaluator DNA calculator, to avoid the presence of 
dimers, cross-dimers, primer dimer, hairpins and secondary structures. Specific 
RT-qPCR primer sequences and their optimal reaction conditions are described 
in Chapter 5. 
 
The RT-qPCR mixture consisted of 5 µL of Express SYBR® GreenER qPCR 
SuperMix Universal, 0.15 µL of forward primer, 0.23 µL of reverse primer and 4 
µL of cDNA, made up to a final volume of 10 µL per reaction with DEPC-treated 
water. Two negative controls (ie. no RT control and no RNA template control) 
were used to verify the absence of contaminations in reactions, as described on 
the previous section. RT-qPCR was carried out in a Mx3000P qPCR System 
(Agilent Technologies, Santa Clara, CA, USA). Thermal cycling was performed 
at 95°C for 2 minutes, followed by 40 cycles of 95°C for 5 seconds and primer 
specific annealing temperature (Ta, °C) for 20 seconds, and a final incubation of 
95°C for 1 minute, primer specific Ta for 30 seconds, followed by 95°C for 30 
seconds. Data was analysed using MxPro qPCR software version 2.0 
(Stratagene, La Jolla, CA, USA). Two reference genes were used to calculate 
the normalisation factor by geNorm version 3.4 algorithms. The relative amount 
of each gene-of-interest expression was normalised to the reference genes 
expression. Microsoft® Excel® version 14.0.1 software was used for delta-delta 
Ct analysis. Statistical analysis was performed using the Prism software 
package (GraphPad Software Inc., La Jolla, CA, USA). 
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2.4.3. Whole Exome Sequencing 
Whole exome sequencing is an efficient strategy used to selectively enrich and 
sequence the protein-coding regions of the genome. As previously described in 
our group (Bagnall et al., 2014), the steps involved are detailed as follows. 
 
2.4.3.1. Exome sequencing library construction and sequencing 
Exome sequencing (library construction, capture and sequencing) was carried 
out at the Macrogen Facility, South Korea. Briefly, approximately 5 µg of 
genomic DNA with a concentration of >100ng/µL was prepared for each sample 
and sent for sequencing. After passing the initial quality control, the genomic 
DNA was fragmented by nebulization to achieve a mean size of ~200bp. The 
fragmented DNA ends were repaired by way of 5’ phosphorylation using the 
enzyme Klenow polymerase. Adenine bases were added to the 3’ end of the 
phosphorylated fragment and ligated to Illumina paired-end adapters that have 
a T-base overhang at their 3’ends. Following ligation, the adapter-ligated 
products were assessed for size distribution on the Agilent Bioanalyzer and 
then PCR amplified. The amplified DNA library was subsequently hybridised 
and enriched using the Illumina TruSeq Exome Enrichment protocol, and the 
exome selected using streptavidin-coated magnetic beads. The exome-
enriched library was then eluted from the beads and PCR amplified. 
Appropriate amount of library were afterwards loaded onto the Illumina flowcell 
and following cluster generation, the captured library was sequenced using the 
Illumina HiSeq2000 Sequencer. This yielded the raw exome data for processing 
within the exome bioinformatics pipeline, which has been compiled in the 
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Molecular Cardiology Laboratory, Centenary Institute, by Dr. Richard Bagnall, 
as described in the following section. 
 
2.4.3.2. Exome sequencing bioinformatics and variant analysis  
Sequence alignment and variant calling was performed against the reference 
human genome (GRCh37/hg19). The raw 101 bp sequencing data were aligned 
using Burrows-Wheeler Alignment Tool (BWA, version 0.7.4) alignment 
program. The software package SAMtools were then used to convert and 
merged the aligned sequence reads to sorted and indexed BAM files with 
reference to their chromosome position. Duplicate reads were removed using 
Picard tools version 1.81. These BAM files were then analysed using a 
sequence variant calling software, called the Genome Analysis Toolkit (GATK) 
program (version 2.7.2), which recalibrated base quality scores, called and 
filtered variants, and then compiled all gene variants from each individual 
sample into a single variant call format (VCF) file. Insertions and deletions 
(Indels) were identified based on the reads mapped with BWA, with its ability to 
align reads that contain gaps to the reference genome. Functional annotations 
of the genetic variants were performed using the SeattleSeq Annotation tool 
version 8.07, with respect to locations (exonic, intronic, splice site, 5’ UTR, 3’ 
UTR, upstream, downstream, or intergenic) and exonic functions (non-
synonymous, synonymous, stop, frameshift insertion or deletion). Allele 
frequencies were generated for known variants in the 1000 Genomes Project, 
dbSNP (build 134), and the National Heart, Lung, and Blood Institute (NHLBI) 
Exome Variant Server (EVS) (6,503 sequenced exome to date). To predict 
  Chapter 2: Materials and Methods 
 
 68 
 
deleterious effects of non-synonymous variants, functional annotation 
algorithms (e.g. SIFT and PolyPhen2), GERP score, which identified 
evolutionarily constrained elements in multiple sequence alignments across 
species, and Gratham score, which categorised codon replacement into classes 
of increasing chemical dissimilarity, were utilised. To eliminate common variants 
and sequencing artifacts, the sample data were also filtered to exclude variants 
present in the in-house exome datasets from unrelated individuals with normal 
trileaflet aortic valve. A visualisation tool, Integrative Genome Viewer (IGV), was 
used to examine aligned sequence reads and genome annotation files, as well 
as to assess coverage and the overall quality of the aligned sequence reads.  
 
With the principal assumption that BAV has an autosomal dominant pattern of 
inheritance, where a single mutation is both sufficient and necessary to cause 
disease, the variant will affect a protein sequence and that the causative 
mutation will occur at a frequency of no more than 1%, the following criteria are 
used to prioritise variants identified by exome sequencing: (i) the presence of 
variants in all exome sequencing samples from affected members within the 
studied family; (ii) the novelty of the variants by excluding those found in the in-
house exome dataset of unrelated individuals with different phenotype and 
those with minor allele frequency (MAF) of >1% in the 1000Genome Project, 
the dbSNP, and the EVS database; (iii) the putative pathogenic effect of the 
gene variants by excluding synonymous, intronic or intergenic variants and by 
including those with non-synonymous missense, nonsense, splice-site gain- or 
loss-of-function variants and frame-shift insertion or deletion mutations; (iv) a 
positive GERP conservation score; (v) the presence of cardiac expression of 
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the genes which harboured the variants. The variants that fulfilled these criteria 
were then considered for downstream validation analysis. 
 
2.4.3.3. Validation of variants identified by exome sequencing 
Following identification of putative disease-causing variants by exome 
sequencing, confirmation on the presence of each variant in the exome-
sequenced family members and assessment of the pattern of variant 
segregation in other family members (affected and non-affected relatives) were 
performed using standard Sanger sequencing of PCR amplicons from genomic 
DNA, in similar manner as described in Chapter 2.4.1.2 to 2.4.1.5.  
 
2.4.4. RNA Sequencing 
Similar to exome sequencing, RNA sequencing uses massive parallel 
sequencing technologies to reveal a comprehensive snapshot of all messenger 
RNA (the “transcriptome”) present in a specific tissue type in a given moment in 
time. Data obtained from RNA sequencing provides information on both gene 
expression and genetic polymorphisms.  
 
2.4.4.1. RNA sequencing library construction and sequencing 
RNA sequencing (library construction, capture and sequencing) was carried out 
at the BGI Facility, Hong Kong. RNA sequencing library was prepared using the 
Illumina TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA, USA) 
from 5µg of total RNA, with a RNA integrity number (RIN) ≥ 7, according to the 
manufacturer’s protocol. Briefly, following DNAse I treatment, magnetic beads 
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with Oligo (dT) are used to isolate mRNA from the total RNA. After mixing with 
the fragmentation buffer, the mRNA is fragmented into short fragments (~100bp 
in size), which are then used as templates to synthesise cDNA. The short cDNA 
fragments are purified, resolved with EB buffer for end reparation and single 
nucleotide A (adenine) addition, and subsequently connected with adapters. 
After agarose gel electrophoresis, the suitable fragments are selected as 
templates for PCR amplification and later sequenced on a HiSeq2000 
(Illumina). The resultant raw RNA sequencing data (in Illumina FASTQ format) 
are then processed within the in-house bioinformatics pipeline, which has been 
compiled in the Molecular Cardiology Laboratory, Centenary Institute, by Dr. 
Richard Bagnall. 
 
2.4.4.2. RNA sequencing bioinformatics pipeline and analysis 
A number of publically available packages, including Bowtie and TopHat, were 
used to map the raw sequence reads data to the reference genome. Initially, 
the FASTQ files were aligned to the human reference sequence (NCBI 
GRCh37/hg19) using Bowtie. However, as Bowtie cannot align reads that span 
introns, TopHat2 version 2.0.6 (Kim et al., 2013) with a transcriptome-index was 
used to guide mapping of splice junction-spanning reads. Aligned reads in BAM 
format were then annotated against the protein-coding mRNA regions and 
analysed using SeqMonk version 0.24.1 platform (Babraham Bioinformatics, 
Cambridge UK), where visualisation of mapped read, data quantification (using 
corrected log2 transformed Reads Per Million Values of non-strand specific, 
unmerged isoform) and percentile normalisation were performed. Differentially 
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expressed genes (DEGs) were identified on the normalised quantification data 
using an intensity difference analysis method.(Brien et al., 2013) A gene was 
classified as up- or downregulated using a cutoff value of more or less than 1.5-
fold expression difference, respectively, between BAV versus TAV, with an 
adjusted p-value <0.05, following post-hoc Bonferroni correction. A small 
number of unannotated genes with uncharacterised protein were excluded from 
subsequent analysis. 
 
Ingenuity Pathway Analysis (IPA) and PANTHER online tools were used to 
assess biological networks and pathways connected to the DEGs. Gene 
Ontology (GO)-based enrichment and KEGG pathway analysis of DEGs were 
performed against a background list of global aortic valve protein-coding 
mRNAs expression, using the Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) bioinformatics resources (version 6.7; NIH). 
Enrichment score of ≥ 1.3 and Benjamini-Hochberg corrected p-value <0.05 
were used as a cut-off for significance. SeqMonk was also utilised to perform 
hierarchical clustering and heat map analysis of DEGs. 
 
2.4.4.3. Validation of differential gene expression observed from RNA-
sequencing data 
Validation of RNA sequencing data was performed on a subset of DEGs-of-
interest. This was performed on total aortic valve RNA from unrelated 
individuals by RT-qPCR, as described in Chapter 2.4.2.2.  
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2.5.  CMR ASSESSMENT OF THE THORACIC AORTA IN BAV DISEASE 
CMR imaging was performed using 1.5 Tesla Phillips Achieva MR scanner 
(Phillips Medical System, Best, Netherland). The study was performed without 
gadolinium contrast administration and consisted of 3 imaging stages, namely 
the resting phase (baseline), exercise (Stage 1 and Stage 2) and recovery 
phase. Exercise was performed using a pneumatic MRI-compatible pedal 
ergometer, which was attached at the foot of the MRI table. A free-breathing 
real-time phase-contrast CMR imaging was employed with sufficient 
spatiotemporal resolution to acquire beat-to-beat hemodynamic information to 
characterize transient blood flow phenomenon and to study aortic wall pulsatility 
associated with each heartbeat, at rest and during exercise. The study was 
performed in approximately 50-60 minutes for each patient. The specifics of the 
study protocol will be discussed in greater details in Chapter 6.2. 
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3.1. INTRODUCTION 
Positive family history for aortic valve disease has been reported in up to 14% 
of patients with BAV, supporting the need for routine echocardiographic 
screening of first-degree relatives (Panayotova et al., 2013). Indeed, familial 
clustering and genetic studies have established that BAV is a highly heritable 
trait and it likely exhibits genetic heterogeneity with variable modes of 
inheritance (Huntington et al., 1997, Cripe et al., 2004).  
 
To date, only mutations in the NOTCH1 gene at chromosome 9q34.3 have 
been linked to the development and progression of BAV in a limited number of 
familial cases and in less than 5% of sporadic cases (Garg et al., 2005, 
McKellar et al., 2007, Mohamed et al., 2006). However, the molecular 
mechanisms by which NOTCH1 missense mutations, or frameshift mutations 
leading to haploinsufficiency result in BAV development in humans remain to be 
elucidated. In mice, deficiency of endothelial nitric oxide synthase (Nos3) and 
Nkx2-5 haploinsufficiency are associated with a higher incidence of BAV (Biben 
et al., 2000, Lee et al., 2000). Again, the mechanisms by which Nos3 and Nkx2-
5 mutations contribute to BAV formation in these mice are presently not well 
understood. Nevertheless, neither of these genes have shown an association 
with human cases of BAV (Lincoln and Yutzey, 2011, Majumdar et al., 2006, 
Schott et al., 1998).  
 
A homeobox-containing transcription factor, NKX2-5 is an attractive candidate 
gene for BAV, given its important role in cardiac development in many 
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organisms, including the zebrafish, frog, chick, mouse and human (Srivastava 
and Olson, 2000, Harvey, 1996). Heterozygote NKX2-5 mutations are 
associated with a diverse range of cardiac malformations in humans (Figure 
3.1), including atrial septal defects with or without atrioventricular conduction 
block, ventricular septal defects, Tetralogy of Fallot, double-outlet right ventricle, 
tricuspid valve abnormalities, and subvalvular aortic stenosis (Benson, 2010, 
Schott et al., 1998). This suggests an essential role of NKX2-5 in atrial, 
ventricular, and conotruncal septation, maintenance of atrioventricular 
conduction, and heart valve formation (Benson, 2010). Located on chromosome 
5q34, NKX2-5 is also known to modulate the extracellular matrix of the aorta 
during embryonic development (Ponticos et al., 2004). This is an interesting 
observation given the frequent presence of aortic abnormalities in patients with 
BAV, which is seen in over 50% of cases (Fedak et al., 2002). Whilst a previous 
study has failed to demonstrate an association between BAV and NKX2-5 
mutation, the study was limited by a small population size (n=19) (Majumdar et 
al., 2006). Therefore, mutations in NKX2-5 cannot yet be excluded as a 
possible cause of BAV based on this study alone and further evaluation in a 
larger cohort is warranted. 
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Figure 3. 1. Diverse cardiac 
malformations associated with 
NKX2-5 mutations.  
Adapted from (Benson, 2010). ASD, 
atrial septal defect; AVB, 
atrioventricular block; DORV, 
double-outlet right ventricle; TOF, 
Tetralogy of Fallot; TVA, tricuspid 
valve abnormality; VSD, ventricular 
septal defect.  
 
 
 
Recently, GATA5 was reported to have an essential role in cardiac 
morphogenesis and aortic valve development (Laforest et al., 2011, Laforest 
and Nemer, 2011), and targeted deletion of Gata5 in mice leads to partially 
penetrant BAV with right and noncoronary leaflet fusion morphology (Laforest et 
al., 2011). Located at chromosome locus 20q13.33, GATA5 is a transcription 
factor that belongs to a sub-group of the GATA family of zinc finger proteins, 
which, together with GATA4 and GATA6, is expressed in an overlapping but 
distinct spatial and temporal pattern in the developing heart (Charron and 
Nemer, 1999, Peterkin et al., 2005). The GATA-4, -5 and -6 proteins share 2 
evolutionarily conserved N-terminal transcriptional activation domains and 2 C-
terminal DNA binding and nuclear localisation zinc-finger domains (Morrisey et 
al., 1997). Unlike GATA4 and GATA6 however, the expression of GATA5 is 
restricted to endocardial cells and endocardial cushions of the outflow tract and 
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atrioventricular canal during cardiogenesis (Laforest and Nemer, 2011) and is 
not maintained in adult cardiovascular structures (Molkentin, 2000). Studies in 
developing murine heart have implicated the important function of GATA4/5/6 
subfamily, which acts cooperatively, in the regulation of endocardial cushion 
development and/or outflow tract morphogenesis (Charron and Nemer, 1999, 
Peterkin et al., 2005, Laforest and Nemer, 2011). Of note, aortic valve 
hypertrophy and stenosis were observed amongst the surviving adult mice with 
Gata4/Gata5 compound mutations (Laforest and Nemer, 2011). Gata5/Gata6 
compound heterozygous mice die during the embryonic or perinatal period due 
to the development of highly penetrant double-outlet right ventricle, suggesting 
disrupted valvulogenesis in Gata5+/-Gata6+/- embryos (Laforest and Nemer, 
2011). Overall, these observations provide support for the essential role of 
GATA5 in the aortic valve and outflow tract morphogenesis in mice. 
Nevertheless, the role of GATA5 in human cases of BAV is not yet clear. 
 
Therefore, this chapter describes the study that sought to investigate the 
relationship between Nkx2-5 and GATA5 mutations and the development of 
non-syndromic BAV with its associated aortopathy in 100 prospectively 
recruited BAV patients. 
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3.2. METHODS 
3.2.1. Study populations 
The study used the BAV cohort and the healthy control population described in 
Chapter 2.3.  Clinical evaluation of the BAV cohort included family history, 
physical examination, and 2D-echocardiography. In each case, BAV was 
confirmed by imaging and/or during aortic valve replacement surgery. BAV 
morphology was classified as anatomically bicuspid when there were 2 
approximately symmetrical leaflets without a raphe; functionally bicuspid when 
the 2 leaflets were unequal in size with the larger leaflet having a central raphe 
due to commissural fusion; or indeterminate when the morphology was 
unrecognisable, e.g. due to heavy calcification. Following informed consent, 20 
mls of peripheral blood and clinical information were collected from each 
patient. The study protocol was approved by the Sydney South West Area 
Health Service ethics committee. 
 
3.2.2. Genetic analysis 
BAV cohort was screened for the presence of disease-causing mutations in the 
2 candidate genes of interest, namely GATA5 and Nkx2-5, by means of direct 
Sanger sequencing. Upon identification, the putative disease-causing variants 
were then checked for their presence amongst the control population, using a 
similar method. Genomic DNA was obtained from peripheral blood leukocytes, 
using method described in Chapter 2.4.1.1. 
 
 Chapter 3: Candidate gene approach in sporadic BAV 
 79 
 
3.2.2.1. Primers design, PCR optimisation and troubleshooting 
Primers flanking the protein coding exons and splice signal sequences of the 
GATA5 and Nkx2-5 genes were designed using the on-line tool Primer3Plus©, 
to produce a product size of approximately 423-850bp, using custom settings 
(Appendix I, Table I-1). Each primer pair was tested across an annealing 
temperature gradient, ranging from 50°C to 65°C, in standard PCR conditions 
(Chapter 2.4.1.2) to determine the temperature at which the primers efficiently 
and specifically amplify the target sequence (Figure 3.2). PCR products were 
visualised using standard gel electrophoresis to determine the optimum primer 
annealing temperature, indicated by a clear, bright, single band of the correct 
product size. For non-specific primer binding, 10% DMSO was added to obtain 
specific primer binding. If this troubleshooting method failed to produce specific 
priming, primers for the region were redesigned and the new set of primers re-
tested for its optimal annealing temperature. The optimal condition and PCR 
annealing temperature to amplify the specific target sequences for different 
primer pairs used in this study are listed in Appendix I, Table I-1.  
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Figure 3. 2. Example of PCR optimisation, using primers designed for 
GATA5 exon 1 to produce an 833bp PCR product size.  
A) Primer temperature optimisation using a temperature gradient ranging from 
50°C to 65°C, in standard PCR conditions. This panel showed an example of an 
unsuccessful temperature gradient optimisation where non-specific binding 
(NSB) appeared at lower temperatures and no band appeared at the expected 
product size. B) The addition of 10% DMSO to the PCR reaction resulted in a 
more specific binding, producing a single product at the expected PCR product 
size. In this case, the optimum annealing temperature (Ta) range was regarded 
to be between 56.4°C to 61°C.  
 
3.2.2.2. Sanger sequencing and variant analyses 
The two and six exons of the coding region of NKX2-5 and GATA5, 
respectively, were sequenced via direct Sanger Sequencing (Chapters 2.4.1.2 
to 2.4.1.5). Briefly, PCR products were amplified using genomic DNAs of the 
study cohort on a DNA Engine Peltier Thermal Cycler. Following PCR product 
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purification process, they were DNA sequenced at the Macrogen Facility, South 
Korea, and analysed for sequence variants using Sequencher version 4.8 
(Gene Codes Corp, Ann Arbor, MI, USA). Upon identification, rare non-
synonymous variants were genotyped in our Control population, utilising the 
same method as described for the study cohort. Reference populations from the 
National Heart, Lung, and Blood Institute Exome Variant Server (NHLBI EVS) 
and 1000 Genomes project were used as additional controls.  
 
The following criteria were investigated for each non-synonymous variant to 
determine pathogenicity: (i) frequency of the variant in control alleles, in the 
NHLBI EVS and in the 1000 Genomes project; (ii) conservation level of the 
amino acid residue amongst protein orthologues and paralogues; (iii) in-silico 
prediction of pathogenicity using the on-line resource SIFT and/or PolyPhen2, 
which predict the possible impact of an amino acid substitution on the structure 
and function of a human protein on the basis of three dimensional structure and 
multiple alignment of homologous sequences. 
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3.3. RESULTS 
3.3.1. Study population characteristics 
Table 3.1 describes the clinical and valvular characteristics of the 100 unrelated 
patients with BAV who participated in the GATA5 and Nkx2-5 candidate genes 
screening. The group comprised 77% males with a mean age at diagnosis of 29 
± 22 years (range 0-63 years). BAV morphology was functionally bicuspid in 
53%, anatomically bicuspid in 17% and indeterminate in 30%. Of the 
functionally bicuspid group, 79.2% (n=42), 18.9% (n=10) and 1.9% (n=1) had 
non-separation of left and right (L-R), right and noncoronary (R-N), and left and 
noncoronary (L-N) leaflets, respectively. BAV was present in a first-degree 
relative in 13% of the cohort. Coexistent cardiovascular anomalies occurred in 
21%, and this was predominantly coarctation of the aorta. 
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Table 3. 1. Patient clinical and valvular characteristics. 
 Anatomically 
bicuspid 
Functionally 
bicuspid 
Indeterminate 
morphology 
Total 
n 17 53 30 100 
Male gender (%) 12 (70.6) 41 (77.4) 24 (80.0) 77 (77) 
Caucasian background (%) 14 (82.4) 45 (84.9) 26 (86.7) 85 (85) 
Mean age at diagnosis 32 ± 18 31 ± 22 25 ± 24 29 ± 22 
Abnormal valve function* (%)  10 (58.8) 28 (52.8) 13 (43.3) 51 (51) 
Concomitant aortopathy# (%) 12 (70.5) 32 (60.4) 15 (50.0) 59 (59) 
Concurrent CHD^ (%) 1 (5.9) 9 (17) 11 (36.7) 21 (21) 
Positive family history (%) 2 (11.8) 5 (9.4) 6 (20.0) 13 (13) 
 
 
*Aortic regurgitation of at least 2/4 in severity and/or aortic stenosis of at least 
moderate severity (defined as mean aortic gradient of ≥ 30mmHg and/or peak 
aortic velocity of ≥ 3.0 m/sec). 
#Aortic dilatation ≥ 40 mm, affecting any part of the aorta from sinus of Valsalva 
to proximal descending aorta. 
^Anatomically bicuspid group, 1 patient with coarctation of the aorta (CoA); 
Functionally bicuspid group, 5 patients with CoA, 1 patient with CoA and mild 
tricuspid valve dysplasia, 1 with supra-aortic ridge and supravalvular aortic 
stenosis, 1 with anomalous left coronary artery, 1 with Shone complex 
(including CoA) and inferior wall left ventricular non compaction; Indeterminate 
group, 6 patients with CoA, 1 with a small ventricular septal defect (VSD), 1 with 
aberrant right subclavian artery origin, 1 with a small patent foramen ovale, 1 
with CoA and primum atrial septal defect and 1 with CoA and muscular VSD.
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3.3.2. GATA5 screening 
PCR amplification and Sanger sequencing for the GATA5 gene screening was 
successfully performed on the DNA of the entire study cohort (Figure 3.3).  
 
 
Figure 3. 3. Example of a successful PCR amplification.  
Gel electrophoresis of GATA5 exon 1 PCR product in 11 out of the 100 study 
cohorts (S1-S11) showed the presence of a single bright and clean band at the 
expected product size (833bp), indicating a successful PCR amplification. PCR 
reaction was performed using 10% DMSO at 57°C annealing temperature (Ta). 
NC indicates negative control (no DNA template). 
 
The findings from the genetic analysis of GATA5 are summarised in Table 3.2. 
Sequencing of all 6 coding exons and splice signal sequences of GATA5 in the 
study cohort revealed 5 non-synonymous, 4 synonymous and 2 intronic 
variants. Of note, 4 non-synonymous variants, Gln3Arg, Ser19Trp, Tyr142His 
and Gly166Ser, were identified in one patient each (MAF = 0.005), and all were 
located in the transcriptional activator domains encoded by exon 1 of GATA5 
(Figure 3.4.A, 3.4.C). The clinical characteristics of the individuals harbouring 
these rare non-synonymous GATA5 variants are summarised in Table 3.3. 
These 4 variants were all found in male patients. Furthermore, genotyping 
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revealed that the c424T>C variation (rs111554140) causing the Tyr142His 
replacement and the c496G>A variation (rs141950357) causing the Gly166Ser 
were absent in 320 control alleles (Table 3.2). The c8A>G nucleotide variant 
(rs113068438) causing the Gln3Arg replacement, and the novel c56C>G 
variant causing the Ser19Trp replacement, were present in 2 out of 320 control 
alleles (MAF = 0.006).  
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3.3.3. Nkx2-5 screening 
PCR amplification and Sanger sequencing of the Nkx2-5 gene screening was 
also successfully performed on the DNA of the entire study cohort. Table 3.4 
summarised the result of the Nkx2-5 gene screening. 
 
Sequencing of the 2 coding exons and splice signal sequences of Nkx2-5 in the 
study cohort revealed 4 synonymous and 2 novel non-synonymous (missense) 
variants. The missense variants, namely c169G>T and c727G>T substitutions, 
resulted in Ala57Ser and Val243Leu replacements, respectively, and they were 
identified in one male patient each (MAF=0.005). These variants were located 
outside the homeobox-containing domain encoded by exon 2 of NKX2-5 (Figure 
3.5A, 3.5C).  
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3.4. DISCUSSION 
The present study investigated, for the first time, the relationship between 
GATA5 gene variations and BAV disease in 100 unrelated, non-syndromic, 
sporadic and familial cases of BAV, with or without its associated aortopathy. 
The study also investigated the correlation between Nkx2-5 gene variations and 
BAV disease within the same patient cohort. Whilst screening of Nkx2-5 failed 
to identify disease-causing mutations in the study cohort, analysis of the GATA5 
gene screening identified the presence of 4 rare non-synonymous variants 
located in the transcriptional activator domains I and II of GATA5, of which 3 
affected highly evolutionarily conserved amino acid residues. These non-
synonymous variants may alter the transcriptional activity of GATA5, and 
therefore may be important in the pathogenesis of BAV disease in humans.  
 
Specifically, the GATA5 Gln3Arg replacement was found in a Caucasian male 
patient aged 62 years with no family history of BAV, who was diagnosed with 
the condition at the age of 56 years, following detection of cardiac murmur 
during routine clinical screening. He had indeterminate BAV morphology that 
was mildly stenotic and associated with mild ascending aortic dilatation. The 
Gln3Arg replacement is present in 23 of 4894 EVS alleles and 2 of 320 control 
alleles. The Gln3 residue occurs within a highly conserved subdomain of 
transcriptional activation domain I of GATA5 gene, and is highly conserved 
amongst the GATA4/5/6 subfamily of vertebrates (Figure 3.4.B). Functional 
importance of the Gln3 residue, at least for GATA4, was demonstrated by its 
replacement with arginine in a construct containing GATA4 activation domain I, 
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which resulted in an 80% reduction in transcriptional activity of a reporter gene 
construct, supporting its pathogenic role (Morrisey et al., 1997). Further, the 
Gln3Arg variant is predicted to be damaging by in-silico analysis using both 
PolyPhen2 (score 0.891) and SIFT algorithms (score 0.001). 
 
The GATA5 Tyr142His replacement was found in a Caucasian male aged 58 
years with sporadic BAV that was due to non-separation of the left and right 
coronary cusps. He had an aortic valve replacement at age 28 years for severe 
aortic stenosis and, subsequently, ascending aortic replacement at age 58 
years for progressive ascending aortic aneurysm. The Tyr142His replacement 
is extremely rare, being present in only 3 out of 6596 EVS alleles (MAF 
0.00045) and is predicted to be ‘possibly damaging’ by PolyPhen2, with a 
Grantham score of 83. The Tyr142 residue is located in a conserved subdomain 
of transcription activation domain II and is highly conserved between GATA4 
and GATA5 of vertebrates (Figure 3.4.B, 3.4.C). Replacement of the equivalent 
tyrosine residue in GATA4 with alanine (Tyr162Ala), in a construct containing 
GATA4 activation domain II, resulted in a 60% reduction in transcriptional 
activity of a reporter gene construct (Morrisey et al., 1997). Together, the 
demonstration of a functional importance of Gln3 and Tyr162 of GATA4 strongly 
suggests that the rare non-synonymous variations at equivalent evolutionarily 
conserved positions in GATA5 (Gln3 and Tyr142) likely impact on 
transcriptional activation of GATA5 target regions and may well contribute to 
BAV development.  
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The novel GATA5 Ser19Trp variation causing the replacement of serine at 
residue 19 for tryptophan (Grantham Score 144) was found in a Caucasian 
male patient aged 28 years without a family history of BAV or other congenital 
heart disease and he had an indeterminate BAV morphology with only trivial 
regurgitation, and without associated aortopathy. The Ser19 residue is 
conserved amongst vertebrate GATA5 proteins, was present in 2 out of 320 
control alleles and 5 out of 4934 EVS alleles, and is predicted to be ‘probably 
damaging’ by PolyPhen2.  
 
The GATA5 Gly166Ser replacement was found in a male patient aged 27 years 
of South Asian background with a positive family history for BAV and 
associated aortopathy. He had a functional BAV due to non-separation of the 
left and right coronary cusps with normal hemodynamics and associated mild to 
moderate dilatation of his aortic root at 42mm. His 59-year old mother also had 
BAV with a left and right coronary cusps non-separation morphology, which was 
associated with mild aortic stenosis and mild to moderate dilatation of her mid 
ascending aorta of 43mm. Interestingly, she also shared the GATA5 Gly166Ser 
variant (Figure 3.6). Unfortunately, no other family members were available for 
testing at the time when this study was conducted. The Gly166Ser replacement 
was only present in 1 out of 6332 EVS alleles, however, the equivalent amino 
acid residue in Gata5 of chicken is also a serine (Figure 3.4.B).  
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Figure 3. 6. Family pedigree of the individual with GATA5 Gly166Ser 
variant with DNA sequence electropherograms showing that the variant 
was inherited from his affected mother. 
 
Meanwhile, screening of Nkx2-5 in this patient cohort revealed the presence of 
2 novel non-synonymous variants, namely Ala57Ser and Val243Leu. The Nkx2-
5 Ala57Ser variant was present in a 26 years old man, who had murmur 
detected at birth, and diagnosed with non-familial case of BAV at the age of 1. 
He subsequently had an aortic valve and ascending aortic replacement at 24 
years of age for moderately severe mixed aortic valve disease and a 50mm 
ascending aortic aneurysm. Inspection of the aortic valve at time of surgery 
revealed a true (anatomical) BAV with a right to left configuration. The Ala57 
residue is conserved amongst human, cattle, rhesus monkey and dog, however 
the equivalent amino acid residue in Nkx2-5 of mouse is also a serine (Figure 
3.5B). The Ala57Ser variant is predicted to be ‘benign’ by Polyphen2 and 
‘tolerated’ by SIFT, with a Grantham score of 99.  
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The NKX2-5 Val243Leu variation (Grantham score 32) was found in a 54 year 
old man, who at the age of 42 was diagnosed with a sporadic case of functional 
BAV, due to fusion of the right and left coronary leaflets, following an 
investigation of a murmur. He subsequently progressed to develop severe 
aortic stenosis, requiring an isolated aortic valve replacement at 53 years of 
age. He was noted to have mild dilatation of his ascending aorta at time of 
surgery and was placed on a yearly surveillance program post-operatively. The 
Val243 residue is a moderately conserved amino acid, although interestingly, 
the equivalent amino acid residue in Nkx2-5 of rat is also a leucine (Figure 
3.5B). The Val243Leu variant is predicted to be ‘benign’ by Polyphen2 and 
‘tolerated’ by SIFT.  
 
Of note, no other cardiovascular malformation was found in these 2 patients 
with the novel Nkx2-5 variants; specifically, there were no septal defects, 
conduction block or Tetralogy of Fallot. Both of these variants were located 
outside the homeobox-containing domain of NKX2-5. Therefore, the 2 non-
synonymous NKX2-5 variants found in the study are unlikely to be the disease-
causing variant in this patient cohort. However, study on Nkx2-5 heterozygous 
mutant mice model had shown that the presence of BAV in the Nkx2-5 
haploinsufficient mice was strictly dependent on genetic background, being 
exclusively found in the C57B1/6 strain (Biben et al., 2000). This suggested the 
presence of another genetic modifier to influence BAV development. Therefore, 
it is entirely plausible that NKX2-5 may still play a role as a modifying factor that 
can induce BAV development in certain genetically susceptible individuals.  
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During this candidate gene study, the NOTCH1 (34 exons, coding a protein of 
2,555 amino acids) and GATA4 genes (6 exons, coding a protein of 442 amino 
acids) were also screened within a small subgroup of these patients (n=14-15). 
However, no disease-causing variants were found during the screening process 
(data not shown). 
 
Overall, there is substantial evidence for a genetic basis to BAV, representing 
anomalies in cardiac development (Cripe et al., 2004, Hinton and Yutzey, 
2011). Yet, the exact mechanisms underlying the pathogenesis of BAV remain 
unclear. Recently, Laforest et al. reported that targeted deletion of Gata5 in 
mice leads to partially penetrant BAV formation, particularly of the R-N 
morphology, thus implicating GATA5 in aortic valve formation (Laforest et al., 
2011). In contrast to GATA4 and GATA6, which are expressed in cardiac 
myocytes and other regions of the heart, GATA5 transcripts in the heart are 
largely restricted to transient expression during embryogenesis in endocardial 
cells and endocardial cushions of the outflow tract and atrioventricular canal 
(Laforest et al., 2011, Laforest and Nemer, 2011). Nevertheless, evidence 
suggests that GATA5 and the 2 other cardiac GATA factors interact during 
endocardial cushion formation and outflow tract remodelling, and together with 
other families of cofactors, work synergistically to regulate gene expression 
during cardiac morphogenesis (Laforest and Nemer, 2011, Peterkin et al., 2005, 
Holtzinger and Evans, 2007).  Importantly, GATA5 regulates several pathways 
involved in endocardial cell differentiation, including those directed by Bmp4, 
Tbx20, and, notably, NOS3 and NOTCH1 (Laforest et al., 2011). Of interest, 
deficiency of NOS3 and mutation of NOTCH1 genes have been associated with 
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BAV development in mice and human, respectively (Garg et al., 2005, Lee et 
al., 2000, Mohamed et al., 2006).  
 
In this study, 3 out of the 4 patients with the rare non-synonymous GATA5 
variants (Gln3Arg, Ser19Trp and Gly166Ser) have rather modest clinical 
pathology. Moreover, there is an observed discrepancy between the severity of 
the clinical manifestation of BAV disease in patients with the Gln3Arg and 
Tyr142His variants and the degree of transcriptional down-regulation in the 
related GATA4 reporter gene construct. Specifically, Tyr142His variant was 
associated with a more severe clinical phenotype albeit less marked reduction 
of GATA4 reporter gene construct transcriptional activity and the vice versa was 
noted with Gln3Arg variant. These observations can probably be explained by 
the presence of genetic heterogeneity in BAV disease, where involvement of 
mutations in diverse genes encoding transcription factors, extracellular matrix 
proteins and various cellular signalling pathways likely to play a contributory 
role in disease development and manifestations (Garg, 2006, Martin et al., 
2007, Ward, 2000). Epigenetic factors, such as micro-RNAs (Nigam et al., 
2010), and environmental influences, such as mechanical shear stress, blood 
pressure and cholesterol level, are also likely to be important in modulating BAV 
disease phenotype, hence contributing to the wide spectrum of disease 
expression. Another explanation for the discrepancy observed between the 
clinical phenotype and the transcriptional activity of GATA4 reporter gene 
construct was that the later study was performed within a cell culture system. 
Therefore, although these findings are suggestive and important, they may not 
be directly translatable to the changes found in-vivo. 
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Following our report (Padang et al., 2012a), the role for GATA5 in human BAV 
disease was further supported by 2 more recent studies. During the screening 
of 110 unrelated BAV cohorts, Shi et al. identified 2 novel heterozygous GATA5 
loss-of-function mutations, Tyr16Asp and Thr252Pro, each occurring in a 
familial case of BAV (Shi et al., 2014). Functional assays revealed that these 2 
mutations significantly reduced the transcriptional activity of GATA5, compared 
with their wild-type counterpart, hence supporting their pathogenic role (Shi et 
al., 2014). Very recently, Bonachea et al. also reported the presence of 2 rare 
heterozygous non-synonymous GATA5 variants during screening of their 78 
BAV cohort, namely Leu233Pro and, notably, Gln3Arg variant (Bonachea et al., 
2014 [Epub ahead of print]). The Gln3Arg variant was found in a male patient 
with BAV and coarctation of the aorta. Providing further support to our findings, 
the pathogenicity of the Gln3Arg variant was strengthened by their in-vitro 
transfection assay, where Gln3Arg variant resulted in a 10-fold reduction of the 
transcriptional activity of GATA5 (Bonachea et al., 2014 [Epub ahead of print]). 
Overall, these studies support our finding on the potential pathogenic role of 
rare non-synonymous GATA5 mutations in human BAV development. 
 
The current study included a group of BAV patients with a mixed morphology, 
with only 10% having a R-N BAV morphology. Since Gata5 deletion in mice 
resulted in R-N BAV, the role of GATA5 may be greater in a cohort of BAV 
patients with a higher proportion of R-N BAV morphology. Further, while the 
control cohort used in the study consisted of individuals without any reported 
heart disease, many have not had echocardiographic examination to exclude 
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BAV, including those control subjects with the Gln3Arg and Ser19Trp. This 
highlights the importance of well-defined control populations, particularly for 
common disorders such as BAV, and especially in the current era of next 
generation sequencing of very large cohorts lacking phenotypic data, such as 
the 1000 Genomes project and EVS, where the discovery of rare sequence 
variations of unknown significance confounds efforts to determine 
pathogenicity. 
 
In conclusion, this candidate gene study supports a role for rare non-
synonymous variations within the highly conserved and functionally important 
GATA5 transcriptional activation domains in the pathogenesis of BAV disease 
in humans. It remains uncertain however if these variants are directly causal or 
serving as critical genetic modifiers where additional genetic or environmental 
factors are required to produce the disease phenotype. Further studies to 
assess the functional consequences of rare non-synonymous GATA5 variants 
in patients with BAV and its associated aortopathy are therefore warranted.  
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4.1. INTRODUCTION 
The impetus for a candidate gene approach, as described in chapter 3, is a 
prior knowledge of potential involvement of the candidate gene(s) in the 
pathogenesis of disease of interest (Marian, 2012). Over the past few decades, 
this technique has been used successfully in identifying a number of single 
gene defects in patients with isolated or nonsyndromic congenital heart disease 
(CHD). For example, identification of GATA4 mutations in families with isolated 
atrial septal defects (Garg et al., 2003), GATA6 mutations in patients with 
truncus arteriosus (Kodo et al., 2009), and the discovery of the relationship 
between TBX5 and TBX20 gene variants in those with septal and valve defects 
(Reamon-Buettner and Borlak, 2004, Kirk et al., 2007). These studies highlight 
that screening high-risk kindred from a large family with multiple affected family 
members can lead to the discovery of pathogenic gene variants (Arrington et 
al., 2012). 
 
However, whilst candidate gene screening has identified causative mutations in 
a number of conditions, this technique has had limited success for many other 
types of CHD (Arrington et al., 2012), including bicuspid aortic valve (BAV) 
disease. The plausible explanations include knowledge that many genes are 
involved in cardiac development (genetic heterogeneity) and each represents a 
candidate for disease; causative mutation(s) may be found in introns or 
regulatory regions that are not typically screened in a candidate gene study; 
and a wide spectrum of disease phenotypes is seen in BAV, even within the 
same family, suggesting BAV may result from the cumulative effect of many 
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partially penetrant variations, i.e. a complex genetic trait, as well as the likely 
presence of genetic modifier loci. Adding to the complexity, at the epigenetic 
level, histone modifications and chromatin remodelling may have substantial 
roles in BAV development by activating or silencing gene expression, whilst 
microRNAs might promote development of BAV by post-transcriptional 
regulation of gene expression. Therefore, alternative approaches may be more 
fruitful to identify causative genetic variants that are responsible for BAV 
development. One successful example is linkage analysis in a large multi-
generation family affected by congenital heart disease and valve calcification 
that led to the identification of mutations in NOTCH1 as a cause of aortic valve 
disease.  
 
Relatively recently, whole genome sequencing has emerged as a method to 
interrogate every nucleotide variation in the genome, however, this is currently 
cost-prohibitive and poses a significant bioinformatics challenge for many 
laboratories. Presently, an alternative and more preferable method is whole-
exome sequencing, which targets a small proportion of the genome at a 
significantly lower cost and simpler bioinformatics burden. Exome sequencing 
offers a powerful unbiased strategy to survey the entire protein-coding region 
(i.e. exons) of the human genome, without consideration for existing data to 
implicate any particular gene in the disease pathogenesis. Although exons 
constitute only ~1% of the human genome, approximately 85% of highly 
penetrant mutations in Mendelian disorders reside within these functional 
regions (Choi et al., 2009). Therefore, exome sequencing has the great 
potential to identify novel, unanticipated pathogenic gene variants in BAV 
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disease. Application of the whole-exome sequencing approach on a well-
characterised multi-generation family with multiple affected family members with 
BAV may be very useful in delineating the genetic basis of BAV disease, where 
the pathogenicity of a putative mutation can be robustly validated by 
demonstrating co-segregation with disease.  
 
Another approach to identify genes that are involved in the development of BAV 
is comparative analysis of mRNA expression levels in normal and diseased 
tissue, either using microarray hybridisation analysis, or more recently, analysis 
of RNA transcripts using next generation sequencing, i.e. RNASeq, as 
described in Chapter 5. 
 
This chapter describes whole-exome sequencing analyses of 2 large families of 
Caucasian background with preponderance for BAV and its associated 
aortopathy. 
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4.2. METHODS 
4.2.1. Study population 
4.2.1.1. Familial cases of BAV (Families A and B) 
Between July 2011 and October 2012, two large families with highly penetrant 
cases of BAV were identified (Family A and Family B). All members of the 
families were invited to participate in the exome sequencing study. Following 
informed consent, participating family members underwent clinical evaluation 
that included 2D-echocardiography and had their blood samples, or, in cases of 
young children (less than 5 years old), saliva collected for DNA isolation. 
Medical records, when available, were reviewed for demographic, clinical and 
surgical data.  
 
4.2.1.2. BAV validation cohort 
Patients with sporadic and nonsyndromic cases of BAV were recruited in 
parallel, as described in Chapter 2.3.1. The study protocol was approved by the 
Sydney South West Area Health Service ethics committee. 
 
4.2.2. Exome sequencing 
4.2.2.1. Library construction and sequencing 
Exome sequencing (library construction, capture and sequencing) was carried 
out at the Macrogen Facility, South Korea, on 3 related DNA samples from each 
family. These belonged to affected family members III:2, IV:3 and IV:5 from 
Family A (Figure 4.1) and affected family members III:3, III:8 and V:10 from 
Family B (Figure 4.2). The process of library construction, capture and 
sequencing are detailed in Chapter 2.4.3.1.  
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While exome sequencing was always attempted on 3 most distantly related 
affected individuals in the family, selection of these individuals (Individuals III:2, 
IV:3 and IV:5 from Family A and Individuals III:3, III:8 and V:10 from Family B) 
was made based on the available list of enrolled family members at the time of 
exome sequencing and the availability of high quality DNA that was suitable for 
sequencing. 
 
4.2.2.2. Bioinformatics and variants analysis 
Raw exome sequencing data were processed using a bioinformatics pipeline 
developed by Dr Richard Bagnall of the Molecular Cardiology Program, 
Centenary Institute, as described in Section 2.4.3.2. This pipeline deposits 
single nucleotide variants (SNV) and insertions/deletions (InDels) for each 
individual patient in a database, with annotations against various genomic 
features. These annotations included chromosome position, gene description, 
dbSNP rsIDs number, genomic evolutionary rate profiling (GERP) score, variant 
location (i.e. exonic, intronic, splice site, 5’ UTR, 3’ UTR, intergenic), 
consequence (i.e. missense, synonymous, stop, frameshift, insertion/deletion, 
etc), several protein annotations (i.e. amino acid substitution and protein 
domain), predicted physiochemical dissimilarities of the replaced codons 
(Grantham score), predictions of possible pathogenicity of an amino acid 
substitution (by Polyphen (Family A) or PolyPhen2 (Family B)), and minor allele 
frequency (MAF) in the 1000 Genomes data and 6500 exomes of the NHLBI 
Exome Sequencing Project (EVS). 
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Variant analysis was performed by retrieving variations from the database with 
the principal assumptions that: 
1. BAV is caused by an autosomal dominant mutation that is both sufficient 
and necessary to cause disease 
2. The causal variant will affect a protein-coding DNA sequence or 
canonical splice signal sequence 
3. The causative mutation will occur at a frequency of no more than 1% in 
publically available data of control populations.  
Based on these postulations, the subsequent variant prioritisation was carried 
out using the following criteria: (i) heterozygous variants present in all 3 exome 
sequencing samples of affected individuals within each family; (ii) the novelty of 
the variants by excluding those that were present in the in-house exome 
dataset of unrelated individuals with different phenotype (4 samples during 
Family A study and subsequently 96 samples during Family B study) and those 
with MAF of >1% in the 1000Genome Project, the dbSNP, and the EVS 
database; (iii) the putative pathogenic effect of the gene variants by excluding 
synonymous, intronic or intergenic variants and by including those with non-
synonymous missense, nonsense, splice-site gain- or loss-of-function variants 
and frame-shift insertion or deletion mutations; (iv) a positive GERP 
conservation score; (v) the presence of aortic valve expression of the genes 
which harboured the variants. These putative disease-causing variants were 
inspected manually using the Integrative Genome Viewer (IGV) visualisation 
tool to examine the overall quality and coverage of the aligned sequence reads 
at the variant site (Figure 4.3). Variants that fulfilled these criteria were then 
considered for validation and co-segregation analysis.  
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4.2.3. Co-segregation study  
Once a variant that fulfilled quality filters was identified, all participating family 
members were genotyped to determine the pattern of variant segregation by 
means of standard Sanger sequencing, as described in Chapters 2.4.1.2 to 
2.4.1.5. Appendix 1, Table I-2 and I-3, listed the primer sequence and PCR 
conditions used in variant segregation analysis for Family A and Family B, 
respectively. Assistance was obtained from Miss Annie Evans, research 
assistant in The Molecular Cardiology Program, Centenary Institute, in 
screening the last 20 variants from Family A, as listed on Appendix 1, Table I-2. 
Validated variations obtained from screening of family members were 
considered as a candidate mutation if the non-reference allele co-segregated 
completely with the disease phenotype and was excluded if it was not observed 
to co-segregate with BAV. 
 
As enrolment of family members in Family A and B occurred sporadically over 2 
to 2.5 years, some individuals were recruited only after the initial co-segregation 
analysis. If a family member was recruited after a variant had been excluded 
from the initial co-segregation study (based on the absence of variant in an 
affected family member recruited earlier who were not exome sequenced), then 
determination of the status of the variant in the later recruited individual was 
deemed unnecessary. Similarly, in the case of sequencing failure, should a 
variant be excluded due to its absence in an affected family member, then the 
failed sequencing attempt was not repeated. In both scenarios, the status of the 
individual was marked “not determined (ND)”. 
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4.2.4. Candidate mutation gene screening in unrelated sporadic BAV 
cohort 
Remaining variants that fulfilled the criteria as candidate mutations were 
reviewed for the available literature, associated gene pathways and molecular 
regulation, levels of gene expression on aortic valve RNA-sequencing data 
(Chapter 5), and existing animal models. The primary candidate gene was then 
selected for direct gene screening in a cohort of 130 unrelated sporadic BAV, 
using method described in Chapters 2.3.1.2 to 2.4.1.5. The aim was to evaluate 
whether there was a higher rate of rare non-synonymous variants within the 
gene of interest amongst the BAV cohort compared to the background 
sequence variation rate amongst the NHLBI EVS European American ‘control’ 
population, which consists of sequence variation data on 4298 exomes. A 
higher rate of rare non-synonymous sequence variation amongst the BAV 
cohort supports the likely importance of the candidate genes in the 
pathogenesis of BAV.  
 
4.2.5. Linkage analysis and screening of poorly covered region in exome 
sequencing 
Genome-wide linkage analysis was performed in Family A, with the assistance 
of Dr Richard Bagnall. Briefly, a genome-wide SNP genotyping array was 
performed at the Australian Genome Research Facility (AGRF, Victoria, 
Australia) utilising the Illumina Cyto-12 BeadChip panel (Illumina, San Diego, 
CA, USA), which consisted of over 200,000 SNP markers. Twelve individuals 
from Family A (II:6, III:2, III:6, III:8, III:12, IV:3, IV:5, IV:10, IV:12, V:1, V:2 and 
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V:7) were genotyped regardless of their clinical status. Linkdatagen was used to 
generate linkage analysis input files for MERLIN using the raw genotype calls 
from the Illumina SNP arrays. Multipoint nonparametric linkage analysis was 
then performed using MERLIN (version 1.1.2). Logarithm of odd ratio (LOD) 
scores were calculated for each marker assuming an autosomal dominant 
mode of inheritance with 70% disease penetrance, a disease allele frequency of 
0.01 and absence of phenocopies. Haplotypes were constructed assuming a 
minimum number of recombination and viewed using Haplopainter. 
 
Identified regions with suggestive linkage (LOD scores ≥ 1.5) were then 
manually inspected using IGV browser to look for regions with poor coverage 
on exome sequencing (i.e. exon regions with less than 10 read-depths). These 
regions were then manually sequenced by means of Sanger sequencing, as 
described in Chapters 2.4.1.2 to 2.4.1.5, and analysed for the presence of 
plausible disease-causing variants, using the same criteria detailed in Chapter 
4.2.2.2. 
 
4.2.6. Statistical analysis 
All data are expressed as mean ± standard deviation (SD). Statistical analysis 
to determine non-random associations between 2 categorical variables was 
performed with Fisher’s exact test.  A two-tailed p-value ≤ 0.05 was considered 
statistically significant. Statistical analyses were performed using GraphPad 
Prism Version 6.0b (GraphPad Software, La Jolla, California, USA). 
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4.3. RESULTS 
4.3.1. FAMILY A 
4.3.1.1. Family A Pedigree and individual characteristics 
The family was of Caucasian background and the pertinent clinical information 
of participating family members are summarised in Figure 4.1 and Table 4.1. 
The proband (Individual IV:5) was a 41 years old man from rural NSW, who was 
diagnosed with a moderately stenotic BAV at the age of 34 years following 
investigation of a murmur. He was also detected to have enlargement of his 
ascending aorta at the time of BAV diagnosis. Over the subsequent 7 years, he 
developed progressive enlargement of his aorta, which was associated with 
intermittent chest pains, triggering a surgical evaluation for his condition and 
subsequent operative intervention. Of note, proband has 3 offspring, all of 
whom were born with congenital cardiac defect(s). This included simple atrial 
septal defect (Individual V:6), BAV (Individual V:7) and hypoplastic left heart 
syndrome, which resulted in the untimely death of Individual V:5 at 3 weeks of 
age. DNA was available for 13 of these individuals and used in the co-
segregation study.  
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Table 4. 1. Clinical characteristics of recruited family members of Family A. 
Pedigree 
position Gender 
Current 
age 
(years) 
Valve 
Type 
Age at 
diagnosis 
(years) 
BAV 
Function Comments 
II:6 Male 90 TAV - - Clinically unaffected  
III:2 Male 69 BAV 57 Severe AS Dilated ascending aorta; AVR age 60  
III:6 Female 65 BAV 20 Moderate AS 
Mild ascending aorta 
and aortic root dilatation 
III:8 Male 63 BAV (R-L) 52 
Mild to 
Moderate 
AR 
No associated 
aortopathy 
III:12 Male 55 TAV - - Clinically unaffected 
III:13 Female 64 TAV - - Clinically unaffected 
IV:3 Female 44 BAV 19 Severe AS Dilated ascending aorta; AVR age 29 
IV:5 Male 41 BAV (R-N) 34 
Moderate 
AS 
Moderate to severely 
dilated ascending aorta; 
AVR and aortic 
replacement age 41 
IV:7 Female 43 TAV - - Clinically unaffected 
IV:10 Female 49 TAV - - Clinically unaffected 
IV:12 Female 41 TAV - - 
Previous infective 
endocarditis with 
subsequent AVR age 31 
V:1 Male 20 TAV - - Clinically unaffected 
V:2 Male 12 TAV - - Clinically unaffected 
V:5 Male Deceased  BAV 3 weeks of age Unknown 
HLHS; died 3 weeks of 
age 
V:6 Female 7 TAV At birth - 
Small ASD diagnosed at 
birth; conservative 
management 
V:7 Male 5 BAV At birth Trivial AR No associated aortopathy 
n/a, not applicable; AVR, aortic valve replacement; TAV, tricuspid (tri-leaflet) 
aortic valve; BAV, bicuspid aortic valve; AS, aortic stenosis; AR, aortic 
regurgitation; R-N, right and non coronary cusps fusion BAV morphology; R-L, 
right and left coronary cusps fusion BAV morphology; HLHS, hypoplastic left 
heart syndrome; ASD, atrial septal defect. 
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4.3.1.2. Exome sequencing analysis and plausible variants list 
Exome sequencing was performed on DNA samples from Individuals III:2, IV:3 
and IV:5 from the pedigree depicted in Figure 4.1. An average of 59,370,400 
reads were generated for each individual sample and an average of 52,780,300 
reads (89.9%) were mapped uniquely to the genome. Approximately 86.5% of 
target exome regions received more than 10 sequence reads and an average of 
48 reads per target base pair was achieved for each exome. Following base 
identification and variant calling, each individual had an average of 67,200 
SNVs. After multiple filtering steps (Figure 4.4), 90 plausible disease-causing 
variants were shared amongst the 3 individuals. Moreover, there was an 
average of 489 coding InDels for each individual, 278 of which were shared. 
After similar filtration steps, removal of duplicate variant calls of InDels with 
multiple accessions ID numbers, and direct visualisation on IGV, 3 InDels were 
included for further analysis. Appendix II, Table II-1 described the 90 prioritised 
and filtered variants and the 3 InDels, which were included in the co-
segregation analysis. 
 
4.3.1.3. Co-segregation study of Family A 
All these prioritised variants and InDels were subsequently analysed for their 
pattern of co-segregation with BAV disease amongst 13 participating family 
members. Apart from those who were exome sequenced, they included those 
who also had BAV and/or the associated aortopathy (III:6, III:8, and V:7) and 
those with normal trileaflet aortic valve (II:6, III:13, IV:7, IV:10, IV:12, V:1 and 
V:2). The result of the segregation analysis of variants performed is 
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summarised in Table 4.2. There were 13 variants that co-segregated with BAV 
disease phenotype within the family. However, based on the aortic valve RNA 
sequencing study (Chapter 5), UGT3A1, GPR98, LMOD2 and B7H6 genes are 
either not expressed or have extremely low level of expressions within the aortic 
valve (FKPM <0.03) and therefore they were filtered out from subsequent 
analysis. The 9 remaining putative disease-causing missense variants (i.e. 
candidate gene mutations) are listed in Table 4.3 
 
 
Figure 4. 4. Filtering steps used to analyse the SNVs obtained from Family 
A exome sequencing result.  
SNV, single nucleotide variations; FKPM, Fragments per Kilobase of transcript 
Per Million mapped reads (of RNA sequencing data), which is proportional to 
the level of expression of the gene of interest within the tissue sample studied. 
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As shown in Table 4.2, candidate gene variants appeared to segregate in an 
autosomal dominant pattern with incomplete penetrance in Family A.  
 
4.3.1.4. Linkage analysis and regions with poor coverage  
As mentioned previously, an average of 13.5% of target exome had inadequate 
coverage amongst the 3 exome sequencing samples, with less than 10 reads 
per target base pair. Meanwhile, genome wide linkage analysis of Family A 
identified 3 regions of suggestive linkage (LOD > 1.5), 2 on chromosome 5 and 
1 on chromosome 9 (Figure 4.5).  
 
Figure 4. 5. Multipoint LOD scores from linkage analyses of Family A. 
 
Concentrating on these 3 areas with the highest linkage peaks and the regions 
with poor coverage, a total of 507 exonic regions were identified to have 
inadequate coverage in at least 1 exome sequencing sample. Manual 
inspection of these regions using IGV browser confirmed 24 regions with either 
incomplete or absence of coverage in all 3 exome samples. These regions were 
later directly screened by Sanger sequencing, using proband’s DNA, to look for 
the presence of plausible causative gene variants and the results are 
summarised in Table 4.4.  
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Screening of these 24 poorly covered exome sequenced regions on the 
proband (Individual IV:5) revealed the presence of 2 rare non-synonymous 
SNVs (MAF < 1%), namely WDR34 Trp60Gly and ADAMTSL2 Val364Ile. 
Genotyping of the WDR34 variant, which resulted from c178T>G variation 
(rs4837292) on the proband revealed that the proband was in fact homozygous 
for the alternate allele. Further, WDR34 c178T nucleotide is a poorly conserved 
nucleotide, which codes for a poorly conserved amino acid Tryptophan at 
position 60, and this substitution is predicted to be functionally tolerated by 
SIFT. Similarly, ADAMTSL2 Val364Ile variant resulted from c1090G>A 
substitution (rs35767802) which was a poorly conserved nucleotide. Further, 
Valine at position 364 were found to be weakly conserved amino acid and its 
substitution to Isoleucine resulted in small physiochemical difference and was 
also predicted to be functionally tolerated by SIFT. Therefore, both variants 
were unlikely to be the causative variants in this family and they were excluded 
from further analysis. 
  
4.3.1.5. Plausible candidate gene (GDNF) screening in unrelated sporadic 
BAV cohort 
Following review of the literature on the candidate genes listed in Table 4.3, the 
gene GDNF (glial cell line-derived neurotrophic factor) was high on the list of 
possible causal variants in this family with BAV as it appeared to have 
functional relevance to BAV pathogenesis. It was therefore selected for 
screening amongst an unrelated sporadic BAV cohort. The clinical 
characteristics of the 130 individuals, which made up this cohort, are described 
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in Table 4.5. The group comprised of 81% males of predominantly Caucasian 
background, with a mean age of 42 ± 14 years. Most (84%) were diagnosed 
with BAV by the age of 40 years or earlier. BAV was present in a first-degree 
relative in 16% of cohort and BAV-related aortopathy was present in nearly 
three-quarters of the cohort. 
 
Table 4. 5. Clinical characteristics of 130 unrelated BAV cohort.  
n = 130 unrelated BAV cohort 
Male gender 105 (81%) 
Current age, mean (range) 42 ± 14 (20-68) years 
67% aged ≤ 50 years 
Age at diagnosis Range: 0-55 years 
84% diagnosed ≤40 years old 
Genetic background 90% Caucasian 
Positive family history of BAV 21 (16%) 
Associated aortopathy 73% 
Coexisting CHD 26% - majority were CoA (79%) 
Cardiovascular events 71% of patients had at least 1 surgery for BAV, the 
related aortopathy and/or associated CHD  
CHD, congenital heart disease; CoA, coarctation of the aorta 
 
Appendix I, Table I-4 listed the primers sequences and corresponding PCR 
conditions used during GDNF gene screening. Table 4.6 summarises the 
combined findings from the genetic analysis of the GDNF gene in this cohort 
and Family A. Sequencing of all the 5 exons and splice signal sequences of 
GDNF, which made up all of its 7 transcripts, revealed 2 non-synonymous 
(missense) variants, 1 synonymous variants, 2 intronic variants and 3 variants 
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in the 5’UTR (Figure 4.6). The Arg93Trp variant was identified exclusively in 
Family A. Meanwhile, the novel Gly105Arg variant was found in a 39 year-old 
unrelated male patient, who was diagnosed with BAV with a right and left 
coronary cusp fusion morphology at the age of 2, following investigation of a 
childhood murmur, and had an associated mild ascending aortic dilatation. 
 
Therefore, GDNF screening in the 130 unrelated patient cohort revealed an 
overall 0.8% rate for the presence of rare non-synonymous (missense) GDNF 
variants in BAV. This rate was comparable to the 1.3% background noise of 
rare non-synonymous variants that are present in the European American EVS 
control cohort (p-value = 0.378 by Fisher’s exact test).  
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Figure 4. 6. Diagrammatic representation of all the GDNF variants found 
during screening of the 130 unrelated BAV cohort and Family A.  
GDNF has 7 transcripts or splice variants (GDNF-001, -201, -004, -002, -003, -
005 and -006) and 5 exonic regions as depicted in the figure above. The exon 
box shaded in blue represented the 5’- and 3’-UTR and the box shaded in 
maroon colour represent the coding exon regions. The positions of the variants 
found during the screening process were marked with dotted lines. Red asterisk 
marked the rare non-synonymous GDNF variant found in Family A 
(rs36119840).  
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4.3.2. FAMILY B 
4.3.2.1. Family B Pedigree and individual characteristics 
The family was of Caucasian background and the pertinent clinical information 
of participating family members are summarised in Figure 4.2 and Table 4.7. Of 
note, the proband (Individual III:3) has an identical twin brother (Individual III:2) 
who also has been diagnosed with BAV and ascending aortic aneurysms 
following family screening. Unfortunately, he declined participation into the 
study and no contact could be made to allow screening of his offspring. 
Alarmingly, the family has a strong history of sudden unexpected death 
affecting males in the earlier 2 generations, mostly occurring in their late 40s or 
early 50s. Unfortunately, due to the geographical remoteness at the time of their 
deaths, no autopsies were ever performed to clarify the exact cause of their 
deaths. Further, based on Family B’s pedigree, heritability of BAV appeared to 
run in autosomal dominant condition with incomplete penetrance, with 
Individuals IV:10 and IV:11 acting as an obligate carrier for the condition. The 
second offspring of Individual IV:10 (i.e. V:10) was born with critical aortic 
stenosis at birth secondary to BAV. He required a percutaneous balloon aortic 
valvuloplasty to relief the critical obstruction immediately after birth, followed by 
a Ross procedure at 6 weeks of life to treat his condition. Of interest, Individual 
IV:11 reported a history of WPW syndrome and his third offspring (V:14) was 
born with complex CHD, which included septal defects, BAV, coarctation of the 
aorta and patent ductus arteriosus.  
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Table 4. 7. Clinical characteristics of recruited family members of Family B. 
Pedigree 
position Gender 
Current 
age 
(years) 
Valve 
Type 
Age at 
diagnosis 
(years) 
BAV 
Function Comments 
III:3 Male 52 BAV (R-L) 51 Mild AS 
Severe ascending aortic 
aneurysm; AVR and aortic 
replacement age 52 
III:8 Male 44 BAV (R-L) 33 Mild AR Mild aortic root dilatation 
IV:9 Female 31 TAV - - Clinically unaffected 
IV:10 Male 31 TAV - - Clinically unaffected 
IV:11 Male 29 TAV - - History of WPW syndrome 
IV:13 Female 27 TAV - - Clinically unaffected 
V:9 Male 6 TAV - - Clinically unaffected 
V:10 Male 4 BAV At birth Critical AS 
Critical AS at birth; had 
PBAV followed by Ross 
procedure at 6 weeks 
V:14 Female 2 BAV At birth Mild AS Complex CHD (ASD, VSD, BAV, CoA, PDA) 
n/a, not applicable; AVR, aortic valve replacement; TAV, tricuspid (tri-leaflet) 
aortic valve; BAV, bicuspid aortic valve; AS, aortic stenosis; AR, aortic 
regurgitation; R-N, right and non coronary cusps fusion BAV morphology; R-L, 
right and left coronary cusps fusion BAV morphology; CHD, congenital heart 
disease; ASD, atrial septal defect; VSD, ventricular septal defect; CoA, 
coarctation of the aorta; PDA, patent ductus arteriosus; PBAV, percutaneous 
balloon aortic valvuloplasty; WPW, Wolf-Parkinson-White syndrome. 
 
4.3.2.2. Exome sequencing result and variants list 
Exome sequencing was performed on DNA samples from Individuals III:3, III:8 
and V:10 from the pedigree depicted in Figure 4.2. An average of 62,062,000 
reads were generated for each individual sample and an average of 59,538,100 
reads (95.9%) were mapped uniquely to the genome. Approximately 90.6% of 
target exome regions received more than 10 sequence reads and an average of 
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57 reads per target base pair was achieved for each exome. Following base 
identification and variant calling, each individual was identified to have an 
average of 75,315 SNVs. After multiple filtering steps (Figure 4.7), 32 plausible 
disease-causing variants were shared amongst the 3 individuals. Appendix II, 
Table II-2 described the 32 prioritised and filtered variants, which were included 
in the co-segregation analysis. 
 
 
Figure 4. 7. Filtering steps used to analyse the SNVs obtained from Family 
B exome sequencing result.  
SNV, single nucleotide variations. 
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4.3.2.3. Co-segregation study of Family B 
Prioritised variants were subsequently analysed for their pattern of co-
segregation with BAV disease amongst 8 participating family members. Apart 
from those who were exome sequenced, they included the child with BAV and 
other complex CHD (V:14) and those with phenotypically normal tri-leaflet aortic 
valve (IV:10, IV:11, IV:13 and V:9). The result of the segregation analysis of 
variants performed is summarised in Table 4.8. Table 4.9 lists the 14 remaining 
plausible missense variants (i.e. candidate gene mutations), which co-
segregated with BAV disease amongst the 8 family members studied. 
 
Table 4. 8. Variant co-segregation analysis of Family B. 
Gene 
Name Variant 
BAV 
TAV TAV 
 
“NORMAL” OBLIGATE CARRIER 
III:3 III:8 V:10 V:14 IV:10 IV:11 IV:13 V:9 
ZNF226   Thr358Met HET HET HET HET HET HET WT HET 
ZNF226  Val83Glu HET HET HET HET HET HET WT HET 
TTF2  Arg838His HET HET HET HET ND ND WT WT 
DENND2C  Ser687Phe HET HET HET HET HET HET WT WT 
DMKN   Val135Leu HET HET HET HET HET HET WT HET 
DMKN   Thr230Met HET HET HET HET HET ND WT HET 
SMG5  His100Gln HET HET HET HET HET HET WT WT 
RAB3A  Tyr65Cys HET HET HET HET HET HET WT HET 
ZDHHC19  Arg224Gly HET HET HET HET HET HET WT HET 
ETV4  Ala426Val HET HET HET HET HET HET WT WT 
ZNF234  Gly602Glu HET HET HET HET HET ND WT HET 
BZRAP1  Glu1154Asp HET HET HET HET HET HET WT WT 
ERBB2   Arg4Trp HET HET HET HET HET HET WT WT 
BRIP1  Asn955His HET HET HET HET HET HET WT WT 
COL6A6  Gly1075Ala HET HET HET WT HET ND WT HET 
SVIL  Ala765Val HET HET HET WT HET ND HET HET 
RBM45  Arg137Trp HET HET HET WT HET WT WT WT 
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Table 4.8. continued 
Gene 
Name Variant 
BAV 
TAV TAV  
“NORMAL” OBLIGATE CARRIER 
III:3 III:8 V:10 V:14 IV:10 IV:11 IV:13 V:9 
SERINC3  Val249Ile HET HET HET WT HET WT ND HET 
KIAA1257  Asp68Tyr HET HET HET WT HET WT HET HET 
ACVR1C  Asn100His HET HET HET WT HET WT WT WT 
DEFB124  Glu71Lys HET HET HET WT HET WT WT HET 
BRD7  Lys328Arg HET HET HET WT HET WT HET WT 
FAM198B  Gly141Glu HET HET HET WT HET HET HET ND 
POLE4  Asp117Gly HET HET HET WT HET ND ND WT 
FUK  Pro392Arg HET HET HET WT HET HET HET WT 
SEMA5B  Gly699Glu HET HET HET WT HET WT HET HET 
MYH7B  Glu372Gly HET HET HET WT HET WT WT HET 
MLKL  Leu10Arg HET HET HET WT HET HET HET WT 
TIAM2  Gly595Ala HET HET HET WT HET ND WT HET 
WTAP  His360Arg HET HET HET WT HET WT WT HET 
ASPG  Ala442Thr HET HET HET WT HET ND ND HET 
Note: Primers could not be designed to screen for the ZNF43 Ser740Phe 
variant due to tandem repeats sequence. Typed in bold are the remaining 
candidate variants. 
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4.4. DISCUSSION 
This study sought to investigate the underlying genetic basis of BAV disease in 
2 large families of Caucasian background with preponderance for BAV and its 
associated aortopathy by means of exome sequencing. In both families, a 
modest number of novel and rare non-synonymous variants were shared in the 
affected family members, although none of the likely pathogenetic variants 
segregated exclusively with the BAV phenotype. Instead, in both families, BAV 
heritability appeared to run in an autosomal dominant pattern with incomplete 
penetrance. Further, both families had a completely different list of shared 
candidate gene variants. While the composition of the lists of shared candidate 
gene variants within the 2 families, apart from the causative variant itself, was 
mostly determined by chance, the fact that the lists were completely different 
between the 2 families, and assuming that the causative variant was within the 
lists, implied that the causative variant responsible for BAV development in 
Family A and B would be different and unique to each family. These factors 
highlighted the complexity of BAV genetics and the likely presence of genetic 
modifiers or other regulatory control during BAV development.  
 
Co-segregation analysis from the whole exome sequencing approach of Family 
A identified 9 heterozygous missense candidate gene variants. Although each 
of these mutations may have a possible role in the pathogenesis of BAV 
disease within the family, high on the list of possible causative genes are 
GDNF, ITGA10 (integrin alpha 10) and MATN1 (matrilin 1 cartilage matrix 
protein). A modulator of collagen fibrillogenesis in cartilaginous tissue, MTN1 
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mutations have been associated with inherited chondrodysplasias and 
idiopathic scoliosis (Segat et al., 2000, Montanaro et al., 2006). Located on 
chromosome 1p35 and mainly expressed in the cartilage, MTN1 expression 
within the heart is transient, occurring solely during embryological heart 
development, where it has been suggested to play a role in regulating cardiac 
collagen fibril formation and assembly (Segat et al., 2000). Consistent with this, 
it is found at a very low level of expression within the adult aortic valves (FKPM 
<0.1, Table 4.3). The MATN1 Arg343Gln variant is a rare variant, which has 
been reported at a MAF of 0.13% on the EVS database and is predicted to be 
possibly damaging by Polyphen. The variant is shared amongst all affected 
individuals of Family A and in 2 unaffected family members (IV:10 and IV:12). 
 
Meanwhile, integrin is an integral membrane protein that is known to participate 
in cell adhesions and cell-surface mediated signalling. ITGA10 gene is located 
on chromosome 1q21 and is primarily expressed in the cartilage, cardiac valves 
and fascia of skeletal muscle (Camper et al., 2001). In humans, deletion of 
ITGA10 occurred as part of TAR syndrome (thrombocytopenia with absent 
radius), a rare autosomal recessive disorder resulting from 200-kb regions 
deletion at chromosome band 1q21.1 (Albers et al., 2013). Of interest, up to 
30% of patients with TAR syndrome have cardiac manifestations, usually in 
form of atrial septal defects and Tetralogy of Fallot (Hall, 1987). The ITGA10 
Arg116Gly variant is a rare variant that has been previously reported with a 
MAF of 0.7% on the EVS database and is of unknown pathogenicity as 
predicted by Polyphen. Like the MATN1 variant, ITGA10 Arg116Gly is shared 
amongst all affected individuals of Family A and in 2 family members with 
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normal aortic valve (IV:10 and IV:12). It has a modest level of expression within 
adult aortic valve (FKPM ~19, Table 4.3). 
 
Top on the list of putative candidate gene mutation in Family A is the GDNF 
gene. Distantly related to the transforming growth factor- β (TGF-β) superfamily, 
GDNF is a gene that encodes a highly conserved neurotrophic factor, playing 
an important role in promoting the survival and differentiation of midbrain 
dopaminergic neurons, as well as being important in kidney morphogenesis and 
spermatogenesis (Airaksinen and Saarma, 2002, Hiltunen et al., 2000). Mice 
with Gdnf deficiency (Gdnf-/-) were observed to have total renal agenesis, 
pyloric stenosis, duodenal dilatation and congenital megacolon (Bahuau et al., 
2001); these findings highly resembled that of Ret deficient mice (Ret-/-), thus 
supporting GDNF as a ligand of RET (Bahuau et al., 2001). GDNF is expressed 
in adult aortic valve at a similar level of expression with Nkx2-5 (FKPM ~1, 
Table 4.3). This is of significance as Nkx2-5 haploinsufficiency is associated 
with a higher incidence of BAV in mice (Biben et al., 2000). Interestingly, a 
crosstalk between GDNF and NOTCH pathway had been reported where 
GDNF, through its Ret/GFRα1 receptor activity can activate NOTCH signalling, 
by upregulating Jag1 (a NOTCH ligand) expression (Kuure et al., 2005). Of 
note, Notch signalling pathway plays an important role during aortic valve 
development and mutations in NOTCH1 has been linked to the development 
and calcific progression of non-syndromic BAV in humans (Garg et al., 2005, 
Niessen and Karsan, 2008). Additionally, previous study in developing rodent 
heart has revealed the presence of mRNA expression of various members of 
the GDNF family receptors (particularly Gfrα1 and Gfrα2) within the endocardial 
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cushion mesenchyme, in the developing and mature valves, and in the walls of 
the aorta and the pulmonary trunk (Hiltunen et al., 2000), suggesting the 
potential role of GDNF signalling in cardiac development. Interestingly, 
morphological examinations of either Gfrα1-/- and Gfrα2-/- mice hearts did not 
reveal any gross structural abnormalities of the atrioventricular and semilunar 
valves or the great vessels (Hiltunen et al., 2000). This indicates that the 
expression of Gfrα receptors mRNAs in valvuloseptal regions may not be 
essential for their proper development and that there may be compensatory or 
redundant mechanisms by other TGF-β superfamily members (Hiltunen et al., 
2000). It is however still highly plausible that GDNF, particularly through GFRα1 
signalling, to have a modulatory role in endocardial cushion and valve 
development in humans. With these in mind, GDNF becomes an attractive 
candidate gene in this study.  
 
The GDNF Arg93Trp variant (rs36119840) found in Family A is a rare variant 
that has also been previously reported with a MAF of 0.28% on the EVS 
database. The Arg residue at position 93 is a highly conserved amino acid 
amongst 14 species, down to the level of zebra fish. Its substitution to the 
amino acid tryptophan results in a moderate physiochemical difference 
(Grantham score of 101) and is predicted to be deleterious by SIFT and 
probably damaging by Polyphen. The GDNF Arg93Trp variant is shared 
amongst all affected individuals of Family A and is also present in 1 unaffected 
family member (V:1). Interestingly, the GDNF Arg93Trp variant has been 
reported to have an important modifier role on a number of human disease 
susceptibility, albeit in a minority of cases, including congenital central 
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hypoventilation syndrome, Hirschsprung disease and pheochromocytoma 
(Bahuau et al., 2001, Amiel et al., 2003, Woodward et al., 1997, Angrist et al., 
1996).  However, none of these diseases were observed amongst individuals 
from Family A. Further, GDNF screening amongst the 130 unrelated sporadic 
BAV cohorts showed a comparable frequency of rare missense variants 
amongst those with BAV and the EVS control population. This later finding thus 
suggests that GDNF mutations do not appear to have a major causative role in 
the pathogenesis of BAV in this sporadic BAV cohort. Nevertheless, it remains 
possible that allelic variation at the GDNF locus may still play an important role 
as a genetic modifier for BAV susceptibility, including in Family A.  
 
On the other hand, co-segregation analysis of the whole exome sequencing 
result of Family B identified 14 missense variants amongst 12 candidate genes. 
Of these genes, high on the list of causative genes are ETV4 (ETS variant 4; 
also known as PEA3 or polyomavirus enhancer activator 3) and ERBB2 (v-erb-
b2 avian erythroblastic leukemia viral oncogene homolog 2) variants.  
 
A transcription factor from the ETS (E26 transformation-specific) subfamily, 
ETV4 plays a role in neuronal, spermatogonial, limb and kidney development 
and is overexpressed in metastatic breast cancers (Clementz et al., 2011, Lu et 
al., 2009). Of interest, in a mouse model investigating kidney morphogenesis, 
Etv4 was shown to be primarily and positively regulated by GDNF and normal 
expression of Etv4 depends strongly on GDNF-Ret signalling (Lu et al., 2009). 
Therefore, these combined exome sequencing findings on the presence of rare 
nonsynonymous variants in GDNF gene in Family A and in ETV4 gene in 
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Family B might provide further support on the role of GDNF signalling in 
influencing BAV susceptibility, where disruptions anywhere along the pathway 
may promote disease development. Furthermore, recent study in human breast 
cancer has demonstrated a link between ETV4 and NOTCH signalling where 
ETV4 (PEA3) can act as a transcriptional activator for both NOTCH1 and 
NOTCH4, which are critical in breast tumorigenesis (Clementz et al., 2011). 
ETV4 can also partner with other activators to regulate genes such as MMP-1/-
3/-7/-9 and, notably, ERBB2 (Clementz et al., 2011), the second candidate 
gene in Family B. The ETV4 Ala426Val variant is found at a MAF of 0.14% in 
the EVS database with a low level of expression in the aortic valve (FKPM 1.4, 
Table 4.9). Alanine at position 426 is a highly conserved amino acid and its 
substitution to Valine is predicted to be probably damaging by PolyPhen2 
(score of 0.991). The variant is present in all affected members of Family B and 
in the obligate carriers, but are absent in Individual IV:13 and V:9 (Figure 4.5). 
 
Finally, the ERBB2 Arg4Trp is found extremely rarely amongst the EVS cohort 
(MAF 0.02%). The Arg residue at position 4 is a highly conserved amino acid. 
Its substitution to the amino acid tryptophan results in a moderate 
physiochemical difference (Grantham score of 101) and is predicted to be 
damaging by Polyphen2 (score of 1). Similar to the ETV4 variant, the ERBB2 
variant is present in all affected members of Family B and in the obligate 
carriers, but are absent in Individuals IV:13 and V:9 (Figure 4.5). The receptor 
ERBB2 is a member of the epidermal growth factor receptor family and its 
overexpression correlates with a worse prognosis for breast cancer patients 
(Lee et al., 1995). ERBB2 has also been shown to be important in cardiac 
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development and its absence resulted in embryonic lethality of the mutant 
erbB2 null mice, associated with a lack of cardiac trabeculation and maturation 
(Lee et al., 1995). Additionally, a significant decrease (30%) in Erbb2 mRNA 
expression has been observed amongst the Tie2-cre+Gata5fl/fl transgenic mouse 
model, which has a 7x higher incidence of BAV development compared to the 
wild-type littermates (Laforest et al., 2011). This places ERBB2 as an attractive 
gene candidate for BAV development in Family B. 
 
The high preponderance for BAV observed in Families A and B provides 
support for a genetic basis of BAV disease. Whilst whole exome sequencing 
analysis from both families produces a different list of candidate gene variants, 
GDNF-related pathway appeared to be mutually affected in both families. This 
provides a clue towards its potential regulatory role in BAV development, which 
warrants further investigation.  
 
This study has a number of limitations that need to be acknowledged. As 
discussed in Chapter 1.4.3, exome sequencing approach can present a 
technical or analytical bioinformatics challenge. The true causative mutation 
might be missed if the variant was located outside the target definition (e.g. 
unannotated genes or non-coding/regulatory variants) or in regions with 
inadequate coverage. The criteria imposed for variant prioritisation and for a 
variant to be classified as putative pathogenic mutation in this study may be too 
stringent and thus the causal variant may have been excluded in the process; 
for example, the GERP cut off or the aortic valve expression level (i.e. FKPM 
value of < 0.03) could be too high. Further, genes that are active during 
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cardiogenesis may not necessarily be expressed in adult cardiovascular 
structures. Therefore, using aortic valve RNA expression level to guide variant 
prioritisation, albeit being set at a very low level, may result in unintentional 
exclusion of pathogenic variant. Additionally, recent study has reported the role 
of rare copy number variants (CNV) in the development of congenital left sided 
heart disease, including BAV (Hitz et al., 2012). CNV analysis however was not 
done as part of this study. Thus, transmission of a copy number variant cannot 
be ruled out as an underlying contributor to BAV in these 2 families. 
Furthermore, the co-segregation studies in both families have been 
unsuccessful in identifying a single causative mutation. This is contributed by 
the lack of additional family members in the pedigree to further filter out the 
non-causative variants. Therefore, this is an ongoing study that needs to be 
continued upon further recruitment of additional family members into the study.  
 
Overall, this study highlights the fact that, even in familial cases of BAV with 
multiple affected family members, identification of the underlying genetic 
aetiology can be very challenging. Whilst whole exome sequencing provides a 
powerful and unbiased approach to study BAV genetics, it is associated with 
significant bioinformatics challenges, including that which relates to the 
assessment of the functional significance and causality of novel or rare 
sequence candidate gene variants, identified by exome sequencing, on disease 
pathogenesis. Nevertheless, the rapid pace of change in sequencing 
technologies will continue to transform clinical medicine, and cardiovascular 
disease is no exception. As exome sequencing becomes the method of choice 
for identifying the genetic causes of heritable cardiovascular disorder, such as 
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BAV, ongoing incorporation of clinical information provided by family screening 
and development of robust approaches to interpret the significance and define 
pathogenicity of segregating rare variants will continue to be very important. 
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5.1. INTRODUCTION 
Bicuspid aortic valve (BAV) is the most common congenital cardiovascular 
malformation, affecting 1.3% of the general population (Michelena et al., 2011, 
Siu and Silversides, 2010). BAV is an important risk factor for aortic valve 
disease and ascending aortic aneurysm (Michelena et al., 2011, Padang et al., 
2012b, Cripe et al., 2004). Structural aortic valve degeneration (SVD), and 
consequent valve dysfunction, is the most common complication of BAV 
disease, which often occurs prematurely and is responsible for up to one-thirds 
of aortic valve replacement in the Western world (McKellar et al., 2010, 
Michelena et al., 2011, Michelena et al., 2008). Valve dysfunction in BAV 
ranges from predominantly stenotic lesions with heavy valve calcification and/or 
fibrosis to predominantly regurgitant lesions with leaflet prolapse, fibrotic 
retraction, malcoaptation from aortic root dilatation, or leaflet destruction from 
infective endocarditis. Furthermore, whilst BAV underlies 70%-85% of stenotic 
aortic valve in children and over 50% of aortic stenosis in adults (Cripe et al., 
2004), different pathological processes appear to be present. In newborn 
infants or young children, BAV-related stenosis is a consequence of thickened 
leaflets with severe restriction in valve orifice opening (Siu and Silversides, 
2010, Tutar et al., 2005), probably signifying a more severe disorder of aortic 
valvulogenesis. Meanwhile, premature leaflet sclerosis and calcific 
degeneration from the abnormal hemodynamic shear stress likely to be 
responsible for BAV-related stenosis during adulthood (Siu and Silversides, 
2010, Tutar et al., 2005). In contrast, although any degree of aortic regurgitation 
can be detected in up to 59% of community cohort with BAV during 
 Chapter 5: RNA sequencing in BAV  
 148 
echocardiography, intervention for isolated severe aortic incompetence is 
relatively uncommon in BAV, affecting only 3-7% of patients (Michelena et al., 
2011, Tzemos et al., 2008, McKellar et al., 2010). These facts highlight the wide 
spectrum of clinical manifestation and outcome of SVD and valve dysfunction in 
BAV. Detection of BAV-related SVD is important, as it is an independent 
predictor of long-term cardiovascular events, including aortic valve surgery and 
cardiac death, even in patients with normally functioning BAV at baseline 
(Michelena et al., 2008).  
 
High heritability rate and familial clustering strongly imply that BAV has an 
underlying genetic basis (Cripe et al., 2004). In humans, mutations of the 
transcription factor NOTCH1 gene are associated with limited cases of familial 
and sporadic BAV, as well as aortic valve calcification, possibly as a result of 
derepression of RUNX2, a downstream transcriptional regulator of osteoblast 
cell fate (Garg et al., 2005). Recently, the presence of rare non-synonymous 
variations within the conserved transcriptional activator domains of GATA5, a 
transcription factor essential to cardiac and aortic valve development, were 
reported in patients with BAV (Chapter 3) (Padang et al., 2012a). Additionally, 
orchestrated regulation of gene transcription is essential during cardiac 
development and valvulogenesis, and disruption to this process likely 
contributes to various cardiac pathologies, including BAV. Microarray profiling of 
microRNA regulators of gene expression highlighted reduced expression of 
miR-26a, miR-30b, and miR-195 in stenotic BAV associated with calcification, 
compared with a regurgitant BAV phenotype (Nigam et al., 2010). These 
microRNAs were shown to modulate the mRNA levels of several calcification-
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related genes in-vitro (Nigam et al., 2010). Further, exon microarray profiling 
has revealed altered gene expression and mRNA splicing in the myocardium of 
patients with hypoplastic left heart syndrome, a condition that is genetically 
related to BAV disease (Hinton et al., 2009, Ricci et al., 2012). Despite these 
recent insights, the molecular mechanism underlying the development of 
phenotype heterogeneity of SVD in BAV disease however remains incompletely 
understood. Further, clinical risk prediction of individual patient’s outcome is 
imprecise and there are currently no treatments to slow or prevent aortic valve 
degeneration. 
 
The tissue transcriptome contains the entire repertoire of all transcripts 
expressed in a given tissue of an organism.  Presently, transcriptome analysis 
using next generation sequencing technologies (RNA-seq) is becoming a 
preferred method of choice over hybridisation-based microarray profiling 
(Kogenaru et al., 2012).  Advantages of RNA-seq include a large dynamic 
range of expression levels that is not affected by on-chip sequence biases, low 
background signal due to perfect matching of sequencing reads, single base 
resolution of transcription boundaries, and the relatively small amount of total 
RNA required for quantification when compared to microarray (Kogenaru et al., 
2012). This current study utilised RNA-seq to profile and compare the 
transcriptomes of non-calcified, primarily regurgitant BAV and calcified, 
primarily stenotic BAV subtypes with calcified stenotic (degenerative) tricuspid 
aortic valves (TAV), and highlight molecular pathways that are disrupted 
following valve degeneration in BAV disease. 
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5.2. METHODS 
5.2.1. Study population and aortic valve collection 
Patients with BAV or TAV, referred for aortic valve or aortic root surgery at the 
Royal Prince Alfred Hospital, Sydney, Australia, were prospectively recruited 
from May to December 2012. Patients with a history of rheumatic heart disease, 
infective endocarditis or connective tissue disorders were excluded. All patients 
underwent clinical evaluation that included family history and pre-operative 2D-
echocardiography where the morphology and functional state of the aortic valve 
was determined according to the American Heart Association and the American 
College of Cardiology guidelines (Bonow et al., 2008). The aortic valve 
morphology and the presence of SVD, as signified by the extent of leaflet 
calcification, thickening, prolapse and/or redundancy, were documented at 
surgery. Calcification was graded mild (<1/3 leaflet area affected) or severe 
(>2/3 leaflet area affected). Immediately following surgical removal, a portion of 
the aortic valve leaflet was immersed in RNAlater solution (Ambion Inc, Austin, 
TX) overnight and stored at -80°C.  
 
All patients gave written informed consent and the study was approved by the 
Sydney South West Area Health Service Ethics Committee.  
 
5.2.2. RNA isolation  
Total valve RNA was isolated from the non-calcified portion of the leaflets using 
TRIzol Reagent (Invitrogen, Life Technologies, CA, USA), using methods 
described in Chapter 2.4.2.1. RNA purity, concentration and integrity were 
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evaluated using a combination of Nanodrop 2000 spectrophotometer (Thermo 
Scientific, MA, USA), 2100 Bioanalyzer (RNA6000 Nano LabChip, Agilent 
Technologies, Santa Clara, CA, USA), and/or agarose gel electrophoresis. 
 
5.2.3. RNA sequencing and gene expression analysis 
RNA-seq was performed on 8 male, DNAse I treated RNA samples having RNA 
integrity number (RIN) ≥ 7 (3 TAV, 5 BAV) (BGI Facility, Hong Kong). The 
specific steps involved in RNA-seq, including library construction, sequencing 
and bioinformatics analyses, were detailed in Chapter 2.4.4.  
 
Briefly, Illumina TruSeq RNA-seq library (Illumina, San Diego, CA, USA) was 
prepared on 5µg total RNA according to the manufacturer’s instructions, and 
100 base paired-end sequenced on a HiSeq2000 (Illumina). FASTQ files were 
aligned to the human reference sequence (NCBI GRCh37/hg19) using Bowtie 
and TopHat2 v2.0.6 (Kim et al., 2013) with a transcriptome-index to guide 
mapping of splice junction-spanning reads (ftp://ftp.ensembl.org/pub/release-
73/gtf/homo_ sapiens/Homo_sapiens.GRCh37.73.gtf.gz). Aligned reads in BAM 
format were then annotated against the protein-coding mRNA regions. 
SeqMonk v.0.24.1 platform (Babraham Bioinformatics, Cambridge UK) were 
utilised to visualise the annotated/mapped read (Figure 5.1), quantify data 
(using corrected log2 transformed Reads Per Million Values of non-strand 
specific, unmerged isoform) and perform percentile normalisation. An intensity 
difference analysis method (Brien et al., 2013) were used to identify 
differentially expressed genes (DEGs) on the normalised quantification data. A 
gene was classified as up- or downregulated using a cut-off value of more or 
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less than 1.5-fold expression difference, respectively, between BAV versus 
TAV, with an adjusted p-value <0.05, following post-hoc Bonferroni correction. 
A small number of unannotated genes with uncharacterised protein were 
excluded from subsequent analysis. 
 
 
Figure 5. 1. Example of visualisation of mapped reads in SeqMonk 
platform over a well-covered region of a gene in Chromosome 9 in 2 BAV 
samples. 
 
SeqMonk was also utilised to perform hierarchical clustering and heat map 
analysis of DEGs. Ingenuity Pathway Analysis (IPA) and PANTHER 
(www.pantherdb.org) were used to assess biological networks and pathways 
connected to the DEGs. Gene Ontology (GO)-based enrichment and KEGG 
pathway analysis of DEGs were performed against a background list of global 
 Chapter 5: RNA sequencing in BAV  
 153 
aortic valve protein-coding mRNAs expression, using the Database for 
Annotation, Visualisation and Integrated Discovery (DAVID) bioinformatics 
resources (version 6.7; NIH). Enrichment score of ≥ 1.3 and Benjamini-
Hochberg corrected p-value <0.05 were used as a cut-off for significance.  
 
5.2.4. Reverse transcription quantitative PCR (RT-qPCR) 
As described in Chapter 2.4.2.2, RT-qPCR was performed using EXPRESS 
SYBR® GreenER qPCR SuperMix (Invitrogen, Life Technologies, CA, USA) on 
a Mx3000P and data analysed using MxPro qPCR software v.2.0 (Stratagene, 
La Jolla, CA, USA). Two reference genes (GAPDH and TFRC) were used to 
calculate the normalisation factor by geNorm v.3.4 algorithm (Vandesompele et 
al., 2002). Relative amounts gene-of-interest expression were normalised to the 
reference genes expression. RT-qPCR primer sequences were listed in 
Appendix 1, Table I-5. 
 
5.2.5. Statistical analysis 
Normally distributed data were reported as mean ± standard deviation (SD). 
Statistical evaluation of parametric data was performed with a two-tailed 
unpaired Student’s t-test using Welch’s correction for data with unequal 
variance. Statistical analysis of RT-qPCR data was performed on the 
normalised relative expression level using the Kruskal-Wallis test with post-hoc 
Dunn’s test for 3 groups comparison and a Mann-Whitney unpaired t-test for 2 
groups comparison. A p <0.05 was considered statistically significant. Statistical 
analyses were performed using GraphPad Prism v.6.0b (GraphPad Software, 
La Jolla, California, USA). 
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5.3. RESULTS 
Between May 2012 to December 2012, aortic valve leaflets from 36 unrelated 
patients were collected and their RNAs extracted. Nine of these RNAs were 
excluded due to poor quality (i.e. degraded RNAs), thus leaving total RNAs 
from the remaining 27 suitable samples (21 BAV and 6 TAV samples) for RT-
qPCR analysis (Figure 5.2). Of these, 5 BAV and 3 TAV RNA samples with a 
RIN >7.0 underwent RNA-seq analysis. Clinical characteristics of the 8 patients 
comprising the RNA-seq cohort were described in Table 5.1; all were males and 
predominantly Caucasian. The three TAV patients had severe calcific 
(degenerative) aortic stenosis and were significantly older at surgery (71±8 
years vs. 53±12 years, p=0.038) compared to the BAV patients, of which two 
had severe calcific aortic stenosis, one had mild aortic stenosis and two had 
moderate or severe aortic regurgitation. 
 
 
Figure 5. 2. Study outline: aortic valve collection and allocations.  
BAV = bicuspid aortic valve; TAV = tricuspid aortic valve; BAVr = BAV with 
leaflet redundancy and either none or no more than mild calcification; BAVc = 
BAV with heavy leaflet calcifications. 
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5.3.1. Differential gene expression profiling in BAV and TAV 
Global gene expression levels of BAV (n=5) and TAV (n=3) demonstrated 
significant correlation (Pearson’s R=0.992; Figure 5.3). Intensity difference 
analysis revealed differential expression of 1,102 probe sets, corresponded to 
59 and 177 genes, that were significantly up- or downregulated, respectively, in 
BAV (Table 5.2; full list in Appendix III, Table III-1). Notably, 7 of the 10 most 
significantly up- and downregulated genes were involved in extracellular matrix 
production and degradation, namely matrix metalloproteinases 13 and 9 
(MMP13, MMP9), LAMC3 (laminin, gamma 3), CHAD (chondroadherin), IBSP 
(integrin-binding sialoprotein), COL11A1 (collagen, type 11α1) and SPP1 
(osteopontin).  
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Amongst these 236 differentially expressed genes (DEGs), IPA identified 4 
major biological networks whose functions were broadly involved in connective 
tissue disorders, tissue morphology, cardiovascular system development and 
function, immune cell trafficking and cell-to-cell signalling and interaction (Table 
5.3). Exploration of GO-related terms similarly revealed overrepresentation of 
extracellular matrix component and biological processes involving inflammatory 
response, ossification, homeostatic and collagen metabolic process (Table 5.4). 
Specific biological functions most significant to the DEGs and considered to be 
pertinent to BAV development and aortic valve degeneration, including calcium 
signalling, connective tissue development, fibrosis and proteolysis, were 
presented in Appendix III, Table III-2. 
 
Hierarchical clustering and heat mapping of the DEGs indicated differences in 
the overall gene expression between BAV and TAV (Figure 5.4). Furthermore, 
heterogeneity within the BAV group was apparent as distinct expression 
patterns separated BAV patients with leaflet redundancy/prolapse and no more 
than mild leaflet calcifications (BAVr) from patients with heavily calcified BAV 
leaflets (BAVc). Expression pattern of BAVc group appeared to be an 
“intermediate pattern” that more resembled the TAV group (particularly sample 
BAV5) and in some contrast to BAVr. Closer inspection of quantitative data of 
DEGs expression within each individual samples further supported this 
observation (data not shown).  
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Figure 5. 4. Hierarchical clustering and heat map in BAV and TAV.  
Hierarchical clustering indicated heterogeneity within the BAV group, separating 
those with heavy calcification (BAVc; BAV4-BAV5) from those with redundant 
leaflets and no more than mild calcification (BAVr; BAV1-BAV3). The 
expression pattern of BAVc represented an intermediate group, with more 
resemblance to the TAV group (particularly sample BAV5). 
 
5.3.2. Comparative analyses of DEGs in subgroups 
Given the heterogeneity observed within the BAV group during hierarchical 
clustering and heat map analysis, DEGs were evaluated between the different 
combinations of subgroup pair, i.e. BAVr versus TAV; BAVr versus BAVc; and 
BAVc versus TAV. Overall, BAVc versus TAV group analyses yielded the 
smallest number of DEGs (Figure 5.5) with a narrower range in the degree of 
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fold-change in gene expressions, compared to the other 2 subgroup pairs. 
Eighty out of 193 DEGs (41%) in BAVc versus TAV group had <2-fold change 
in their mRNA expression level, whilst none of the 265 DEGs in BAVr versus 
BAVc group and only 1 out of 224 DEGs (0.4%) in BAVr versus TAV group had 
a similar degree of alteration (Appendix III, Table III-3, III-4 and III-5). Further, 
side-by-side comparison of selected extracellular matrix and cardiac-related 
genes-of-interest revealed similar trend in the direction of change (up- or 
downregulation) and the degree of fold change in BAVr versus BAVc and BAVr 
versus TAV group. Dysregulation of these genes were however less notable in 
BAVc versus TAV group (Appendix III, Table III-6). These observations 
suggested that BAVc expression pattern was more similar to the TAV rather 
than the BAVr group. 
 
 
Figure 5. 5. Bar graph comparing the number of DEGs amongst the 
different subgroup pairs.  
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Analyses of GO-related terms enrichment clusters from the different 
comparative subgroup analyses revealed that dysregulation of extracellular 
matrix genes and focal adhesion-related genes to be a common feature of SVD 
amongst the 3 comparative subgroups (Appendix III, Table III-7A, III-7B and III-
7C). Meanwhile, ossification and inflammatory response gene clusters 
overexpression were notable in both BAVc and TAV when compared to the 
BAVr. 
 
5.3.3. Validation of RNA-seq data 
Total RNA isolated from 31 aortic valve leaflet preparations obtained from 27 
unrelated patients, including the 8 samples used in the RNA-seq experiment, 
were included to in the RT-qPCR validation study and analysed simultaneously 
with 2 overarching aims. First, to provide technical validation of the RNA-seq 
findings by validating a subset of DEGs-of-interest by RT-qPCR using the same 
RNAs used in the RNA-seq experiments. Second, to provide biological 
validation of the RNA-seq findings by performing RT-qPCR on the same 
selection of genes-of-interest using RNAs from different patients. The results 
obtained from the validation experiments were then extrapolated to the 
remaining non-validated genes. RT-qPCR validation data were analysed by 
comparing the gene expression level amongst the TAV, BAVr and BAVc 
subgroups. 
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Clinical characteristics of the validation groups are summarised in Appendix III, 
Table III-8. The validation groups consisted of 8, 10 and 13 total valve RNA 
samples obtained from 6 TAV, 9 BAVr and 12 BAVc patients, respectively, 
majority of whom were male and of Caucasian background. In 2 BAV and 2 
TAV patients in whom excess aortic valve leaflet tissues were available, 2 total 
RNA preparations were made from each patient, extracted from different part of 
the leaflets and treated as separate samples to maximise the number of total 
RNA available for statistical analysis. 
 
Nine DEGs-of-interest from the overall BAV versus TAV comparative analysis 
were selected for RT-qPCR analyses, namely ACAN (aggrecan), CHI3L1 
(cartilage glycoprotein-39), COL6A6 (collagen, type 6α6), IBSP, LAMC3, 
MMP13, MMP7, MMP9 and SPP1.  
 
Overall, RT-qPCR analyses validated the differential expression between BAVr 
versus TAV on all of the selected genes-of-interest (Figure 5.6). RT-qPCR also 
validated the differential expression of 5 of these genes (ACAN, COL6A6, 
LAMC3, MMP13 and MMP7) in the BAVr compared to BAVc group. RNA-seq 
however found no significant difference in the expressions of CHI3L1, COL6A6, 
IBSP, LAMC3 and MMP13 in the BAVc versus TAV group and these too were 
verified by the RT-qPCR analysis. This indicated a relatively good agreement 
between the RNA-seq and the RT-qPCR results. 
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5.3.4. Identification of shared and unique pathways 
To identify unique and common genes that were important in the pathogenesis 
of SVD amongst subgroups, a Venn diagram was constructed using the DEGs 
gene list specific to different subgroup pairs (Figure 5.7; full gene list on 
Appendix III, Table III-9). The rationale was that DEGs between the BAVr 
versus TAV group would consist of genes that were not only responsible for 
BAV leaflet redundancy/prolapse or calcification in TAV but also BAV 
development; whilst BAVr versus BAVc comparison would highlight genes 
responsible for the different form of SVD in BAV leaflets and possibly, genes 
determining distinct BAV morphology. Similarly, BAVc versus TAV comparison 
could give insights to the shared versus differential calcification-related 
pathways and possibly, also BAV origin.  
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Figure 5. 7. Venn diagram showing overlap in the number of differentially 
expressed genes between analysed subgroups.  
Gene lists of compartments A-G (insert) were summarised in Appendix III, 
Table III-9. 
 
Nineteen DEGs were shared amongst all the subgroup pair comparisons, which 
included genes regulating cell adhesion (ACAN, TIMD4 (T-cell immunoglobulin 
and mucin domain containing 4) and FCRL5 (Fc receptor-like protein 5)), 
developmental process (IGLL5 (immunoglobulin lambda-like polypeptide 5), 
CNTFR (ciliary neurotrophic factor receptor), MYOC (myocilin) and ACAN) and 
matrix protease MMP9 (gelatinase B). Within the 114 overlapping genes 
between BAVr versus TAV and BAVr versus BAVc intersect (i.e. compartment 
D on Figure 5.6 insert), there was a common pattern of extracellular matrix-
related genes dysregulation, including significant upregulation of inflammatory 
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response genes, serpin protease inhibitors (SERPINA1, SERPINE1), and 
calcification-related genes (BGLAP (osteocalcin), DLL4 (delta-like 4, NOTCH 
ligand), GFAP (glial fibrillary acidic protein), HBA1/HBA2 (haemoglobin, alpha), 
MMP1 and SPP1) in the BAVc and TAV, compared to the BAVr group. 
Interestingly, IPA identified these calcification-related genes as downstream 
affecters of NOTCH1 signalling pathway.  Moreover, downregulation of 
metalloprotease ADAMTS9 (a disintegrin and metallopeptidase with 
thrombospondin type 1 motif 9) was uniquely observed in BAVr versus TAV 
subgroup pair.  
 
Unique pattern of DEGs regulating cardiogenesis and/or heart valve 
development was also noted between different subgroup pairs. Namely, within 
71 DEGs unique to BAVr versus TAV there were developmental factors HAND2 
(heart and neural crest derivatives expressed 2), EYA1 (eyes absent homolog 1 
(Drosophila)), GREM1 (gremlins1), SEMA6B (semaphorin 6B) and cardiac 
transcription factor GATA4. Upregulation of transcription factor TBX20 (T-box 
20) was observed uniquely within BAVr versus BAVc, whilst upregulation of 
COL13A1 and downregulation of WNT7A (wingless-type MMTV integration site 
family, member 7A) were unique to BAVc versus TAV. Further, increased 
expression of valve progenitor markers COL2A1, COL11A1, ACAN and MMP13 
(collagenase-3) were observed in both BAVc and TAV compared to BAVr. 
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5.4. DISCUSSION 
The present study described genome-wide differential transcriptome profiling 
behind SVD in human BAV and TAV using RNA-seq for the first time. The data 
obtained from the study provides new insight into the molecular basis of 
phenotype heterogeneity seen in this complex disorder. Differential gene 
expression profiles were observed amongst BAV patients, dividing them into 
two subgroups: those with calcification predominant disease (BAVc) and those 
with primarily redundant leaflet degeneration (BAVr). The gene expression 
pattern of BAVc was found to be more similar to the TAV rather than the BAVr 
group. Comparative functional analysis of the DEGs revealed the presence of 
shared and unique genes/pathways between the different subgroup pairs. 
Dysregulation of extracellular matrix genes and genes regulating cellular 
adhesions appeared to be a common feature of SVD in both BAV and TAV. 
Meanwhile, significant overexpression of ossification and inflammatory 
response genes were seen in both BAVc and TAV with notable downregulation 
of the NOTCH1 signalling pathway. This implied the presence of a common 
terminal pathway in genes regulating valvular calcification in both BAV and 
TAV. A unique pattern of differential expression of genes controlling cardiac 
and/or heart valve development was also identified amongst the subgroups. In 
particular, downregulation of ADAMTS9 and ACAN were observed in the BAVr 
compared to the TAV. Furthermore, there was notable downregulation of 
semaphorins signalling through SEMA6B and SEMA3F in BAVr and BAVc, 
respectively, compared to the TAV group. Taken together, these findings 
indicated the presence of distinct gene expression signatures that marked the 
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different type of SVD in BAV, compared to TAV, supporting the emerging theory 
that BAV is heterogeneous with respect to molecular events in disease 
progression (Figure 5.8). 
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Central to the pathogenesis of human heart valve disease is the disruption of 
the normal valve homeostatic process, which leads to abnormal leaflet 
architectural organisation and disproportionate alteration of extracellular matrix 
constituents (Padang et al., 2012b).  Imbalance of proteases MMPs and 
ADAMTS expression can accelerate leaflet degradation process, by changing 
the structural composition of the valve matrix, leading to pathological 
remodelling, SVD and subsequent valve dysfunction. In this study, 4 MMPs 
were differentially expressed, namely MMP1, MMP7, and, notably, MMP9 and 
MMP13, but not MMP2. The matrix remodelling enzyme gene MMP13 was 
found to be the most highly upregulated gene in the degenerative TAV and 
BAVc groups, compared to the extremely low expression in BAVr, suggesting 
its importance in valvular calcification.  
 
MMP13 is a major collagenase that plays an important role during 
cardiogenesis and heart valve development, with catalytic activity 
predominantly on type II collagen and aggrecan matrix constituents (Borzi et al., 
2010, Cheek et al., 2012). In degenerative bone disease model, such as 
osteoarthritis, MMP13 facilitates chondrocyte terminal differentiation by 
ensuring concerted upregulation of RUNX2 (runt-related transcription factor 2), 
VEGF (vascular endothelial growth factor), and active β-catenin signalling 
pathways, which induce osteoblastogenesis and new bone formation (Borzi et 
al., 2010). Given the presence of a shared molecular mechanism regulating 
heart valve, cartilage, and bone development, which can be reactivated in adult 
valve disease (Lincoln et al., 2006), it is conceivable that MMP13 induces 
calcific valve phenotype in either BAV or TAV through similar mechanism. 
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Meanwhile, significant dysregulation of MMP9 was commonly observed 
amongst all 3 subgroups comparison. Normally involved in type IV collagen and 
elastin degradation, increase in MMP9 activity had been detected in vascular 
pathologies, such as abdominal aortic aneurysms, and in diseased BAV 
compared to diseased or normal TAV leaflets (Koullias et al., 2004). In some 
contrast, this study showed that significant increase in MMP9 activity can be 
observed in heavily calcified leaflets of either TAV (highest activity) or BAV 
origin (BAVc), compared to the lower expression in the minimally calcified BAVr 
(lowest activity) group. Nevertheless, in concordance to other previous studies 
(Edep et al., 2000, Fondard et al., 2005), this indicated the presence of 
enhanced proteolytic/elatolytic activity of MMP9 in calcified leaflets, in both BAV 
and TAV. As inflammatory cells (e.g. macrophages and neutrophils), but not 
valvular interstitial cells, are prevalent MMP9 producers, this indirectly implied a 
higher degree of inflammation in heavily calcified and stenotic leaflets, 
compared with redundant and regurgitant leaflets, which is in support of 
previous study (Fondard et al., 2005). Indeed, inflammatory infiltration of 
activated macrophages and T-cells has been reported in human stenotic aortic 
valve (Moreno et al., 2011, Nagy et al., 2011). Notably, no significant differential 
expression of tissue inhibitor of MMPs (TIMPs) was observed within the 
dataset, suggesting the presence of net proteolytic activity of MMPs in valve 
disease pathogenesis.  
 
This study provided further evidence that BAV-related calcification occurred in a 
similar fashion to that seen in patients with calcific TAV, where it is an active 
biological process involving inflammation, oxidation, angiogenesis, extracellular 
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matrix remodelling/fibrosis, and atherosclerosis-like ectopic calcification, with 
bone-like mineralisation of the aortic side of the valve leaflet (Bosse et al., 
2009). Indeed, shared upregulation of osteogenic gene programs were 
observed between the BAVc and TAV groups, which included upregulation of 
bone-specific transcription factor SP7 (osterix), bone differentiation marker 
IBSP and BGLAP, NOTCH ligand DLL4, MMP1 and MMP9 proteases, and 
bone biomineralisation marker SPP1 (osteopontin); many of which interact with 
or known as part of the downstream signalling pathway of the transcription 
factor NOTCH1 (Engin et al., 2008, Rusanescu et al., 2008). In fact, the 
NOTCH1 signalling pathway appeared to be downregulated in these calcific 
leaflets, probably mediated through the reduction in NOTCH1-mediated 
repression of Runx2 activity (Rusanescu et al., 2008), a central transcriptional 
regulator of osteoblast cell fate, which resulted in the observed upregulation of 
SP7 and SPP1 activities. This is an interesting finding as missense and 
frameshift mutations of NOTCH1 gene, leading to haploinsufficiency, are 
associated with human BAV, as well as calcific aortic stenosis in both BAV and 
TAV patients (Ducharme et al., 2013, Garg et al., 2005). This suggested that 
NOTCH1 signalling pathway may be a common terminal pathway in aortic valve 
calcification, although further study is required to elucidate the initial molecular 
event that may have triggered the initiation of calcification process in both BAV 
and TAV. Such events are likely to be multifactorial in origin, involving complex 
interplay between genetic, epigenetic, environmental, and hemodynamic 
factors. 
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Whilst many pathways regulating calcific aortic stenosis have been described, 
genetic and molecular factors leading to intrinsic BAV leaflet redundancy, 
prolapse and subsequent development of aortic regurgitation remain mostly 
unknown. Recently, adult murine models with Adamts9 haploinsufficiency have 
been shown to develop aortic valve thickening, enlargement (redundancy) and 
even malformation, as well as ascending aortic wall anomalies (Kern et al., 
2010). Important in cardiovascular development and/or allostasis, the 
proteoglycanase ADAMTS9 is involved in cleavage of large proteoglycan 
aggrecan (ACAN) and versican, two important components of human valve 
matrix. Interestingly, downregulation of ADAMTS9 and ACAN were observed in 
the BAVr compared to the TAV. It is hypothesised that reduced ADAMTS9 
expression in the BAVr group likely resulted in reduced ACAN processing, its 
pathological accumulation and consequent downregulation at gene expression 
level. Hence, this might contributed to redundant leaflet phenotype in the BAVr 
group.  
 
Further, the study observed lower expression of valve progenitor markers 
COL2A1 and COL11A1 in the BAVr compared to the BAVc and TAV groups. 
This implied that synthesis of collagen, a structural protein, might be 
downregulated in the BAVr group, giving the aortic valve a lower tensile 
strength. Over time, this structural abnormality likely contributes to progressive 
leaflet laxity, redundancy and chronic valvular dysfunction (i.e. regurgitation), as 
seen in end-stage disease amongst those with regurgitant BAV. 
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Human genetic studies are beginning to provide evidence that developmental 
pathways important in valvulogenesis also contribute to adult valve disease 
(Lincoln et al., 2006). This is supported by the current RNA-seq study, which 
demonstrated unique pattern of dysregulation of foetal genes important in 
cardiac and heart valve development amongst the study subgroups. Of 
particular interest were unique upregulation of TBX20 in BAVr compared to the 
BAVc group; as well as unique downregulation of SEMA6B and SEMA3F in 
BAVr versus TAV and BAVc versus TAV groups, respectively.  
 
Transcription factor TBX20 is a member of a highly conserved T-box gene 
family that is implicated in cardiac muscle maturation and is strongly expressed 
in the endocardial cushion mesenchyme during heart development (Kirk et al., 
2007). Human TBX20 mutations, including a gain-of-function mutation, are 
associated with adult-onset cardiomyopathy, septal defects, and interestingly, 
coarctation of the aorta, mitral and aortic valve abnormalities (Kirk et al., 2007, 
Posch et al., 2010). Mouse embryos with a partial RNAi-mediated knockdown of 
Tbx20 expression show severe hypoplasia of atrioventricular (aortic and 
pulmonary) valve, further supporting its critical role in valve development 
(Takeuchi et al., 2005). Interestingly, TBX20 interacts with other cardiac 
developmental transcriptional factors, including TBX5, GATA4, GATA5 and 
Nkx2-5 (Kirk et al., 2007, Posch et al., 2010). Notably, Nkx2-5 
haploinsufficiency and targeted deletion of Gata5 in mice had been associated 
with BAV development. Therefore, the observed upregulation of TBX20 in BAVr 
versus BAVc group was indeed hypothesis stimulating with regard to its 
contribution to human BAV development, which was probably mediated through 
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its interaction with the cardiac GATA factors and Nkx2-5 (Laforest et al., 2011, 
Biben et al., 2000).  
 
Semaphorins comprise a diverse family of secreted, transmembrane and GPI-
linked proteins that shared a conserved cysteine-rich sema domain (Kruger et 
al., 2005). Semaphorins are major regulators of morphogenesis, involved in a 
variety of processes ranging from neural connectivity, angiogenesis, immune-
regulation, cardiac and bone development, to cancer biology (Kruger et al., 
2005). In particular, class 3 and 6 semaphorins, as well as semaphorin receptor 
Plexins, signalling are important in cardiogenesis and outflow tracts formation, 
which in part are mediated by their regulatory role in neural crest cells (NCC) 
migration (Kruger et al., 2005, Toyofuku et al., 2008). Necessary for normal 
outflow tract septation and formation/remodelling of the semilunar valves, 
abnormal NCC migration and condensation within the outflow endocardial 
cushion during cardiogenesis in mice has been linked to the development of 
BAV and abnormalities of the aortic root and ascending aortic wall (Jain et al., 
2011, Phillips et al., 2013). The perceived downregulation of SEMA6B and 
SEMA3F in BAVr and BAVc, compared to TAV, respectively were therefore 
exciting finding as this may give the first clue into the role of semaphorins in the 
development of human BAV. Further, this may also provide the molecular link 
between the abnormal valve patterning and the predisposition to ascending 
aortic dilatation within the BAV cohort, in addition to hemodynamic factors.  
 
Even after focusing the present analyses to the protein-coding mRNAs 
expression profiling, extracting biological meaning from RNA-seq data 
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continues to pose a major challenge, as the amount of data available is 
overwhelming and challenging to interpret. To facilitate interpretation, this study 
relied heavily on the available bioinformatics tools and literature, which may 
create some limitations, as to date many gene functions and molecular 
pathways are yet to be elucidated. Further, the current study is limited by the 
unavailability of structurally normal TAV as the ideal comparative control group 
and therefore, a number of important genes related to the anomaly itself could 
probably be missed during the analysis. The lack of an ideal control group has 
also made analysis for differential stimuli for inflammatory activation and 
calcification between BAV and TAV highly challenging. The study is also limited 
by the relatively small sample size of the RNA-seq group. The latter was partly 
contributed by the difficulty in obtaining sufficient quantity of high quality total 
valve RNAs, especially from heavily calcified leaflets that would be suitable for 
RNA-seq purpose. Moreover, wide variability was observed amongst a number 
of samples within each subgroup on RT-qPCR data. This may reflect the fact 
that each individual samples, even those within the same subgroups, might be 
at a different stage of disease process. Also, different posttranslational and/or 
epigenetic regulation was likely to be present in different individuals, further 
contributing to heterogeneity in gene expression and subsequently their 
phenotype. Finally, the current study analysis was limited to the end-stage form 
of the valve disease process, whilst the initiating factor that drives the disease 
onset remains to be elucidated. Further studies are therefore required to 
validate these findings in a larger cohort. Nevertheless, the data obtained in this 
study provides an invaluable insight into genome-wide differential gene 
expression patterns within BAV disease compared to TAV. 
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In conclusion, this study presented the first global comparative transcriptome 
profiling of human BAV disease compared to TAV using RNA-seq. The study 
demonstrated the relatively close resemblance of gene expression patterns of 
calcified human BAV and calcified human TAV leaflets, with shared 
upregulation of inflammatory pathways and downregulation of NOTCH1 
signalling, suggesting a common mechanism of calcific leaflet degeneration in 
both BAV and TAV. Dysregulation of ADAMTS9 and ACAN were likely to 
contribute to leaflet redundancy or prolapse in BAV disease. This study has 
also identified the unique dysregulation of foetal gene programs, including the 
potential role of semaphorins in the development of BAV and its related 
aortopathy. Understanding of genetic pathways leading to SVD is important, as 
it is a precursor of overt clinical valve dysfunction. The present limitation of 
pharmacological treatment in delaying or stopping valve disease progression 
has left surgical therapies as the most effective, but not necessarily the ideal 
“cure” for end-stage valve dysfunction in both BAV and TAV. Improvement in 
our understanding of gene and molecular pathways involved in the 
pathogenesis of SVD in BAV will help to foster the development of new 
therapies that halt progressive leaflet degeneration, with the ultimate goal of 
reducing the overall health burden created by this complex, albeit common, 
human disease. 
 
 Chapter 6: Real time exercise CMR imaging in BAV 
 181 
 
 
 
 
 
 
CHAPTER 6: REAL TIME EXERCISE CMR 
IMAGING IN THE EVALUATION OF AORTIC 
BIOMECHANICS IN BAV DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Chapter 6: Real time exercise CMR imaging in BAV 
 182 
 
6.1. INTRODUCTION 
As the most common form of congenital heart defects (CHD) in adults, affecting 
~1.3% of the population worldwide, BAV is responsible for more deaths and 
complications than the combined effects of all other CHD (Fedak et al., 2002, 
Siu and Silversides, 2010). Although valvular dysfunction is the most common 
complication of a bicuspid aortic valve, dilatation of any segment of the proximal 
aorta from the aortic root to the aortic arch, the so-called BAV-related 
aortopathy, is present in over 50% of affected individuals (Verma and Siu, 2014, 
Fedak et al., 2002), usually occurring at a younger age in BAV than it does in 
patients with the normal tricuspid aortic valves (TAV).  As aortic dilatation has a 
propensity for dissection and rupture, BAV-related aortopathy is a potentially 
lethal disease. Thus, it warrants life-long periodic monitoring, with possible early 
prophylactic surgical intervention to prevent unfavourable outcome. 
 
As an important adjunct to the traditional transthoracic echocardiography 
assessment of BAV disease, Cardiac Magnetic Resonance (CMR) imaging 
provides the unique ability to provide comprehensive three-dimensional (3D) 
data combined with accurate flow imaging in the assessment of BAV-related 
aortic pathologies (Quenot et al., 2005). Not only does CMR imaging allow for 
detailed assessment of the left ventricle, the aortic valve and the aorta in one 
examination, it also provides highly reproducible and accurate measurements.  
One may argue that CMR currently has the potential to serve as a ‘one-stop 
shop’ for many patients with BAV disease (Shenoy et al., 2014), although the 
lack of institutional access, limited local expertise, high cost and individual 
 Chapter 6: Real time exercise CMR imaging in BAV 
 183 
 
patient-related factors (i.e. presence of metallic device, claustrophobia, etc.) 
may limit its widespread adoption at the present time. Nevertheless, given the 
need for life-long routine serial arch imaging and the lack of radiation exposure 
that is associated with CT angiography, MR imaging appears to be the imaging 
modality of choice in the long-term follow-up of aortic pathologies in this group 
of often relatively young patients.  
 
It is well-established that individuals with BAV disease have larger aortic 
annulus, sinus and proximal ascending aorta compared to those with TAV 
(Cecconi et al., 2005, Nkomo et al., 2003) and progressive aortic dilatation 
occurs more commonly in those with larger aortas at baseline (Holmes et al., 
2007, Michelena et al., 2011). Further, accumulating evidence suggests that 
BAV-related aortopathy has a highly heterogeneous phenotypic expression, 
even amongst patients with specific valve fusion pattern and similar level of 
valve dysfunction (Barker et al., 2012, Girdauskas et al., 2011a, Hope et al., 
2012, Schaefer et al., 2008). This likely reflects the diversity in genetic, 
molecular, rheologic, and clinical features underlying aortic abnormalities in 
BAV (Verma and Siu, 2014). Whilst studies have linked genetics to the 
development of BAV-related aortopathy, the important role of valve-related 
alterations in aortic hemodynamic and their impact in the underlying aortopathy 
have been increasingly recognised (Girdauskas et al., 2011a). Recently, studies 
based on flow-sensitive 4D CMR have provided irrefutable evidence that the 
modified hemodynamic environments associated with BAV, even a ‘normally 
functioning one’, can cause altered wall shear stress in the ascending aorta, 
which may trigger maladaptive vascular remodelling (Hope et al., 2011, Hope et 
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al., 2012, Mahadevia et al., 2014). Indeed, intrinsic aortic wall abnormalities 
from accelerated degeneration of the aortic media have been reported in 
thoracic aortic tissue of BAV patients, including decreased fibrillin, elastin 
fragmentation, matrix disruption and apoptosis (Fedak et al., 2002). These 
intrinsic wall abnormalities are likely to have negative impacts on aortic 
biomechanical properties, such as aortic wall elasticity and compliance, which 
may in turn impact on aortic aneurysm development and growth rate. 
 
However, not every individual with BAV develops aortic dilatation (Michelena et 
al., 2011, Tadros et al., 2009). In those who do, many (up to 43%) may not 
progress (Detaint et al., 2014); and in those who do progress, the rate of 
progression varies significantly between individual patients, independent of 
baseline aortic diameter, BAV morphology or valve dysfunction (except in a 
smaller subset of those with aortic regurgitation and sinus of Valsalva dilatation) 
(Detaint et al., 2014). This suggests the presence of inherent differences in how 
each individual aorta of BAV patients responds to hemodynamic shear stress 
associated with activities of daily living. This inherent variability in aortic 
mechanical properties may explain the generally higher growth rate of 
ascending aortic dilatation in patients with BAV compared to TAV and may be 
used to categorise those BAV patients who are ‘progressor’ or ‘non-progressor’ 
in terms of aortic dilatation. Therefore, the hypothesis behind this study is that 
the increased hemodynamic shear stress produced by exercise can be used to 
identify the differential aortic wall mechanical properties between BAV patients 
with predisposition for BAV-related aortopathy and those with TAV, and thus 
allowing identification of those at risk for adverse events.  
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CMR imaging has previously been established as an accurate non-invasive tool 
for assessment of aortic stiffness, compliance and distensibility (Melina et al., 
2002, Metafratzi et al., 2002). Conventionally, this is performed using a 
combination of ECG-gated spin echo, retrospectively gated bSSFP (balanced 
steady state free precession) cine sequences and standard phase-contrast 
CMR imaging (Metafratzi et al., 2002). This approach requires breath-holding 
and regular cardiac rhythm, rendering it impractical for exercising individuals. 
Recently, a free-breathing high-resolution real-time phase-contrast cine CMR 
imaging technique has been developed and successfully used to detail 
physiological blood flow changes in the ascending aorta, even during Valsalva 
and Mueller manoeuvres, with high reliability and sufficient spatiotemporal 
resolution (Sohns et al., 2013, Lin et al., 2012c).    
 
To the best of our knowledge, real-time CMR imaging has not previously been 
used to study the impact of exercise on the differential aortic wall mechanical 
properties, namely aortic distensibility, compliance and stiffness index, between 
patients with BAV and TAV. Accordingly, the current pilot study sought to use 
real-time CMR imaging to identify the differential aortic wall mechanical 
properties in response to hemodynamic stress, at rest and during exercise, 
between BAV patients and those with TAV, in the absence of significant valve 
dysfunction or overt aortic dilatation.  
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6.2. PATIENTS AND METHODS 
6.2.1. Study populations 
Between September 2013 and January 2014, 6 patients with BAV and 6 age- 
and gender-matched healthy subjects were prospectively studied with CMR 
imaging at the Royal Prince Alfred Hospital, Sydney, Australia. The patients 
with BAV were identified and recruited from our institutional BAV disease 
database.  Inclusion criterion was the presence of BAV as diagnosed by 
echocardiography. Exclusion criteria were evidence of more than mild aortic 
stenosis (peak aortic velocity of ≥3.0 m/sec on echocardiography) and/or 
regurgitation as per the American Heart Association and the American College 
of Cardiology guidelines (Bonow et al., 2008), more than mild ascending aortic 
dilatation (≥4.5cm), co-existing aortic coarctation or other forms of congenital 
heart disease, Marfan syndrome or other connective tissue disorders, previous 
surgery or intervention of the aorta or aortic valve, usage of beta blockers or 
non-dihydropyridines calcium channel blockers, and general contraindications 
to CMR imaging. Clinical characteristics and functional status as expressed as 
New York Heart Association class of the patients were obtained from the 
medical records and/or clinical direct assessment. 
 
Age- and gender-matched healthy volunteers consisted of PhD students or 
employees at the Centenary Institute, Sydney, Australia, in whom BAV or other 
congenital cardiac pathology had been excluded by clinical history, physical 
examination and echocardiography. The study protocol was approved by the 
Sydney South West Area Health Service Human Research Ethics Committee 
and all subjects gave informed consent at the time of the CMR scan. 
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6.2.2. CMR imaging 
CMR imaging was performed using 1.5 Tesla Phillips Achieva MR scanner 
(Phillips Medical System, Best, Netherland). The study protocol is summarised 
in Table 6.1. Dr. Rajesh Puranik and/or Dr. Madhusudan Ganigara provided co-
supervision during all CMR studies. 
 
Table 6. 1. CMR imaging protocol used in the study. 
CMR Imaging Protocol 
BP and BSA measurement ☐  
Routine resting image 
(baseline) 
1. T1-scout scan (planning) ☐  
2. 3-point plan cine across aortic arch ☐  
3. LVOT cine  ☐  
4. Aortic flow ☐  
5. Sagittal oblique NAVIGATOR ☐  
Free breathing, real 
time (RT) phase 
contrast flow and cine 
CMR imaging 
 
 
 
 
1. Baseline RT flow 
• RT-flow* 
• RT-cine* 
☐  
2-3 minutes exercise 
2. Exercise Stage 1 RT flow 
• RT-flow* 
• RT-cine* 
☐  
Rest followed by 2-3 minutes exercise 
3. Exercise Stage 2 RT flow 
• RT-flow* 
• RT-cine* 
☐  
Rest 3 minutes 
4. Recovery RT flow 
• RT-flow* 
• RT-cine* 
☐  
*All real time (RT)-flow and RT-cine assessment were performed at 4 different 
levels, as depicted by the figure insert, namely: (1) Pulmonary artery level, to 
obtain proximal ascending aorta and proximal descending aorta diameters; (2) 
transverse arch level; and (3) right hemidiaphragm level to obtain diaphragmatic 
aorta diameter. BP, blood pressure; BSA, body surface area; LVOT, left 
ventricular outflow tract. Image adopted from www.ucaorta.org/aortic-arch.html 
with modification. 
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6.2.2.1. Baseline (resting) CMR data 
6.2.2.1.1. Aortic cine imaging 
Evaluation of the dynamic changes across the aortic arch and LVOT 
morphology was assessed using cine CMR imaging. Retrospectively gated 
steady-state free precession (bTFE, balanced turbo field echo) cine CMR 
images of the aortic long axis, along the ascending, transverse, arch and 
descending aorta were routinely undertaken. The LVOT was examined in two 
perpendicular views. The following imaging parameters were used: repetition 
time [TR] = 2.9 - 3.5 ms; echo time [TE] = 1.4 - 1.6 ms; flip angle = 60°; slice 
thickness = 10 mm; matrix = 256 x 192; field of view = 340 mm; and temporal 
resolution ≤ 40 ms; acquired during a single breath-hold.  
 
6.2.2.1.2. Aortic dimensions: 3-D sagittal oblique NAVIGATOR 
Measurements were acquired with a non-contrast, free breathing NAVIGATOR-
gated 3D balanced fast field echo (FFE) CMR sequence, where the data was 
acquired in mid-diastole and during expiration (Figure 6.1). Slices were 
obtained in the sagittal plane in several contiguous locations to ensure 
complete coverage of the thoracic aorta. Imaging parameters were TR = 4.7 
ms; TE = 2.3 ms; flip angle = 90°; slice thickness = 1.0 mm; matrix = 192 x 512; 
field of view = 400 mm. Aortic measurements were made systematically at the 
level of the proximal ascending aorta, transverse aortic arch, proximal 
descending aorta and distal descending aorta at the level of the diaphragm.  
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Figure 6. 1. Example of aortic dimension measurements using images 
obtained using 3D Sagital Oblique NAVIGATOR sequence in a patient with 
BAV. 
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6.2.2.1.3. Aortic flow quantification: Phase Contrast Data 
Assessment of aortic blood flow was acquired by use of a flow-sensitive 2D T1 
fast field echo sequence (T1-FFE; TR = 4.4 ms; TE= 2.8 ms; flip angle = 15°; 
slice thickness = 10 mm; field of view = 360 mm; matrix = 176 x 256; 40 heart 
phases; phase contrast velocity encoding of 200 cm/sec) acquired during a 
breath-hold. Imaging plane was located at the midpoint of the ascending aorta 
(at the level of main pulmonary artery bifurcation), where through-plane flow 
data was acquired by use of retrospective cardiac gating. Arterial blood flow 
was calculated from phase contrast images by use of a semiautomatic vessel 
edge-detection algorithm (Reportcard, GE) with manual operator correction. Net 
forward flow within the proximal ascending aorta (ml) and aortic regurgitation 
fraction (%) was calculated as total aortic flow minus backward aortic flow and 
percent backward aortic flow over total aortic flow, respectively.  
 
6.2.2.2. Exercise-based free breathing real-time CMR data  
6.2.2.2.1. Exercise protocol during CMR imaging 
Participants performed progressive resistance exercise using a custom built 
pneumatic MRI-compatible pedal ergometer, which was attached to the foot of 
the MRI table. The exercise study consisted of 2 stages; Stage 1 was achieved 
when participants achieved at least 30% of their maximum predicted heart rate 
(MPHR) and Stage 2 when at least 60% of MPHR was reached. A higher 
intensity exercise was not included in the protocol as excessive movements 
may degrade the quality of the data. The MPHR was calculated adding either 
30% or 60% of the participant’s heart rate reserve (HRR), depending on the 
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stage of exercise performed, to the resting heart rate. The HRR was obtained 
by subtracting the resting heart rate from the maximum predicted heart rate (i.e. 
220 minus participant’s age at the time of the study).   
 
Participants were monitored while pedalling in a recumbent position against a 
low to moderate level of resistance and at a moderate level of cadence for a 
period of 3-5 minutes. Regular prompts were provided during the test to 
progressively increase the level of exercise until the predetermined target heart 
rate was achieved, following which data acquisition was commenced (using free 
breathing real-time CMR imaging; Chapter 6.2.2.2.2). Participants continued to 
exercise during the scanning. The total scan time during each stage of exercise 
was less than 2 minutes. Periodic automated left brachial blood pressure and 
continual oxygen saturation measurements (Medrad® Veris® MR Vital Signs 
Monitor, Bayer Health Care, Pennsylvania, USA) were obtained throughout the 
testing procedure. Participants were given a 3-minute rest period between the 2 
exercise stages. At the completion of 2nd stage of exercise, participants were 
given a 3- to 5-minute period of recovery, following which the final real-time 
data acquisition was obtained. 
 
6.2.2.2.2. Free breathing real-time flow and cine CMR imaging 
Imaging slices for real-time CMR imaging were obtained in the axial plane of 3 
locations of interest, specifically: (1) at the main pulmonary artery level, to 
obtain proximal ascending aorta and proximal descending aorta diameters; (2) 
at the transverse arch level, at the mid point between the origin of left common 
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carotid and left subclavian artery; (3) at the right hemidiaphragm level to obtain 
diaphragmatic aorta diameter. Real-time cine and flow measurements were 
performed on these imaging planes at 4 study phases: at rest (baseline), during 
stage 1 and stage 2 of exercise when the targeted MPHR was reached, and 
finally, during recovery. Each flow data set consisted of 100 consecutive 
dynamic scan, free breathing, real-time (no ECG-triggering), 2D T1-FFE 
sequence, 60 seconds acquisition (TR =11.0 ms; TE = 4.9 ms; flip angle = 15°; 
slice thickness = 10 mm; matrix = 112 x 144; field of view = 400 mm; flow 
encoding velocity 200 cm/sec). Each cine data set consisted of 40 consecutive, 
free breathing, real-time (no ECG-triggering), balance turbo field echo (bTFE) 
sequence with sensitivity encoding (SENSE) acquisition (TR = 2.7 – 3.5 ms; TE 
= 1.3 – 1.5 ms; flip angle = 50°; slice thickness = 10 mm; matrix = 192 x 224; 
field of view = 400 mm).  
 
6.2.3. Analysis of aortic mechanical properties  
Analyses of aortic biomechanical properties, including aortic regional 
compliance, distensibility and aortic stiffness index (β), were performed at the 
proximal ascending aorta and diaphragmatic aorta at rest (baseline) and during 
exercise, using the real-time cine CMR data.  
 
Arterial compliance is defined as the absolute change in area for a given 
pressure step at a fixed vessel length and is the reciprocal of arterial stiffness 
(Antonini-Canterin et al., 2009). Aortic compliance (in mm2/mmHg) is calculated 
as (Amax – Amin)/(SBP – DBP) (Antonini-Canterin et al., 2009), with Amax and Amin 
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as maximal and minimal cross-sectional lumen area (in mm2) of the aortic 
segment studied, and SBP and DBP as systolic and diastolic brachial blood 
pressure (in mmHg), respectively.  
 
In contrast, aortic distensibility is defined as the relative compliance, or the 
relative change in area for a given pressure step increase (Antonini-Canterin et 
al., 2009).  Aortic wall distensibility assessment (in cm2dyne-110-6) by CMR 
imaging is calculated according to the following formula (Cavalcante et al., 
2011): (Amax – Amin)/(Amin x [SBP – DBP] x 1,000). Meanwhile, aortic stiffness 
index (β) is a surrogate marker of the stiffness of the vascular wall and is 
calculated as ln(SBP /DBP)/([ Amax – Amin]/ Amin) (Shibata and Levine, 2011, Tian 
and Chesler, 2012). 
 
6.2.4. Statistical analysis 
All data are presented as mean ± standard deviation (SD). The means of 
quantitative data involving 2 independent groups were analysed using a 2-tailed 
unpaired Student’s t-test. A 2-tailed paired-samples Student’s t-test was used to 
compare various measures of aortic mechanical properties at rest and during 
exercise amongst subjects within a group. Fisher’s exact test was used to 
assess relationship between groups with dichotomous variables. A 2-tailed p-
value ≤ 0.05 was considered statistically significant. Statistical analyses were 
performed using GraphPad Prism Version 6.0b (GraphPad Software, La Jolla, 
California, USA). 
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6.3. RESULTS 
6.3.1. Study population 
Between September 2013 and January 2014, 12 individuals (6 BAV and 6 age- 
and gender-matched healthy control) participated in the exercise CMR study. 
The baseline characteristics of the study participants are summarised in Table 
6.2. The BAV group comprised of 3 males (50%) with a mean age of 33 ± 6 
years at time of CMR imaging, which by study design, was similar to the control 
group. There were no significant differences between the BAV and the control 
group in terms of body mass index (BMI), body surface area (BSA), history of 
hypertension, or resting blood pressures. All patients were free from any 
cardiac symptoms at the time of CMR imaging with New York Heart Association 
functional class 1 and had normal LV function by resting echocardiography. 
Two-thirds of the BAV group had echocardiographic evidence of no more than 
mild valvular dysfunction (aortic stenosis and/or regurgitation). Further, whilst 
not overtly dilated, individuals with BAV had a significantly larger proximal 
ascending aorta compared to the control group (3.29 ± 0.31 cm vs 2.56 ± 0.24 
cm, p=0.001). There was no significant difference between the 2 groups in 
terms of transverse arch, proximal descending or diaphragmatic aortic 
dimensions. 
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Table 6. 2. Study cohort characteristics. 
Characteristics BAV (n=6) Control (n=6) p-value 
Age at CMR imaging (years) 33 ± 6 33 ± 7 0.965 
Male gender (%) 3 (50) 3 (50) 1.000 
Height (m) 1.64 ± 0.12 1.72 ± 0.07 0.177 
Weight (kg) 67 ± 19 64 ± 9 0.703 
BMI (kg/m2) 24.6 ± 4.8 21.4 ± 1.8 0.161 
BSA* (m2) 1.72 ± 0.29 1.75 ± 0.15 0.8330 
Hypertension (%) 1 (17)^ 0 (0) 1.000 
NYHA functional class I 6 (100) 6 (100) 1.000 
Normal LV function, EF>55% (%) 6 (100) 6 (100) 1.000 
Valvular function    
Normal 2 6 - 
Mild AS and/or AR 4$ 0 - 
Resting blood pressure (mmHg)    
Resting SBP  109 ± 12 112 ± 7 0.609 
Resting DBP  71 ± 11 68 ± 8 0.577 
Maximum aortic dimension (cm)#    
Proximal ascending aorta  3.29 ± 0.31 2.56 ± 0.24 0.001 
Transverse arch  2.00 ± 0.26 2.01 ± 0.14 0.924 
Proximal descending aorta  2.04 ± 0.36 2.02 ± 0.23 0.925 
Diaphragmatic aorta  1.75 ± 0.23 1.75 ± 0.24 0.991 
*Body surface area (BSA) is calculated using DuBois & DuBois formula (BSA = 
0.20247 x height (m)0.725 x weight (kg)0.425); $One patient has a mixed mild AS 
and AR, 1 has trivial AR and 2 has mild AS; ^One BAV patient has a history of 
mild hypertension, which was well controlled with a low dose angiotensin-II 
receptor blocker; #Measurements taken from 3D sagittal oblique NAVIGATOR 
CMR images. AS, aortic stenosis; AR, aortic regurgitation; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; PP, pulse pressure; NYHA, New York 
Heart Association.  
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6.3.2. Exercise data 
Table 6.3 summarises the exercise haemodynamic data amongst the 2 groups. 
Complete resting haemodynamic parameters were obtained from all patients. 
Compared to the BAV group, the control group had a lower resting heart rate 
(58 ± 5 vs 69 ± 10 beats per minute (bpm), p=0.036) and a slightly wider resting 
pulse pressure (44 ± 2 vs 38 ± 6 mmHg, p=0.039), despite having similar 
systolic and diastolic blood pressure levels.  
 
All patients in the BAV group achieved the target MPHR for stage 1 exercise 
whilst only 2 (33%) achieved the heart rate target for stage 2 exercise. 
Meanwhile, only 4 (67%) and 1 (17%) participants from the control group 
achieved the target MPHR for stage 1 and 2 exercise, respectively. Although all 
patients tolerated the exercise regime and no adverse events occurred during 
the test, calf muscle fatigue was commonly reported by participants who did not 
achieve the exercise target, which prevented them from performing a higher 
level of exercise. This resulted in an overall lower heart rate level observed in 
the control group compared to the BAV group during stage 1 of exercise (98 ± 2 
vs 111 ± 8 bpm, p=0.005).  
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Table 6. 3. Exercise haemodynamic data.  
Characteristics BAV  Control  p-value 
Number of patients, n (%) 6 (100) 6 (100) - 
Resting haemodynamic    
Heart rate (bpm) 69 ± 10 58 ± 5 0.036 
SBP (mmHg) 109 ± 12 112 ± 7 0.609 
DBP (mmHg)  71 ± 11 68 ± 8 0.577 
Pulse pressure (mmHg) 38 ± 6 44 ± 2 0.039 
Stage 1 exercise haemodynamic    
Heart rate (bpm) 111 ± 8 98 ± 2 0.005 
SBP (mmHg) 124 ± 17 131 ± 9* 0.425 
DBP (mmHg) 76 ± 19 78 ± 8* 0.828 
Pulse pressure (mmHg) 48 ± 5 53 ± 8* 0.254 
Patients achieving target MPHR for S1 exercise, n (%) 6 (100) 4 (67) - 
Patients achieving target MPHR for S2 exercise, n (%) 2 (33) 1 (17) - 
*These values were obtained from 5 out of the 6 participants in the control 
group due to sphygmomanometer failure occurring in 1 control participant at 
time of exercise. S1, stage 1 exercise; S2, stage 2 exercise; MPHR, maximum 
predicted heart rate; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. 
 
As three-quarters of the study population did not achieve the predetermined 
heart rate target for stage 2 exercise, from this point forward, analyses were 
performed only on participants with complete data sets available from stage 1 
exercise. This included data from 6 BAV patients (100%) and 3 healthy controls 
(50%). Three control participants were excluded from the exercise analysis due 
to failure to reach the exercise target for stage 1 (n=2) and sphygmomanometer 
malfunction at time of exercise (n=1), which precluded the necessary blood 
pressure assessment.  
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6.3.3. Real time exercise CMR imaging 
In general, real time measurements for dynamic evaluation of aortic dimensions 
were feasible in all patients, both at rest and during moderate level of exercise 
(Figure 6.2), provided that the same upper body position was maintained on the 
MRI table whilst exercising. Of note, alteration of the aortic imaging plane 
occurred in one-third of the study participants as they inadvertently moved up 
the MRI table whilst exercising at a higher intensity (particularly during stage 2 
of exercise), thus precluding comparative measurements to be made in these 
patients. Nevertheless, good spatiotemporal resolution was observed from the 
free-breathing real-time exercise CMR images, even when image acquisitions 
were performed with a heart rate of 150 bpm at the time of exercise.  
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Figure 6. 2. Real time (RT) CMR images of thoracic aorta at the level of 
main pulmonary artery bifurcation in a patient with BAV.   
Images were taken at rest (A, C and D) and during stage 2 of exercise (B), with 
heart rates of 70 bpm and 135 bpm, respectively. The images at the top panel 
(A, B) showed good spatiotemporal resolution of RT CMR imaging even during 
exercise. This allowed accurate assessments of the dynamic change in aortic 
area with each cardiac cycle as depicted by the lower panel, during maximal (C) 
and minimal aortic flow (D). PA, pulmonary artery; Asc Ao, ascending aorta; 
Desc Ao, descending aorta. 
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The biomechanical properties of the proximal ascending aorta and 
diaphragmatic aorta are compared between the BAV and the control groups in 
Table 6.4. Overall, no significant differences were observed in aortic 
distensiblity, compliance or stiffness between the 2 study groups, at rest or 
during low-level exercise, either at the level of proximal ascending aorta or 
diaphragmatic aorta. However, an immediate reduction of the proximal 
ascending aortic compliance was seen amongst subjects with BAV following a 
short period of resistance exercise using pedal ergometer (3.87 ± 1.25 and 2.89 
± 1.79 mm2/mmHg at rest and exercise, respectively, p=0.035), albeit a low 
intensity one (Stage 1 exercise) (Table 6.5). Furthermore, exercise resulted in a 
significant reduction of aortic distensibility at the level of proximal ascending 
aorta (5.84 ± 2.61 vs 3.89 ± 2.89 cm2dyne-110-6 at rest vs exercise, respectively, 
p=0.019) and diaphragmatic aorta (8.24 ± 2.08 vs 6.66 ± 1.68 cm2dyne-110-6 at 
rest vs exercise, respectively, p=0.030) amongst the BAV cohort (Table 6.5). 
Whilst similar trends for reduction in aortic compliance and distensibility in 
response to exercise were also observed amongst the control group, they did 
not reach statistical significance. 
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6.4. DISCUSSION 
The purpose of the current pilot study was to use free-breathing real-time CMR 
imaging to evaluate the differential aortic wall mechanical properties in 
response to hemodynamic stress at rest and during exercise between patients 
with BAV and TAV, in the absence of significant valve dysfunction or overt 
aortic dilatation. This study showed that free-breathing real-time CMR imaging 
was able to provide adequate spatial and temporal resolutions to allow dynamic 
structural assessment of the aorta, at rest and during exercise, even with a 
rapid heart rate response of up to 150 bpm. In addition, whilst this study did not 
detect differential aortic mechanical properties between the BAV and control 
groups, immediate reduction in a number of measures of aortic elastic 
properties were observed amongst the BAV cohort in response to a brief period 
of low level resistance exercise. This included reduction in proximal ascending 
aortic compliance and distensibility, and interestingly, a decrease in aortic 
distensibility beyond the aortic arch, at the level of diaphragmatic aorta. This 
pilot study therefore provided an important foundation for further evaluation in a 
larger cohort to validate these findings. 
 
Previous studies have established CMR imaging as a valuable noninvasive, 
accurate and reproducible tool to evaluate aortic wall function (Melina et al., 
2002, Metafratzi et al., 2002). Unlike the standard applanation tonometry, which 
gives an average measure of the overall arterial stiffness, CMR imaging 
enables the detection of more subtle changes in regional stiffness of the aortic 
segment of interest (Cavalcante et al., 2011). Further, CMR ability to provide a 
 Chapter 6: Real time exercise CMR imaging in BAV 
 
204 
 
full 3-dimensional visualization of the aorta enables the imaging plane to be 
placed perpendicular to the vessel wall in a reproducible location, thus allowing 
accurate assessment of aortic distensibility and compliance (Cavalcante et al., 
2011). These assessments are traditionally performed at rest and during breath 
holds, as high CMR image quality requires regular heart rhythm and constant 
cardiac position. Exercise therefore poses a significant challenge for standard 
CMR image acquisition, as a reliable ECG signal is difficult to obtain (due to 
magneto-hydrodynamic turbulence) and vigorous respiration causes cardiac 
translation, resulting in blurring or ghosting of images collated across cardiac 
cycles and spatial planes (La Gerche et al., 2013). To overcome this challenge, 
a free-breathing real-time CMR imaging technique has recently been developed 
and successfully used to evaluate biventricular volumes quantification during 
high-intensity exercise with high reproducibility and accuracy (La Gerche et al., 
2013). In response to this finding, the present study evaluated the feasibility of 
real-time CMR imaging in evaluating the arterial mechanics in patients with BAV 
during moderate intensity exercise. Here, our study showed that free-breathing 
real time CMR imaging was indeed able to provide adequate spatial and 
temporal resolutions to allow dynamic structural assessment of the aorta, both 
at rest and during exercise. This likely has important implications for the 
development of future imaging protocols and other large vessels researches. 
 
However, the present study did not detect a significant difference in measures 
of aortic elastic properties between the BAV and control groups, either at rest or 
exercise. This result is unexpected and is in contrast to previous studies that 
have shown the presence of significantly reduced resting aortic elasticity in 
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patients with BAV, even at the non-dilated stage, which not only affects the 
proximal part of the aorta but also extends into the entire aorta (Nistri et al., 
2008, Grotenhuis et al., 2007, de Wit et al., 2013, Forsell et al., 2014). It is 
highly likely that the inherent limitation created by a small sample size used in 
this pilot study has resulted in insufficient power to detect a significant 
difference. Hence, further evaluation in a larger cohort is required. 
 
Nevertheless, this study was able to detect an immediate alteration in aortic 
biomechanical properties amongst patients with BAV in response to a brief 
period of low-level resistance exercise, using a pneumatic pedal ergometer. 
The reductions in aortic distensibility and/or compliance were noted in both the 
ascending thoracic aorta and diaphragmatic aorta. While this finding is in 
agreement with a previous study which has shown that one bout of resistance 
exercise can acutely and transiently decreases central arterial compliance in 
healthy individuals (DeVan et al., 2005), this study is the first to investigate the 
impact of resistance exercise on arterial mechanics in individuals with BAV. As 
intense physical exertion, such as weight lifting, have been causally linked as 
an inciting event leading to aortic dissection (Hatzaras et al., 2007), this finding 
is important as it provides additional mechanistic insights into this potentially 
fatal event. Indeed, a combined effect of the inherent weakness in the 
mechanical properties of the aortic wall of BAV patients, a further reduction in 
aortic elasticity (or increasing aortic stiffness) occurring acutely during 
resistance exercise, and exercise-induced rise in central arterial blood 
pressures likely results in critically high wall tension that exceeds the tensile 
strength of the aortic wall, hence predisposing them to tearing at time of intense 
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exercise. Notably, the risk of aortic dissection in patients with BAV was 
approximately 8 times higher than the general population (Michelena et al., 
2011).  
 
However, the reason behind the acute reduction in aortic elasticity, or increased 
in aortic stiffness, during resistance exercise is not entirely clear. It had been 
suggested that an increase in sympathetic adrenergic vasoconstrictor tone and 
impaired endothelial function could be responsible for this phenomenon (DeVan 
et al., 2005, Pratley et al., 1994, Raastad et al., 2001). Interestingly, aerobic 
exercise, such as running, had been shown to give the opposite effect where an 
increased in arterial compliance was observed immediately following the 
exercise. Similarly, the mechanism behind this observation is unclear and could 
be related to sympathoinhibition after aerobic exercise (Seo et al., 2013). 
Therefore, given the contrasting effect of the different type of exercises on 
aortic mechanical properties, further study using a larger cohort that compares 
the impact of aerobic and resistance exercise on BAV aortas, in those with and 
without aortic dilatation, would be important. This has significant clinical 
implications whilst recommending an individualised exercise prescription in 
patients with BAV. 
 
Further, although not overtly dilated, the presence of BAV in the study cohort 
was associated with significantly larger ascending aortic dimension, compared 
to the healthy controls with TAV, which is consistent with previous reports 
(Puranik et al., 2009, Padang et al., 2014). Given the common occurrence of 
ascending aortic dilatation and/or aneurysm in BAV and the presence of 
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inherent structural wall abnormality in the ascending aorta of BAV patients, 
irrespective of the underlying valve haemodynamic, a meticulous life-long 
surveillance protocol is clearly warranted in this group of patients, in case of 
progressive aortic enlargement over time (Padang et al., 2014). 
 
This study has a number of limitations to be acknowledged. As a pilot study, 
this study was conducted in a small sample size and thus has inadequate 
power to conclusively address the research question. A larger study is therefore 
needed. All MRI-based measurements in the present study were made solely 
by the author of this thesis. Therefore, inter-observer variability and 
reproducibility need to be evaluated prior to its future application. Further, whilst 
real-time CMR imaging can achieve good spatiotemporal resolution for 
measurements of dynamic changes within the vascular wall, a constant position 
on the MRI table during image acquisition whilst exercising remains important. 
Alteration in imaging plane as subjects shifted their position upwards on the 
MRI table was observed in one-third of the study during stage 2 of exercise, 
precluding further analysis. In the future, this could be avoided by providing a 
fixed shoulder harness, attached to the table, to prevent upwards shifting during 
intense exercise. Additionally, three-quarters of the study participants failed to 
reach the heart rate target for stage 2 exercise, as calf muscle fatigue 
prevented more vigorous exercise, thus limiting the heart rate response when 
patients cadence on the pedal ergometer gradually decreased. Different types 
of exercise during CMR imaging should therefore be considered, such as using 
programmable cycle ergometer. Also, as previously mentioned, a comparative 
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study on the impact of the different type of exercises on BAV aortas should be 
undertaken. 
 
In conclusion, this pilot study supports the use of free-breathing real time CMR 
imaging in the assessment of dynamic structural alteration of the aorta in 
response to haemodynamic variations at rest and during exercise. Further study 
with a larger cohort is required to conclusively evaluate the differential impact of 
exercise on aortic wall mechanical properties between patients with BAV and 
TAV. A clinical correlation to evaluate the relationship between the degree of 
alteration in their aortic elastic properties and long-term outcomes in terms of 
aortic events would be equally important. Identification of different aortic 
mechanical properties between patients with BAV and TAV, or even amongst 
the BAV patients themselves (i.e. between those with and without aortic 
dilatation), during episodes of increased haemodynamic stress is important as it 
could potentially be used as imaging biomarker to identify patients with a more 
‘malignant’ disease course. For this purpose, CMR imaging is indeed an 
invaluable non-invasive imaging tool for the assessment and follow-up of 
patients with this relatively common syndrome. 
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7.1. SUMMARY AND FUTURE RESEARCH 
Whilst the familial clustering and heritability of BAV disease have been 
increasingly recognised in the past 4 decades, the underlying genetic basis of 
BAV in humans remains mostly undetermined. And although clinical 
heterogeneity seen in BAV possibly reflects complex and variable interplay 
between specific gene mutations, modifier loci, epigenetic control and 
environmental influences (particularly haemodynamic basis), the gene and 
molecular pathways that drive specific phenotypic expression and determine 
disease progression / outcome are not well understood. Moreover, identification 
of individuals with BAV who are at the highest risk for related complications 
presents a highly challenging task for most clinicians today.  The work carried 
out in this thesis aimed to address these gaps in our present knowledge of BAV 
disease. The work focused on many aspects of BAV disease, from the 
investigation of genetics underlying BAV development using candidate gene 
approach (Chapter 3) and whole exome sequencing (Chapter 4), elucidation of 
genes and molecular pathways that determine valve degeneration in adult 
patients with BAV by means of RNA sequencing (Chapter 5), to efforts in 
identifying novel imaging biomarkers that can potentially be used to predict 
those with the highest risk for adverse aortic complications using state-of-the-art 
real-time exercise CMR imaging (Chapter 6). An overview of the studies 
completed in this project is presented in Figure 7.1. Much of the work carried 
out in this thesis will form a foundation for future research, building on the 
genetic data obtained from exome and RNA sequencing studies, as well as 
clinical and imaging data obtained from the CMR study. 
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7.1.1. Identification of causative and modifier genes in BAV disease 
BAV is a clinically heterogeneous disorder with valve dysfunction and related 
aortopathy being the major complications. However, despite it being the most 
common congenital heart defect in adults that is accountable for more deaths 
and complications than the combined effects of all the other congenital heart 
defects, the underlying genetic basis of BAV is mostly unknown (Padang et al., 
2012b, Siu and Silversides, 2010). Genetic studies and familial clustering 
demonstrate that BAV is a highly heritable disease (Cripe et al., 2004, Garg et 
al., 2005, Siu and Silversides, 2010). Until recently, only mutations in the 
transcriptional regulator NOTCH1 gene have been linked to the development 
and calcific progression of non-syndromic BAV in humans, in a limited number 
of familial cases and ~4% of sporadic cases (Garg et al., 2005, McKellar et al., 
2007, Mohamed et al., 2006). For the remaining majority, the underlying genetic 
basis of BAV is undetermined.  
 
Recently, studies in animal models have demonstrated the essential role of 
GATA5 in cardiac morphogenesis and aortic valve development (Laforest et al., 
2011, Laforest and Nemer, 2011). Further, in 2011, Laforest et al. reported that 
targeted deletion of Gata5 in mice led to partially penetrant BAV (Laforest et al., 
2011). At the time of commencement of this PhD, there had been no study that 
evaluated the role of GATA5 mutation in human BAV disease. 
 
Following Laforest et al. work on Gata5-/- murine model, this project first 
evaluated the role of GATA5 mutation in human BAV disease. The results are 
 Chapter 7: Summary and Conclusions 
 
213 
 
presented in Chapter 3, which reported the presence of rare non-synonymous 
variants within the transcriptional activator domains I and II of the GATA5 gene, 
affecting 4 out of the 100 prospectively recruited BAV cohort. These variants 
may alter the transcriptional activity of GATA5 and thus may contribute to BAV 
development. This study was first to provide support for the potential role of 
GATA5 in the development of human BAV disease. This finding was 
subsequently reinforced by 2 more recent studies, using 2 independent BAV 
cohorts, and the pathogenicity of the variants found were supported by in-vitro 
assays (Bonachea et al., 2014 [Epub ahead of print], Shi et al., 2014). However, 
it remains uncertain if rare non-synonymous GATA5 variants are directly 
causative or serve as critical genetic modifiers and future studies that explore 
this relationship are warranted.  
 
Further, while this finding is important, - like the NOTCH1 gene and similar to 
findings from the other studies -, GATA5 variants are not responsible for the 
majority of cases of BAV. Hence, the project also explored a number of other 
candidate genes, including investigating the relationship between NKX2-5 
mutations and BAV in the same patient cohort, as well as screening the 
NOTCH1 and GATA4 genes in a small subset of the study cohort. However, no 
potentially pathogenic variants were identified during screening of these 
candidate genes. Therefore, further investigation to explore new candidate 
genes for BAV disease is needed. 
 
Meanwhile, advancements in sequencing-based technologies over the past 
decade have resulted in the emergence of massively parallel sequencing 
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technologies, such as whole exome sequencing. Whole exome sequencing is a 
powerful tool in the study of complex diseases, such as BAV, as it provides an 
unbiased, cost-effective, and comprehensive genetic screening strategy 
(Bamshad et al., 2011, Towne et al., 2013), which allows discovery of novel, 
unanticipated pathogenic gene variants that play a role in disease development. 
 
Given the limitation and the relatively low success rate of candidate gene 
approach in the study of BAV genetics, whole exome sequencing studies were 
then adopted to investigate the genetics underlying familial cases of BAV 
(Chapter 4). Exome sequencing data was obtained on 6 affected individuals 
originating from 2 large families with preponderance for BAV and the related 
aortopathy (i.e. 3 individuals per family). There were 3 key findings resulting 
from the subsequent co-segregation analyses in this study. Firstly, heritability of 
familial cases of BAV appeared to be autosomal dominant with incomplete 
penetrance and highly variable clinical manifestations. Secondly, the 2 families 
had a completely different list of shared candidate gene variants. Assuming that 
the causative variant was present within the lists, this implied that different 
genetic mutations to be responsible for the development of BAV in Family A 
and B. While this finding is not completely unexpected, it supported a previous 
observation that suggested the presence of mutations in diverse genes (i.e. 
genetic heterogeneity) to be responsible for the development of BAV in different 
families (Cripe et al., 2004). Finally, this study identified mutations in the GDNF-
related pathway to be mutually occurring in both families, thus providing some 
clues toward its potential regulatory role in BAV development, which warrants 
further investigation.  
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Overall, findings from the candidate gene approach and exome sequencing 
studies highlighted the complex and heterogeneous nature of BAV genetics and 
the likely presence of genetic modifiers or other regulatory control during BAV 
development. Whilst the genetic basis of BAV in the majority of cases remains 
to be elucidated, this project has given new insights into the underlying genetic 
basis of BAV in humans. It also has provided a platform for future research, in 
particular studies that continue to build on the genetic analyses performed to 
date, including the completion of co-segregation studies in both families upon 
further recruitment of additional family members and performing rare copy 
number variant analysis on the available exome data. 
 
7.1.2. Molecular pathways underlying structural valve degeneration in 
BAV 
The work in this thesis subsequently focused on the molecular pathogenesis 
behind structural valve degeneration in human BAV disease. Structural valve 
degeneration (SVD) and consequent valve dysfunction is the most common 
complication of BAV disease, which is highly heterogeneous in its clinical 
manifestation. It is believed that aberrant and variable modulation of both 
qualitative and, to a larger extent, quantitative level of gene expression at the 
level of the aortic valve, e.g. through splice site variation, 3’-untranslated 
regulatory regions, noncoding RNAs and the direct interactions of transcription 
factors, likely contribute to the marked phenotypic heterogeneity observed in 
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SVD in BAV disease. To investigate this further, transcriptome interrogation 
was performed using RNA sequencing.  
 
RNA sequencing is particularly useful in providing a snapshot assessment on 
the present state of gene expression for a given cell or tissue, which ultimately 
is the product of interaction between genetic factors, environmental influences 
and even the effect of the disease state itself on the transcriptome (Churko et 
al., 2013, Schnabel et al., 2012). Elucidation of distinct gene expression 
signatures in different BAV disease states can therefore provide insight into 
perturbed molecular pathways contributing to a specific valve disease 
phenotype, such as a predominantly calcific BAV with stenosis or a 
predominantly regurgitant BAV with leaflet redundancy. In turn, this may lead to 
the identification of novel therapeutic target that aims at delaying or stopping 
valve disease progression.  
 
Findings in Chapter 5 described, for the first time, the result of genome-wide 
differential transcriptome profiling underlying SVD in human BAV compared to 
TAV using RNA sequencing. The study identified that differential gene 
expression profiles existed even within the BAV group themselves, dividing 
them into those with calcification predominant disease and those with primarily 
redundant leaflet degeneration. Further, it demonstrated the relatively close 
resemblance of gene expression patterns of calcified human BAV and TAV 
leaflets, with shared upregulation of inflammatory pathways and downregulation 
of NOTCH1 signalling, indicating a common mechanism of calcific leaflet 
degeneration in both BAV and TAV. This finding on the importance of NOTCH1 
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signalling in the development of calcific aortic valve stenosis in both BAV and 
TAV supported results from previous studies that showed the presence of rare 
functional DNA variants at the NOTCH1 locus in patients with severe aortic 
stenosis in the context of BAV and TAV (Garg et al., 2005, Ducharme et al., 
2013). Moreover, a unique pattern of dysregulation of foetal gene programs was 
also identified amongst the different study subgroups. This provides further 
support to a growing body of evidence, which suggests that developmental 
pathways important in valvulogenesis also contribute to adult valve disease 
(Lincoln et al., 2006). Taken together, these findings indicated the presence of 
distinct gene expression signatures that marked the different type of SVD in 
BAV, compared to TAV, supporting the emerging theory that BAV is 
heterogeneous with respect to molecular events in disease progression (Fedak, 
2008). Further research however is necessary to confirm these findings and 
determine if these differential gene expression patterns and molecular 
mechanisms can be exploited for new clinical therapies. 
 
7.1.3. Utility of real-time exercise CMR imaging in BAV-related aortopathy 
In the final part of this thesis, my work concentrated on the identification of new 
clinical markers to improve risk stratification of BAV patients who are at risk for 
developing adverse aortic complications. Here, the project investigated the role 
of state-of-the-art real-time CMR imaging in the evaluation of differential aortic 
wall mechanical properties between patients with BAV and TAV in response to 
hemodynamic stress at rest and during exercise, which can potentially be used 
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as an imaging biomarker to predict those with a more aggressive disease 
phenotype (Chapter 6).  
 
BAV-related aortopathy, another common complication of BAV disease that 
affects over 50% of patients (Fedak et al., 2002), is a potentially lethal condition 
due to the propensity for dissection or rupture. Similar to the valvular 
manifestation, BAV-related aortopathy has a highly heterogeneous phenotypic 
expression and both genetic and haemodynamic factors contribute to its 
development (Padang et al., 2013). Further, the rate of progression and clinical 
outcome of those with BAV-related aortopathy varies significantly between 
individual patients (Detaint et al., 2014). This suggests the presence of inherent 
differences in how each individual aorta responds to haemodynamic shear 
stress associated with activities of daily living. Presently, making a clinical 
prediction regarding which patient has a more ‘malignant’ disease phenotype, 
and thus would benefit from an earlier and/or more extensive intervention, is a 
highly challenging task for most clinicians, and yet, it has important surgical 
implications. There is therefore a pressing need for the identification of novel, 
non-invasive imaging biomarker that can predict for the development of adverse 
outcome in those with predispositions for BAV-related aortopathy. 
 
This awareness had led to a pilot study utilising free-breathing real-time CMR 
imaging to evaluate the differential aortic mechanical properties between 
patients with BAV and TAV in response to exercise, as described in Chapter 6. 
The hypothesis behind this study was that the increased hemodynamic shear 
stress produced by exercise could exaggerate the differential aortic wall 
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mechanical properties between BAV patients with predisposition for BAV-
related aortopathy and those with TAV, thus identifying those at risk for adverse 
events.  
 
This study had 2 key findings. Firstly, it demonstrated that free-breathing real-
time CMR imaging was able to provide the necessary spatial and temporal 
resolution to allow accurate dynamic structural assessment of the aorta, both at 
rest and during exercise, even with a heart rate response as high as 150 bpm. 
This finding has important implications for the development of future imaging 
protocols and other large vessel research. Secondly, whilst this study did not 
detect a statistically significant difference on aortic mechanical properties 
between patients with BAV and TAV, presumably a result of the inherent 
limitation created by a small sample size, the study identified an immediate 
reduction of aortic elastic properties amongst patients with BAV in response to 
a brief period of resistance exercise. While this finding is in agreement with a 
previous study which shows that one bout of resistance exercise can acutely 
and transiently decreases central arterial compliance in healthy individuals 
(DeVan et al., 2005), this study is the first to investigate the impact of resistance 
exercise on arterial mechanics in individuals with BAV. As intense physical 
exertion, particularly resistance exercise such as weight lifting, have been 
causally linked as an inciting event leading to aortic dissection (Hatzaras et al., 
2007), this finding is important as it provides additional mechanistic insights into 
this potentially fatal event, especially since the risk of aortic dissection in 
patients with BAV was approximately 8 times higher than the general population 
(Michelena et al., 2011).  
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This study therefore provided an important foundation for further evaluation in a 
larger cohort to validate these findings, as well as to conclusively evaluate the 
impact of exercise on the differential aortic wall mechanical properties between 
patients with BAV and TAV. Data obtained from such studies have important 
clinical implications in areas where evidence-based medicine is presently 
lacking. Indeed, they can potentially be used as imaging biomarkers to identify 
high-risk patients with rapidly progressing aortic dilatations or even as a guide 
whilst recommending an individualised exercise prescription for patients with 
BAV, who are often relatively young but at a higher risk of adverse aortic 
events.  
 
7.1.4. Clinical significance of research 
The findings presented in this thesis, coupled with previous studies, provide 
mounting evidence on the complex and heterogeneous nature of BAV genetics 
and the likely presence of genetic modifiers or other regulatory control during 
BAV disease development and progression. While the results from the genetic 
studies presented in this thesis may not be directly or immediately be applicable 
to the present day-to-day clinical management of BAV disease, they have 
added new insights into the current understanding of the genetic and molecular 
basis underlying BAV development and subsequent valve degeneration and 
dysfunction. These findings are therefore important given the present limitation 
of available therapeutic armamentarium in delaying or halting BAV-related valve 
disease progression, which has left surgical therapies as the most effective, but 
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not necessarily the ideal ‘cure’. Indeed, results obtained from this thesis have 
provided an important step forward in our understanding of gene and molecular 
pathways involved in the pathogenesis of human BAV disease, which will help 
foster the development of new therapies that halt disease progression. 
 
Finally, while the present attempt to identify novel imaging biomarkers in BAV-
related aortopathy using CMR imaging is inconclusive, the study has laid a 
foundation for future research in a larger cohort and established the feasibility 
and the potential application of real-time free-breathing exercise CMR imaging 
for other large vessel researches. Further, the result of this study indicated the 
need for a comparative study that evaluates the impact of different type of 
exercise on aortas of patients with BAV, as our preliminary data, together with 
others, hinted that they could be different. Such a study will have significant 
implications on the clinical management of patients with BAV, as it will allow 
clinicians to make personalised exercise prescriptions that have been tailored to 
each individual’s risk for adverse aortic complications. In turn, this will likely 
translate to improved quality of life and outcomes of patients with BAV. 
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7.2. CONCLUDING REMARKS 
In conclusion, the studies presented in this thesis have contributed to the 
present understanding of the underlying genetic and molecular basis of BAV 
disease development and progression in humans. While much work remains, 
the studies in this thesis have identified important questions, which will form the 
basis for future research aimed at identification of molecular targets for potential 
therapies to halt or even stop valve disease progression. The project also has 
laid an important foundation for future real-time exercise CMR imaging-based 
work in efforts to identify novel imaging biomarkers that can be used to better 
risk stratify those with BAV-related aortopathy. Overall, the work in this thesis 
have provided an important step forward in our efforts to gain greater 
understanding on the pathogenetic basis of BAV disease and one step closer 
towards our ultimate goal in reducing the overall health burden created by this 
complex, albeit common, human disease.    
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Appendix III. RNA sequencing in BAV 
Table III- 1. Complete list of differentially expressed genes between the 
BAV (BAV1-BAV5) and TAV (TAV1-TAV3) groups (p<0.05 with post-hoc 
Bonferroni correction). 
UPREGULATED GENES  IN BAV (BAV1-BAV5) vs. TAV (TAV1-TAV3) 
Gene 
symbol Gene annotation 
Fold 
change 
Adjusted 
p-value 
FAM149A family with sequence similarity 149, member A 4.79 0.0330 
HLA-DRB5 major histocompatibility complex, class II, DR beta 5  4.68 0 
SPOCK3 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 3.35 5.37E-09 
CHST9 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9  3.26 0.0308 
MATN4 matrilin 4  2.81 0.0270 
EYA1 eyes absent homolog 1 (Drosophila)  2.79 0.0025 
C1orf51 chromosome 1 open reading frame 51  2.71 0.0046 
MUC20 mucin 20, cell surface associated  2.67 4.44E-04 
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1  2.56 4.81E-05 
MAPK4 mitogen-activated protein kinase 4  2.55 0.0165 
C17orf97 chromosome 17 open reading frame 97  2.53 0.0161 
GSTM1 glutathione S-transferase mu 1 2.51 0.0082 
ARHGDIG Rho GDP dissociation inhibitor (GDI) gamma  2.43 0.0267 
RIMS4 regulating synaptic membrane exocytosis 4  2.36 6.10E-04 
KIRREL3 kin of IRRE like 3 (Drosophila) 2.30 0.0320 
CLU clusterin  2.28 5.15E-04 
NR1D1 nuclear receptor subfamily 1, group D, member 1  2.24 3.40E-05 
IGSF10 immunoglobulin superfamily, member 10 2.19 1.18E-05 
TMEM56 transmembrane protein 56  2.19 0.0022 
MYH10 myosin, heavy chain 10, non-muscle 2.19 0.0454 
POLR2J2 polymerase (RNA) II (DNA directed) polypeptide J2  2.15 5.95E-04 
LAMC3 laminin, gamma 3 2.11 8.32E-06 
PLCH1 phospholipase C, eta 1  2.11 0.0387 
TCEAL2 transcription elongation factor A (SII)-like 2  2.08 0.0040 
CHAD chondroadherin  2.06 1.28E-04 
GBP3 guanylate binding protein 3  2.01 0.0026 
PKP2 plakophilin 2 2.00 0.0277 
HLF hepatic leukemia factor 1.99 0.0020 
MAPT microtubule-associated protein tau  1.97 0.0061 
GFAP glial fibrillary acidic protein 1.95 0.0080 
PDZRN4 PDZ domain containing ring finger 4 1.93 0.0348 
TNXB tenascin XB  1.92 0.0057 
PIK3IP1 phosphoinositide-3-kinase interacting protein 1 1.92 0.0244 
CNTFR ciliary neurotrophic factor receptor 1.91 0.0285 
SLC6A1 solute carrier family 6 (neurotransmitter transporter, GABA), member 1 1.89 0.0400 
DBP D site of albumin promoter (albumin D-box) binding protein 1.87 0.0080 
S100B S100 calcium binding protein B  1.87 0.0087 
DSP desmoplakin 1.87 0.0140 
MASP1 mannan-binding lectin serine peptidase 1 (C4/C2 activating component of 
Ra-reactive factor) 
1.86 0.0029 
NSG1 Neuron-specific protein family member 1  1.82 0.0098 
PER1 period homolog 1 (Drosophila)  1.81 0.0041 
ERAP2 endoplasmic reticulum aminopeptidase 2  1.80 0.0029 
COL6A6 collagen, type VI, alpha 6  1.80 0.0129 
HNRNPD heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA 
binding protein 1, 37kDa) 
1.78 0.0230 
COL13A1 collagen, type XIII, alpha 1 1.78 0.0483 
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Table III-1 continued 
UPREGULATED GENES  IN BAV (BAV1-BAV5) vs. TAV (TAV1-TAV3) 
Gene 
symbol Gene annotation 
Fold 
change 
Adjusted 
p-value 
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8 1.76 0.0076 
UPK3BL uroplakin 3B-like 1.75 0.0142 
SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group)  1.75 0.0392 
TMEM132E transmembrane protein 132E  1.73 0.0116 
ATOH8 atonal homolog 8 (Drosophila)  1.72 0.0392 
TEF thyrotrophic embryonic factor 1.71 0.0223 
HAND2 heart and neural crest derivatives expressed 2 1.71 0.0329 
LTBP4 latent transforming growth factor beta binding protein 4  1.68 0.0384 
NR1D2 nuclear receptor subfamily 1, group D, member 2  1.62 0.0466 
GATA4 GATA binding protein 4  1.60 0.0446 
SYNM synemin, intermediate filament protein  1.60 0.0480 
PTN pleiotrophin  1.58 0.0277 
POLR2J3 polymerase (RNA) II (DNA directed) polypeptide J3  1.58 0.0388 
RASA4B RAS p21 protein activator 4B  1.57 0.0413 
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Table III-1 continued 
DOWNREGULATED GENES IN BAV (BAV1-BAV5) vs. TAV (TAV1-TAV3) 
Gene 
symbol Gene annotation 
Fold 
change 
Adjusted 
p-value 
IGLL5 immunoglobulin lambda-like polypeptide 5  -30.05 0 
RP11-
1280I22.1 
Plasma cell-induced resident endoplasmic reticulum protein -25.56 0 
DEFA1 defensin, alpha 1  -24.99 0.0054 
DEFA1B defensin, alpha 1B  -20.65 0.0080 
MMP13 matrix metallopeptidase 13 (collagenase 3)  -19.06 0 
IGJ immunoglobulin J polypeptide, linker protein for immunoglobulin alpha 
and mu polypeptides  
-16.73 0 
CD79A CD79a molecule, immunoglobulin-associated alpha  -15.80 0 
MTRNR2L8 MT-RNR2-like 8  -14.69 4.02E-09 
PPBP pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)  -13.76 0.0019 
FCRL5 Fc receptor-like 5 -13.49 5.99E-13 
GPIHBP1 glycosylphosphatidylinositol anchored high density lipoprotein binding 
protein 1 
-12.92 2.26E-07 
MAT1A methionine adenosyltransferase I, alpha  -12.74 0.0014 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) -12.21 5.24E-08 
BHLHA15 basic helix-loop-helix family, member a15  -11.15 0.0300 
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV 
collagenase)  
-11.08 0 
CCL7 chemokine (C-C motif) ligand 7 -11.08 0.0073 
AMPD1 adenosine monophosphate deaminase 1  -10.72 0.0019 
SP7 Sp7 transcription factor  -10.20 1.38E-10 
SPIB Spi-B transcription factor (Spi-1/PU.1 related)  -10.00 0.0068 
TDO2 tryptophan 2,3-dioxygenase  -9.99 6.12E-10 
HLA-DOB major histocompatibility complex, class II, DO beta  -9.96 0.0193 
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 -9.34 1.48E-05 
KLK4 kallikrein-related peptidase 4  -9.28 0.0157 
IBSP integrin-binding sialoprotein  -8.65 0 
RASSF6 Ras association (RalGDS/AF-6) domain family member 6  -8.50 2.46E-04 
BTNL9 butyrophilin-like 9  -8.40 0.0288 
C1orf130 chromosome 1 open reading frame 130  -8.13 0.0493 
IFITM5 interferon induced transmembrane protein 5  -8.01 0.0284 
FCRL3 Fc receptor-like 3  -7.78 0.0175 
PNOC prepronociceptin  -7.62 0.0362 
DACH1 dachshund homolog 1 (Drosophila) -7.19 0.0392 
BMP3 bone morphogenetic protein 3 -7.10 0.0074 
SPP1 secreted phosphoprotein 1 -7.07 0 
CXCL13 chemokine (C-X-C motif) ligand 13  -6.73 9.90E-05 
PAX5 paired box 5 -6.60 0.0177 
CMA1 chymase 1, mast cell  -6.54 1.57E-06 
TSPAN10 tetraspanin 10 -6.54 0.0081 
NR5A2 nuclear receptor subfamily 5, group A, member 2  -6.42 0.0396 
EMR1 egf-like module containing, mucin-like, hormone receptor-like 1  -6.21 0.0439 
DERL3 Der1-like domain family, member 3  -6.14 2.21E-11 
ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary)  -6.12 0.0017 
PRND prion protein 2 (dublet) -5.87 0.0026 
MS4A1 membrane-spanning 4-domains, subfamily A, member 1  -5.80 4.15E-06 
POU2AF1 POU class 2 associating factor 1 -5.79 2.61E-10 
CBLN4 cerebellin 4 precursor  -5.57 0.0070 
FLT4 fms-related tyrosine kinase 4  -5.56 1.22E-05 
AQP9 aquaporin 9  -5.54 1.42E-04 
CXCL5 chemokine (C-X-C motif) ligand 5  -5.27 1.35E-04 
CHIT1 chitinase 1 (chitotriosidase) -5.26 1.06E-11 
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Table III-1 continued 
DOWNREGULATED GENES IN BAV (BAV1-BAV5) vs. TAV (TAV1-TAV3) 
Gene 
symbol Gene annotation 
Fold 
change 
Adjusted 
p-value 
COL11A1 collagen, type XI, alpha 1 -4.84 0 
HBA2 hemoglobin, alpha 2  -4.75 0 
HBA1 hemoglobin, alpha 1  -4.68 1.27E-13 
APOC2 apolipoprotein C-II -4.62 0.0127 
EBF2 early B-cell factor 2  -4.56 1.64E-04 
TM4SF19 transmembrane 4 L six family member 19  -4.44 5.87E-04 
COL2A1 collagen, type II, alpha 1 -4.23 0.0024 
APOC4 apolipoprotein C-IV  -4.12 0.0074 
HBB hemoglobin, beta  -4.11 0 
TIMD4 T-cell immunoglobulin and mucin domain containing 4  -4.07 7.80E-07 
SCUBE1 signal peptide, CUB domain, EGF-like 1  -3.95 0.0268 
SLAMF7 SLAM family member 7  -3.91 2.28E-07 
C10orf81 chromosome 10 open reading frame 81  -3.87 6.28E-06 
SGCA sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) -3.82 3.29E-06 
MMP1 matrix metallopeptidase 1 (interstitial collagenase) -3.80 0.0416 
HLA-DQB2 major histocompatibility complex, class II, DQ beta 2  -3.77 1.02E-04 
GREM1 gremlin 1  -3.72 8.37E-04 
SDS serine dehydratase  -3.66 0.0034 
CCL3 chemokine (C-C motif) ligand 3 -3.64 5.85E-07 
TM4SF18 transmembrane 4 L six family member 18  -3.56 4.53E-05 
CXorf36 chromosome X open reading frame 36  -3.54 4.03E-04 
GPHA2 glycoprotein hormone alpha 2  -3.52 3.00E-05 
DLL4 delta-like 4 (Drosophila)  -3.51 0.0028 
EGFLAM EGF-like, fibronectin type III and laminin G domains  -3.41 0.0012 
IL1RN interleukin 1 receptor antagonist  -3.38 0.0037 
DNASE1L3 deoxyribonuclease I-like 3 -3.37 0.0132 
LRRC15 leucine rich repeat containing 15  -3.35 6.49E-08 
MMRN1 multimerin 1  -3.31 1.48E-05 
PLA2G2D phospholipase A2, group IID  -3.29 0.0249 
VMO1 vitelline membrane outer layer 1 homolog (chicken)  -3.24 2.98E-04 
GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine 
esterase 1)  
-3.24 0.0111 
BGLAP bone gamma-carboxyglutamate (gla) protein  -3.14 1.02E-05 
APOC1 apolipoprotein C-I  -3.11 1.52E-06 
ADAMDEC1 ADAM-like, decysin 1  -3.09 0.0359 
CCL3L1 chemokine (C-C motif) ligand 3-like 1  -3.08 0.0408 
PIM2 pim-2 oncogene  -3.05 3.24E-11 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)  -3.05 6.80E-11 
SLC11A1 solute carrier family 11 (proton-coupled divalent metal ion transporters), 
member 1  
-3.05 5.80E-09 
HDC histidine decarboxylase  -3.04 0.0317 
THNSL2 threonine synthase-like 2 (S. cerevisiae) -3.03 4.21E-06 
FAIM3 Fas apoptotic inhibitory molecule 3  -2.99 8.97E-04 
CXCL9 chemokine (C-X-C motif) ligand 9  -2.96 6.19E-05 
KCNK2 potassium channel, subfamily K, member 2  -2.96 0.0261 
TPSD1 tryptase delta 1  -2.96 0.0363 
PLVAP plasmalemma vesicle associated protein  -2.95 1.40E-09 
GZMK granzyme K (granzyme 3; tryptase II)  -2.94 0.0037 
CTSG cathepsin G -2.93 0.0034 
CCL21 chemokine (C-C motif) ligand 21  -2.89 4.30E-08 
TREM1 triggering receptor expressed on myeloid cells 1  -2.87 8.74E-04 
LTB lymphotoxin beta (TNF superfamily, member 3)  -2.87 0.0096 
CCL14 chemokine (C-C motif) ligand 14  -2.84 3.94E-04 
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Table III-1 continued 
DOWNREGULATED GENES IN BAV (BAV1-BAV5) vs. TAV (TAV1-TAV3) 
Gene 
symbol Gene annotation 
Fold 
change 
Adjusted 
p-value 
CCL4 chemokine (C-C motif) ligand 4  -2.80 0.0198 
SDC1 syndecan 1 -2.78 4.10E-04 
NELL2 NEL-like 2 (chicken)  -2.76 0.0229 
COL10A1 collagen, type X, alpha 1  -2.75 9.21E-08 
TSPAN13 tetraspanin 13  -2.74 0.0480 
CPA3 carboxypeptidase A3 (mast cell)  -2.70 6.94E-05 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit)  -2.69 2.92E-08 
WNT7A wingless-type MMTV integration site family, member 7A  -2.66 0.0445 
MATK megakaryocyte-associated tyrosine kinase  -2.58 0.0306 
TPSAB1 tryptase alpha/beta 1 -2.57 1.49E-05 
SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2  
-2.57 1.05E-04 
SLAMF6 SLAM family member 6  -2.57 0.0048 
IL21R interleukin 21 receptor  -2.56 0.0080 
GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine 
esterase 3)  
-2.54 0.0204 
APLN apelin  -2.51 0.0109 
IRF4 interferon regulatory factor 4 -2.50 0.0338 
FMO3 flavin containing monooxygenase 3  -2.48 6.13E-05 
CST7 cystatin F (leukocystatin)  -2.45 0.0335 
GLRX glutaredoxin (thioltransferase)  -2.42 3.04E-06 
NDUFA4L2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 -2.40 1.58E-06 
ISM1 isthmin 1 homolog (zebrafish) -2.38 1.97E-04 
CCL19 chemokine (C-C motif) ligand 19  -2.35 1.48E-05 
ACP5 acid phosphatase 5, tartrate resistant  -2.34 1.04E-06 
TMEM200A transmembrane protein 200A  -2.34 0.0277 
ZAP70 zeta-chain (TCR) associated protein kinase 70kDa  -2.31 0.0387 
ITK IL2-inducible T-cell kinase  -2.30 0.0396 
NUP210 nucleoporin 210kDa  -2.28 0.0049 
RGS16 regulator of G-protein signalling 16  -2.28 0.0098 
SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5  -2.28 0.0409 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog  -2.21 0.0444 
GPR68 G protein-coupled receptor 68  -2.18 0.0016 
ADRA2A adrenergic, alpha-2A-, receptor  -2.18 0.0024 
DPP4 dipeptidyl-peptidase 4 -2.12 0.0364 
CHST1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 -2.11 0.0091 
CLEC5A C-type lectin domain family 5, member A  -2.08 0.0132 
TREM2 triggering receptor expressed on myeloid cells 2  -2.06 0.0055 
F3 coagulation factor III (thromboplastin, tissue factor)  -2.06 0.0391 
TP53I11 tumor protein p53 inducible protein 11  -2.05 6.18E-05 
CD3E CD3e molecule, epsilon (CD3-TCR complex)  -2.05 0.0053 
MFAP5 microfibrillar associated protein 5  -2.04 0.0054 
ACAN aggrecan  -2.03 1.42E-04 
A2M alpha-2-macroglobulin -2.02 6.99E-04 
AOAH acyloxyacyl hydrolase (neutrophil) -2.00 0.0132 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) -1.99 1.62E-04 
VCAM1 vascular cell adhesion molecule 1  -1.97 3.55E-04 
IKZF3 IKAROS family zinc finger 3 (Aiolos) -1.97 0.0110 
PILRA paired immunoglobin-like type 2 receptor alpha  -1.93 0.0374 
NFASC neurofascin  -1.93 0.0456 
IFI30 interferon, gamma-inducible protein 30  -1.92 0.0299 
UCP2 uncoupling protein 2 (mitochondrial, proton carrier)  -1.91 0.0285 
STMN2 stathmin-like 2  -1.91 0.0312 
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Table III-1 continued 
DOWNREGULATED GENES IN BAV (BAV1-BAV5) vs. TAV (TAV1-TAV3) 
Gene 
symbol Gene annotation 
Fold 
change 
Adjusted 
p-value 
PCDH17 protocadherin 17  -1.91 0.0489 
ITGAL integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated 
antigen 1; alpha polypeptide)  
-1.90 0.0362 
CHI3L2 chitinase 3-like 2  -1.87 0.0034 
LBH limb bud and heart development homolog (mouse)  -1.87 0.0049 
SLPI secretory leukocyte peptidase inhibitor -1.86 0.0408 
FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog  -1.85 0.0408 
NPIPL2 nuclear pore complex interacting protein-like 2  -1.84 0.0368 
KRT18 keratin 18  -1.84 0.0416 
ZFAT zinc finger and AT hook domain containing  -1.83 0.0432 
TMEM119 transmembrane protein 119 -1.83 0.0460 
SMOC2 SPARC related modular calcium binding 2  -1.81 0.0121 
TMC8 transmembrane channel-like 8 -1.81 0.0409 
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 -1.77 0.0369 
SMOC1 SPARC related modular calcium binding 1  -1.74 0.0031 
PNP purine nucleoside phosphorylase -1.74 0.0100 
HMOX1 heme oxygenase (decycling) 1  -1.74 0.0130 
DDX39B DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B  -1.74 0.0228 
PLAU plasminogen activator, urokinase  -1.73 0.0213 
CRHBP corticotropin releasing hormone binding protein  -1.72 0.0109 
TINAGL1 tubulointerstitial nephritis antigen-like 1  -1.72 0.0233 
ZNF266 zinc finger protein 266  -1.71 0.0361 
MS4A7 membrane-spanning 4-domains, subfamily A, member 7  -1.69 0.0060 
CD53 CD53 molecule  -1.62 0.0408 
ITGA7 integrin, alpha 7  -1.62 0.0480 
SRGN serglycin  -1.61 0.0381 
PCDH18 protocadherin 18  -1.60 0.0480 
 
 
A
pp
en
di
ce
s 
 
 
24
8 
Ta
bl
e 
III
- 
2.
 P
er
tin
en
t 
bi
ol
og
ic
al
 p
ro
ce
ss
es
 w
ith
 r
el
ev
an
ce
 t
o 
B
A
V 
de
ve
lo
pm
en
t 
an
d 
ao
rt
ic
 v
al
ve
 d
eg
en
er
at
io
n 
as
 
id
en
tif
ie
d 
by
 IP
A
. 
C
at
eg
or
y 
Fu
nc
tio
ns
 A
nn
ot
at
io
n 
p-
va
lu
e 
N
o.
 
Pe
rt
ur
be
d 
m
ol
ec
ul
es
/g
en
es
 
C
ar
di
ov
as
cu
la
r 
D
is
ea
se
 
A
or
tic
 d
is
or
de
r 
2.
03
E
-0
5 
8 
G
A
TA
4,
IL
1R
N
,M
M
P
13
,M
M
P
7,
M
M
P
9,
M
Y
H
10
,P
LA
U
,S
D
C
1 
S
te
no
si
s 
of
 a
or
tic
 v
al
ve
 
2.
15
E
-0
4 
5 
B
G
LA
P
,M
M
P
1,
M
M
P
9,
S
P
P
1,
V
C
A
M
1 
C
al
ci
fic
at
io
n 
of
 a
or
tic
 v
al
ve
 
3.
19
E
-0
4 
3 
B
G
LA
P
,IB
S
P
,S
P
P
1 
H
ea
rt 
D
is
ea
se
 
4.
65
E
-0
4 
29
 
A
D
R
A
2A
,A
P
LN
,B
G
LA
P
,C
C
L3
L1
/C
C
L3
L3
,C
H
I3
L1
,C
LU
,D
P
P
4,
D
S
P
,E
Y
A
1,
FL
T4
, 
G
A
TA
4,
G
S
TM
1,
H
A
N
D
2,
H
B
A
1/
H
B
A
2,
H
M
O
X
1,
IB
S
P
,IL
1R
N
,IT
G
A
L,
K
C
N
K
2,
LT
B
P
4,
 
M
M
P
1,
M
M
P
7,
M
M
P
9,
M
Y
H
10
,P
K
P
2,
P
LA
U
,S
G
C
A
,S
P
P
1,
V
C
A
M
1 
 
A
ne
ur
ys
m
 
4.
96
E
-0
4 
6 
M
M
P
13
,M
M
P
7,
M
M
P
9,
P
LA
U
,S
D
C
1,
S
P
P
1 
C
ar
di
ov
as
cu
la
r 
S
ys
te
m
 
D
ev
el
op
m
en
t 
an
d 
Fu
nc
tio
n 
D
ev
el
op
m
en
t o
f c
ar
di
ov
as
cu
la
r 
sy
st
em
 
6.
84
E
-0
6 
 
35
 
A
D
R
A
2A
,A
P
LN
,C
C
L7
,C
D
3E
,C
M
A
1,
C
O
L1
1A
1,
C
O
L1
3A
1,
C
O
L2
A
1,
D
LL
4,
D
S
P
,E
Y
A
1,
 
F3
,F
G
R
,F
LT
4,
G
A
TA
4,
G
R
E
M
1,
G
S
TM
1,
H
A
N
D
2,
H
B
A
1/
H
B
A
2,
H
B
B
,H
LA
D
Q
B
1,
H
M
O
X
1
,IT
G
A
7,
K
IT
,M
M
P
1,
M
M
P
13
, 
M
M
P
9,
M
Y
H
10
,P
K
P
2,
P
LA
U
,P
LV
A
P
,P
TN
,S
M
O
C
2,
S
P
P
1,
 
V
C
A
M
1 
A
dh
es
io
n 
of
 e
nd
ot
he
lia
l c
el
ls
 
3.
55
E
-0
4 
8 
C
C
L3
,C
C
L3
L1
/C
C
L3
L3
,C
C
L4
,C
TS
G
,IT
G
A
L,
P
P
B
P
,S
P
P
1,
V
C
A
M
1 
M
or
ph
ol
og
y 
of
 c
ar
di
ov
as
cu
la
r 
sy
st
em
 
5.
08
E
-0
4 
22
 
A
P
LN
,C
O
L1
0A
1,
C
O
L2
A
1,
D
LL
4,
E
Y
A
1,
F3
,F
LT
4,
G
A
TA
4,
G
FA
P
,H
A
N
D
2,
H
B
A
1/
H
B
A
2,
 
H
B
B
,H
M
O
X
1,
 IL
1R
N
,M
M
P
9,
M
Y
H
10
,P
IM
2,
P
K
P
2,
P
LA
U
,P
LV
A
P
,S
P
P
1,
V
C
A
M
1 
M
or
ph
ol
og
y 
of
 a
or
ta
 
6.
30
E
-0
4 
5 
E
Y
A
1,
G
A
TA
4,
H
A
N
D
2,
M
Y
H
10
,S
P
P
1 
C
el
l D
ea
th
 a
nd
 
S
ur
vi
va
l 
A
po
pt
os
is
 
 
7.
83
E
-0
7 
73
 
A
2M
,A
D
C
Y
A
P
1,
C
C
L1
9,
C
C
L2
1,
C
C
L3
,C
C
L3
L1
/C
C
L3
L3
,C
C
L4
,C
D
3E
,C
D
53
,C
H
I3
L1
,C
LE
C
5A
,C
LU
,C
N
TF
R
,C
O
L2
A
1,
C
TS
G
,D
A
C
H
1,
D
LL
4,
D
N
A
S
E
1L
3,
D
P
P
4,
D
S
P
,E
Y
A
1,
F3
,
FA
IM
3,
FC
G
R
1A
,F
G
R
,F
LT
4,
G
A
TA
4,
G
LR
X
,G
R
E
M
1,
G
ZM
A
,G
ZM
B
,H
A
N
D
2,
H
B
A
1/
 
H
B
A
2,
H
LF
,H
M
O
X
1,
IK
ZF
3,
IL
1R
N
,IR
F4
,IS
M
1,
IT
G
A
7,
IT
K
,K
IT
,K
R
T1
8,
LT
B
,M
A
P
T,
 
M
M
P
1,
M
M
P
7,
M
M
P
9,
M
S
4A
1,
N
R
1D
1,
P
A
X
5,
P
E
R
1,
P
IK
3I
P
1,
P
IM
2,
P
K
P
2,
P
LA
U
,P
N
P
, 
P
O
U
2A
F1
,P
TN
,R
A
S
S
F6
,S
10
0B
,S
D
C
1,
S
LC
2A
3,
S
LP
I,S
P
IB
,S
P
P
1,
S
R
G
N
,T
IM
D
4,
 
TP
S
A
B
1/
TP
S
B
2,
TR
E
M
1,
U
C
P
2,
W
N
T7
A
,Z
A
P
70
 
C
el
l S
ig
na
lli
ng
 
Fl
ux
 o
f C
a2
+ 
1.
83
E
-1
3 
25
 
A
2M
,A
D
C
Y
A
P
1,
C
C
L1
4,
C
C
L1
9,
C
C
L2
1,
C
C
L3
,C
C
L3
L1
/C
C
L3
L3
,C
C
L4
,C
C
L7
,C
D
3E
,C
D
79
A
,C
X
C
L1
3,
 
C
X
C
L5
,D
E
FA
1 
(in
cl
ud
e 
ot
he
rs
),F
3,
FC
G
R
1A
,F
G
R
,IT
K
,K
IT
,K
LK
4,
 
M
A
P
T,
M
M
P
1,
M
S
4A
1,
P
P
B
P
,Z
A
P
70
 
M
ob
ili
sa
tio
n 
of
 C
a2
+ 
2.
01
E
-0
7 
20
 
A
2M
,A
D
C
Y
A
P
1,
C
C
L1
9,
C
C
L2
1,
C
C
L3
,C
C
L3
L1
/C
C
L3
L3
,C
C
L4
,C
C
L7
,C
D
3E
,C
X
C
L1
3,
C
X
C
L9
,D
E
FA
1 
(in
cl
ud
e 
ot
he
rs
),F
C
G
R
1A
,F
C
R
L3
,IT
K
,K
IT
,P
IL
R
A
,T
P
S
D
1,
TR
E
M
1,
 
ZA
P
70
 
Q
ua
nt
ity
 o
f C
a2
+ 
2.
40
E
-0
7 
22
 
A
2M
,A
D
C
Y
A
P
1,
A
D
R
A
2A
,C
C
L1
9,
C
C
L2
1,
C
C
L3
,C
C
L3
L1
/C
C
L3
L3
,C
C
L4
,C
C
L7
,C
D
3E
,
C
X
C
L1
3,
C
X
C
L9
,H
B
A
1/
H
B
A
2,
IB
S
P
,M
A
P
T,
P
LA
U
,P
P
B
P
,P
R
N
D
,S
P
P
1,
TP
S
A
B
1/
TP
S
B
2
,V
C
A
M
1,
W
N
T7
A
 
 
 
 
 
 
A
pp
en
di
ce
s 
 
 
24
9 
Ta
bl
e 
III
-2
 c
on
tin
ue
d 
C
at
eg
or
y 
Fu
nc
tio
ns
 A
nn
ot
at
io
n 
p-
va
lu
e 
N
o.
 
Pe
rt
ur
be
d 
m
ol
ec
ul
es
/g
en
es
 
C
el
l 
si
gn
al
lin
g 
(c
on
tin
ue
) 
S
ig
na
lli
ng
 o
f C
a2
+ 
8.
76
E
-0
5 
6 
A
2M
,A
D
C
Y
A
P
1,
C
D
3E
,C
X
C
L9
,IT
G
A
L,
ZA
P
70
 
R
el
ea
se
 o
f C
a2
+ 
1.
12
E
-0
4 
11
 
A
2M
,C
C
L1
9,
C
C
L2
1,
C
C
L3
,C
C
L4
,F
C
G
R
1A
,IT
K
,P
R
N
D
,R
G
S
16
,S
P
P
1,
ZA
P
70
 
S
yn
th
es
is
 o
f n
itr
ic
 o
xi
de
 
4.
57
E
-0
4 
12
 
A
C
P
5,
A
D
C
Y
A
P
1,
C
TS
G
,H
D
C
,H
M
O
X
1,
IL
1R
N
,P
LA
U
,S
10
0B
,S
LC
7A
2,
S
P
P
1,
TR
E
M
1,
U
C
P
2 
C
el
lu
la
r 
A
ss
em
bl
y 
an
d 
O
rg
an
is
at
io
n 
O
rg
an
is
at
io
n 
of
 c
ol
la
ge
n 
fib
ril
s 
5.
04
E
-0
5 
5 
A
C
A
N
,C
O
L1
1A
1,
C
O
L2
A
1,
G
R
E
M
1,
TN
X
B
 
P
ol
ym
er
is
at
io
n 
of
 c
yt
os
ke
le
to
n 
1.
64
E
-0
4 
2 
C
D
3E
,IT
K
 
O
rg
an
is
at
io
n 
of
 fi
la
m
en
ts
 
1.
91
E
-0
4 
10
 
A
C
A
N
,C
O
L1
1A
1,
C
O
L2
A
1,
D
S
P
,G
FA
P
,G
R
E
M
1,
K
R
T1
8,
M
FA
P
5,
P
LA
U
,T
N
X
B
 
C
el
lu
la
r 
Fu
nc
tio
n 
an
d 
M
ai
nt
en
an
ce
 
C
el
lu
la
r h
om
eo
st
as
is
 
6.
64
E
-1
1 
56
 
A
2M
,A
D
C
Y
A
P
1,
A
D
R
A
2A
,B
H
LH
A
15
,C
C
L1
4,
C
C
L1
9,
C
C
L2
1,
C
C
L3
,C
C
L3
L1
/C
C
L3
L3
,C
C
L4
,C
C
L7
, C
D
3E
,C
D
79
A
,C
TS
G
,C
X
C
L1
3,
C
X
C
L5
,D
E
FA
1 
(in
cl
ud
es
 o
th
er
s)
, D
LL
4,
F3
, 
FC
G
R
1A
,F
G
R
,G
A
TA
4,
 G
ZM
A
, 
G
ZM
B
,G
ZM
K
,H
D
C
,H
LA
D
Q
B
1,
H
M
O
X
1,
IL
1R
N
,IL
21
R
, 
IR
F4
,IT
G
A
L,
IT
K
,K
C
N
K
2,
K
IT
,K
LK
4,
 
K
R
T1
8,
LT
B
,M
A
P
T,
M
M
P
1,
M
S
4A
1,
P
A
X
5,
P
IM
2,
 
P
LA
U
,P
N
P
,P
P
B
P
,P
R
N
D
,S
10
0B
,S
G
C
A
,S
LA
M
F6
,S
LC
11
A
1,
S
LC
14
A
1,
S
P
IB
,S
P
P
1,
 
U
C
P
2,
ZA
P
70
 
C
el
lu
la
r 
M
ov
em
en
t 
M
ig
ra
tio
n 
of
 c
el
ls
 
2.
77
E
-1
5 
73
 
A
2M
,A
C
A
N
,A
D
C
Y
A
P
1,
A
D
R
A
2A
,A
Q
P
9,
C
C
L1
4,
C
C
L1
9,
C
C
L2
1,
C
C
L3
,C
C
L3
L1
/C
C
L3
L
3,
C
C
L4
,C
C
L7
,C
D
3E
,C
H
I3
L1
,C
H
S
T1
,C
LE
C
5A
,C
LU
,C
M
A
1,
C
TS
G
,C
X
C
L1
3,
C
X
C
L5
, 
C
X
C
L9
,D
E
FA
1 
(in
cl
ud
es
 
ot
he
rs
),D
LL
4,
D
P
P
4,
E
B
F2
,F
3,
FG
R
,F
LT
4,
G
FA
P
,G
LR
X
, 
G
R
E
M
1,
 
G
ZM
B
,H
D
C
,H
M
O
X
1,
IL
1R
N
,IL
21
R
,IT
G
A
L,
IT
G
A
X
,IT
K
,K
IT
,L
TB
,M
A
P
T,
 
M
A
T1
A
,M
A
TK
,M
M
P
1,
M
M
P
13
,M
M
P
7,
M
M
P
9,
M
Y
H
10
,N
R
1D
1,
P
E
R
1,
P
IK
3I
P
1,
P
LA
U
, 
P
N
O
C
,P
O
U
2A
F1
,P
P
B
P
,P
TN
,R
G
S
16
,S
10
0B
,S
D
C
1,
S
LP
I,S
P
7,
S
P
O
C
K
3,
S
P
P
1,
S
Y
N
M
, 
TP
S
A
B
1/
TP
S
B
2,
TP
S
D
1,
TR
E
M
1,
TR
E
M
2,
U
C
P
2,
V
C
A
M
1,
ZA
P
70
 
C
on
ne
ct
iv
e 
Ti
ss
ue
 
D
ev
el
op
m
en
t 
an
d 
Fu
nc
tio
n 
M
in
er
al
is
at
io
n 
of
 b
on
e 
9.
65
E
-0
5 
9 
A
C
P
5,
C
O
L2
A
1,
G
R
E
M
1,
IB
S
P
,IF
IT
M
5,
M
M
P
13
,P
TN
,S
P
P
1,
S
R
G
N
 
C
on
de
ns
at
io
n 
of
 
ca
rti
la
ge
 
tis
su
e 
1.
33
E
-0
4 
4 
A
C
A
N
,C
O
L1
1A
1,
C
O
L2
A
1,
W
N
T7
A
 
O
rg
an
is
m
al
 
In
ju
ry
 
an
d 
A
bn
or
m
al
iti
es
 
Fi
br
os
is
 
2.
39
E
-0
4 
19
 
A
D
R
A
2A
,C
X
C
L1
3,
C
X
C
L9
,D
S
P
,F
3,
FL
T4
,H
B
B
,H
M
O
X
1,
IL
1R
N
,K
IT
,L
R
R
C
15
,M
M
P
1,
 
M
M
P
13
,M
M
P
7,
 M
M
P
9,
P
LA
U
,R
G
S
16
,S
G
C
A
,S
P
P
1 
C
al
ci
no
si
s 
5.
78
E
-0
4 
5 
B
G
LA
P
,C
O
L2
A
1,
IB
S
P
,M
M
P
9,
S
P
P
1 
P
ro
te
in
 
D
eg
ra
da
tio
n 
P
ro
te
ol
ys
is
 
1.
26
E
-0
5 
14
 
C
M
A
1,
C
P
A
3,
C
TS
G
,D
P
P
4,
G
ZM
A
,G
ZM
B
,K
LK
4,
LT
B
P
4,
M
M
P
1,
M
M
P
13
,M
M
P
7,
M
M
P
9,
P
LA
U
,S
D
C
1 
D
eg
ra
da
tio
n 
of
 p
ro
te
in
 
8.
27
E
-0
5 
19
 
C
LU
,C
M
A
1,
C
P
A
3,
C
TS
G
,D
P
P
4,
G
P
IH
B
P
1,
G
ZM
A
,G
ZM
B
,IF
I3
0,
IL
1R
N
,K
LK
4,
LT
B
P
4,
 
M
M
P
1,
M
M
P
13
, M
M
P
7,
M
M
P
9,
P
IM
2,
P
LA
U
,S
D
C
1 
M
ol
ec
ul
ar
 c
le
av
ag
e 
of
 p
ro
te
in
 
fra
gm
en
t 
1.
37
E
-0
4 
11
 
C
M
A
1,
C
P
A
3,
C
TS
G
,D
P
P
4,
G
ZM
A
,G
ZM
B
,K
LK
4,
LT
B
P
4,
M
M
P
13
,M
M
P
9,
P
LA
U
 
 
 
 
 
 
A
pp
en
di
ce
s 
 
 
25
0 
Ta
bl
e 
III
-2
 c
on
tin
ue
d 
C
at
eg
or
y 
Fu
nc
tio
ns
 A
nn
ot
at
io
n 
p-
va
lu
e 
N
o.
 
Pe
rt
ur
be
d 
m
ol
ec
ul
es
/g
en
es
 
Ti
ss
ue
 
D
ev
el
op
m
en
t 
D
ev
el
op
m
en
t 
of
 
co
nn
ec
tiv
e 
tis
su
e 
7.
38
E
-0
6 
15
 
A
C
A
N
,C
LE
C
5A
,C
O
L1
0A
1,
C
O
L1
1A
1,
C
O
L2
A
1,
D
LL
4,
H
A
N
D
2,
H
B
A
1/
H
B
A
2,
H
B
B
,K
IT
, 
M
M
P
13
,P
E
R
1,
S
LC
14
A
1,
V
C
A
M
1,
W
N
T7
A
 
O
rg
an
is
at
io
n 
of
 
ex
tra
ce
llu
la
r 
m
at
rix
 
3.
78
E
-0
5 
8 
D
P
P
4,
E
G
FL
A
M
,G
FA
P
,IB
S
P
,M
M
P
9,
S
M
O
C
1,
S
M
O
C
2,
TN
X
B
 
C
ar
til
ag
e 
de
ve
lo
pm
en
t 
3.
05
E
-0
4 
8 
A
C
A
N
,C
O
L1
0A
1,
C
O
L1
1A
1,
C
O
L2
A
1,
H
A
N
D
2,
M
M
P
13
,P
E
R
1,
W
N
T7
A
 
A
dh
es
io
n 
of
 e
pi
th
el
ia
l c
el
ls
 
5.
12
E
-0
4 
7 
C
LU
,C
TS
G
,F
3,
IT
G
A
L,
LA
M
C
3,
P
LA
U
,S
LP
I 
Ti
ss
ue
 
M
or
ph
ol
og
y 
D
eg
ra
da
tio
n 
of
 
ex
tra
ce
llu
la
r 
m
at
rix
 
2.
57
E
-0
5 
5 
C
M
A
1,
M
M
P
1,
M
M
P
13
,M
M
P
9,
P
LA
U
 
D
eg
ra
da
tio
n 
of
 
co
nn
ec
tiv
e 
tis
su
e 
8.
75
E
-0
5 
7 
A
2M
,A
C
A
N
,C
TS
G
,F
C
G
R
1A
,IL
1R
N
,M
M
P
13
,S
LP
I 
  
Appendices 
  251 
Table III- 3. Complete list of differentially expressed genes (DEGs) 
between the BAVr (BAV1-BAV3) and TAV (TAV1-TAV3) groups (p<0.05 
with post-hoc Bonferroni correction), sorted by fold change. 
DEGs in BAVr versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
HLA-DRB5 major histocompatibility complex, class II, DR beta 5 8.77 0 
SLC6A20 solute carrier family 6 (proline IMINO transporter), member 20  6.61 1.70E-04 
SPOCK3 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3  5.49 5.93E-08 
CHST9 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9  5.44 0.0256 
NPPC natriuretic peptide C  5.00 1.45E-04 
CNTFR ciliary neurotrophic factor receptor 4.76 1.19E-06 
PLCH1 phospholipase C, eta 1 4.35 8.69E-05 
IGSF10 immunoglobulin superfamily, member 10 4.10 1.77E-08 
CADM2 cell adhesion molecule 2 3.66 0.0010 
SOX10 SRY (sex determining region Y)-box 10 3.63 0.0110 
HMGCLL1 3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1  3.59 0.0227 
RIMS4 regulating synaptic membrane exocytosis 4  3.58 5.39E-06 
GFAP glial fibrillary acidic protein  3.57 5.38E-07 
EPB41L4B erythrocyte membrane protein band 4.1 like 4B 3.56 0.0295 
EYA1 eyes absent homolog 1 (Drosophila) 3.48 0.0366 
COL6A6 collagen, type VI, alpha 6  3.47 1.24E-05 
SCN7A sodium channel, voltage-gated, type VII, alpha 3.46 0.0381 
MYH10 myosin, heavy chain 10, non-muscle  3.41 0.0050 
LAMC3 laminin, gamma 3  3.38 6.39E-06 
MED12L mediator complex subunit 12-like 3.37 0.0022 
CTSE cathepsin E 3.35 0.0293 
KIF1A kinesin family member 1A  3.35 0.0056 
TRHDE thyrotropin-releasing hormone degrading enzyme  3.23 0.0219 
TMEM56 transmembrane protein 56 3.12 0.0012 
CLU clusterin 3.11 2.56E-04 
TMEM132C transmembrane protein 132C 3.08 3.47E-05 
ERAP2 endoplasmic reticulum aminopeptidase 2 3.07 3.48E-05 
RBP1 retinol binding protein 1, cellular 3.07 0.0144 
MAPT microtubule-associated protein tau 3.01 0.0010 
IL1RL1 interleukin 1 receptor-like 1 2.98 0.0147 
KIRREL3 kin of IRRE like 3 (Drosophila)  2.98 0.0125 
LCNL1 lipocalin-like 1  2.95 0.0148 
NWD1 NACHT and WD repeat domain containing 1 2.80 0.0384 
PDZRN4 PDZ domain containing ring finger 4  2.76 0.0082 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide  2.73 0.0029 
MUC20 mucin 20, cell surface associated  2.69 0.0303 
MYOC myocilin, trabecular meshwork inducible glucocorticoid response 2.69 0.0048 
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Table III-3 continued 
DEGs in BAVr versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; 
bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)  
2.68 0.0177 
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8  2.63 0.0016 
TNXB tenascin XB 2.61 0.0052 
SCARA5 scavenger receptor class A, member 5 (putative)  2.61 0.0026 
PKP2 plakophilin 2 2.61 0.0150 
CPEB1 cytoplasmic polyadenylation element binding protein 1  2.61 0.0366 
S100B S100 calcium binding protein B  2.56 0.0082 
HLF hepatic leukemia factor 2.54 0.0180 
CHAD chondroadherin  2.52 0.0015 
CLDN11 claudin 11 2.51 0.0161 
NSG1 Neuron-specific protein family member 1  2.49 0.0033 
TCEAL2 transcription elongation factor A (SII)-like 2  2.49 0.0164 
SLC6A1 solute carrier family 6 (neurotransmitter transporter, GABA), member 1  2.46 0.0030 
COL4A3 collagen, type IV, alpha 3 (Goodpasture antigen)  2.42 0.0298 
PTGDS prostaglandin D2 synthase 21kDa (brain) 2.41 0.0112 
PPP1R1B protein phosphatase 1, regulatory (inhibitor) subunit 1B  2.41 0.0040 
GBP3 guanylate binding protein 3 2.38 0.0048 
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8  2.33 0.0294 
GATA4 GATA binding protein 4  2.33 0.0079 
SFRP1 secreted frizzled-related protein 1  2.23 0.0461 
EMILIN3 elastin microfibril interfacer 3 2.19 0.0170 
SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 2.10 0.0461 
DHCR24 24-dehydrocholesterol reductase  2.09 0.0351 
HAND2 heart and neural crest derivatives expressed 2 2.08 0.0110 
NFIA nuclear factor I/A 2.00 0.0499 
NTRK2 neurotrophic tyrosine kinase, receptor, type 2  1.93 0.0490 
MMP13 matrix metallopeptidase 13 (collagenase 3)  -186.53 0 
IGLL5 immunoglobulin lambda-like polypeptide 5  -101.77 0 
RP11-
1280I22.1 
Plasma cell-induced resident endoplasmic reticulum protein -78.85 0 
IGJ immunoglobulin J polypeptide, linker protein for immunoglobulin alpha 
and mu polypeptides 
-54.04 0 
GPIHBP1 glycosylphosphatidylinositol anchored high density lipoprotein binding 
protein 1 
-42.61 6.06E-05 
CCL7 chemokine (C-C motif) ligand 7  -42.05 0.0125 
CD79A CD79a molecule, immunoglobulin-associated alpha  -40.93 0 
IBSP integrin-binding sialoprotein -39.43 0 
SP7 Sp7 transcription factor  -36.34 2.78E-07 
FCRL5 Fc receptor-like 5 -33.70 1.18E-09 
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV 
collagenase)  
-32.29 0 
TDO2 tryptophan 2,3-dioxygenase  -32.25 1.17E-09 
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Table III-3 continued 
DEGs in BAVr versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
MTRNR2L8 MT-RNR2-like 8  -31.05 4.01E-06 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine)  -29.87 5.54E-06 
PPBP pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)  -29.06 0.0358 
SPIB Spi-B transcription factor (Spi-1/PU.1 related)  -28.63 0.0379 
AMPD1 adenosine monophosphate deaminase 1  -28.15 0.0039 
FLT4 fms-related tyrosine kinase 4  -24.65 5.93E-08 
KLK4 kallikrein-related peptidase 4 -23.71 0.0191 
EMR1 egf-like module containing, mucin-like, hormone receptor-like 1 -21.91 0.0216 
CBLN4 cerebellin 4 precursor  -21.68 0.0067 
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 -21.37 5.94E-05 
MAT1A methionine adenosyltransferase I, alpha -21.35 0.0053 
PRND prion protein 2 (dublet) -20.87 2.08E-04 
SPP1 secreted phosphoprotein 1 -20.35 0 
BMP3 bone morphogenetic protein 3  -20.01 0.0043 
CXCL13 chemokine (C-X-C motif) ligand 13  -18.99 1.80E-04 
PNOC prepronociceptin -17.52 0.0490 
FCRL3 Fc receptor-like 3  -17.14 0.0100 
AQP9 aquaporin 9  -16.97 7.47E-04 
CXCL5 chemokine (C-X-C motif) ligand 5 -15.09 0.0017 
RASSF6 Ras association (RalGDS/AF-6) domain family member 6 -14.79 0.0017 
POU2AF1 POU class 2 associating factor 1  -13.46 7.72E-09 
DERL3 Der1-like domain family, member 3  -12.75 3.30E-09 
MMP1 matrix metallopeptidase 1 (interstitial collagenase) -11.69 0.0072 
COL11A1 collagen, type XI, alpha 1 -10.92 0 
MS4A1 membrane-spanning 4-domains, subfamily A, member 1  -10.63 9.63E-05 
C10orf81 chromosome 10 open reading frame 81  -10.52 1.02E-08 
ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary)  -10.26 0.0146 
APOC2 apolipoprotein C-II  -9.86 0.0196 
HBA2 hemoglobin, alpha 2 -9.29 0 
COL2A1 collagen, type II, alpha 1  -9.10 1.34E-04 
HBA1 hemoglobin, alpha 1 -9.03 0 
EBF2 early B-cell factor 2 -8.98 0.0011 
GJB2 gap junction protein, beta 2, 26kDa -8.64 0.0366 
CXorf36 chromosome X open reading frame 36 -8.61 2.31E-06 
DLL4 delta-like 4 (Drosophila) -8.53 8.56E-05 
SCUBE1 signal peptide, CUB domain, EGF-like 1 -8.25 0.0474 
CCL3 chemokine (C-C motif) ligand 3 -8.23 9.08E-09 
SLAMF7 SLAM family member 7 -7.92 3.42E-08 
CHIT1 chitinase 1 (chitotriosidase)  -7.79 9.26E-08 
HBB hemoglobin, beta -7.79 2.36E-12 
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Table III-3 continued 
DEGs in BAVr versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
TM4SF19 transmembrane 4 L six family member 19 -7.75 0.0020 
GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine 
esterase 1) 
-7.66 0.0068 
LRRC15 leucine rich repeat containing 15  -7.64 0 
KCNK2 potassium channel, subfamily K, member 2 -7.15 0.0036 
TM4SF18 transmembrane 4 L six family member 18  -6.97 7.07E-06 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)  -6.76 1.20E-10 
TIMD4 T-cell immunoglobulin and mucin domain containing 4  -6.53 1.50E-06 
CMA1 chymase 1, mast cell  -6.51 8.37E-05 
COL10A1 collagen, type X, alpha 1  -6.35 2.35E-10 
BGLAP bone gamma-carboxyglutamate (gla) protein -6.32 5.22E-05 
DLX5 distal-less homeobox 5 -6.26 0.0097 
SDC1 syndecan 1 -6.08 4.56E-06 
TREM1 triggering receptor expressed on myeloid cells 1  -5.75 3.69E-05 
PLA2G2D phospholipase A2, group IID -5.75 0.0306 
HLA-DOB major histocompatibility complex, class II, DO beta  -5.62 0.0292 
SDS serine dehydratase -5.61 0.0296 
CCL14 chemokine (C-C motif) ligand 14  -5.52 6.55E-04 
GREM1 gremlin 1 -5.43 0.0074 
PLVAP plasmalemma vesicle associated protein -5.37 2.90E-07 
IL1RN interleukin 1 receptor antagonist  -5.25 0.0100 
KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15  -5.22 0.0075 
PIM2 pim-2 oncogene -5.14 2.86E-09 
NELL2 NEL-like 2 (chicken)  -5.08 0.0028 
SLC11A1 solute carrier family 11 (proton-coupled divalent metal ion transporters), 
member 1 
-4.95 2.25E-06 
CCL4 chemokine (C-C motif) ligand 4 -4.95 0.0029 
IRF4 interferon regulatory factor 4  -4.88 5.90E-04 
APOC1 apolipoprotein C-I -4.81 2.93E-05 
CCL21 chemokine (C-C motif) ligand 21  -4.65 5.94E-06 
ACAN aggrecan -4.56 5.37E-09 
TMEM200A transmembrane protein 200A -4.55 0.0011 
SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 -4.51 0.0031 
SGCA sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)  -4.50 0.0032 
GALNT3 Polypeptide GalNAc transferase 3 -4.40 0.0073 
VMO1 vitelline membrane outer layer 1 homolog (chicken) -4.26 0.0010 
SLAMF6 SLAM family member 6 -4.08 0.0013 
FAIM3 Fas apoptotic inhibitory molecule 3  -4.06 0.0022 
ISM1 isthmin 1 homolog (zebrafish)  -4.05 1.34E-04 
GPHA2 glycoprotein hormone alpha 2  -3.97 0.0060 
ADRA2A adrenergic, alpha-2A-, receptor -3.95 1.77E-06 
LTB lymphotoxin beta (TNF superfamily, member 3) -3.91 0.0127 
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Table III-3 continued 
DEGs in BAVr versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
MATK megakaryocyte-associated tyrosine kinase  -3.80 0.0379 
NDUFA4L2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 -3.77 4.39E-06 
IL21R interleukin 21 receptor -3.74 0.0112 
RGS16 regulator of G-protein signalling 16  -3.71 0.0013 
SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2 
-3.71 4.41E-04 
GPR68 G protein-coupled receptor 68 -3.64 2.10E-05 
FMO3 flavin containing monooxygenase 3 -3.64 1.01E-04 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit)  -3.63 3.16E-07 
GZMK granzyme K (granzyme 3; tryptase II) -3.52 0.0224 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) -3.35 3.97E-06 
CHST1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1] -3.29 0.0085 
SEMA6B sema domain, transmembrane domain (TM), and cytoplasmic domain, 
(semaphorin) 6B 
-3.28 0.0052 
ST14 suppression of tumorigenicity 14 (colon carcinoma)  -3.24 0.0221 
CLEC5A C-type lectin domain family 5, member A -3.23 0.0049 
CXCL9 chemokine (C-X-C motif) ligand 9 -3.22 9.41E-05 
SLC44A3 solute carrier family 44, member 3 -3.22 0.0457 
VCAM1 vascular cell adhesion molecule 1 -3.19 4.46E-07 
PTP4A3 protein tyrosine phosphatase type IVA, member 3 -3.17 0.0011 
F3 coagulation factor III (thromboplastin, tissue factor) -3.12 0.0116 
CA12 carbonic anhydrase XII -3.11 0.0203 
NUP210 nucleoporin 210kDa -3.09 0.0186 
SLPI secretory leukocyte peptidase inhibitor -3.07 0.0039 
STMN2 stathmin-like 2 -3.01 7.78E-04 
IFI30 interferon, gamma-inducible protein 30 -2.95 2.57E-05 
TREM2 triggering receptor expressed on myeloid cells 2 -2.92 0.0296 
ACE angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 -2.92 0.0201 
FPR1 formyl peptide receptor 1 -2.91 0.0032 
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9  -2.90 0.0490 
MMRN1 multimerin 1 -2.88 0.0039 
TNC tenascin C -2.87 8.98E-05 
APLN apelin -2.82 0.0366 
GLRX glutaredoxin (thioltransferase) -2.81 0.0019 
CD52 CD52 molecule -2.79 0.0401 
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 1  
-2.78 0.0046 
ACP5 acid phosphatase 5, tartrate resistant -2.78 1.23E-05 
TP53I11 tumor protein p53 inducible protein 11  -2.74 9.28E-05 
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) -2.69 0.0461 
S100A9 S100 calcium binding protein A9  -2.64 0.0082 
CCL19 chemokine (C-C motif) ligand 19 -2.62 0.0244 
    
Appendices 
  256 
Table III-3 continued 
DEGs in BAVr versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
AOAH acyloxyacyl hydrolase (neutrophil) -2.59 0.0244 
CCL18 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) -2.57 0.0056 
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1 -2.55 0.0057 
MYO1G myosin IG  -2.54 0.0378 
CD3E CD3e molecule, epsilon (CD3-TCR complex) -2.52 0.0165 
MFAP5 microfibrillar associated protein 5 -2.48 0.0221 
KIAA1199 KIAA1199 -2.46 0.0115 
TSPAN11 tetraspanin 11  -2.45 0.0191 
ITGAL integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated 
antigen 1; alpha polypeptide)  
-2.42 0.0195 
SMOC2 SPARC related modular calcium binding 2  -2.40 0.0180 
TMEM119 transmembrane protein 119 -2.36 0.0043 
C1orf162 chromosome 1 open reading frame 162  -2.33 0.0372 
CR1 complement component (3b/4b) receptor 1 (Knops blood group)  -2.32 0.0385 
A2M alpha-2-macroglobulin  -2.31 0.0085 
CADM1 cell adhesion molecule 1  -2.30 0.0487 
KCNN4 potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 4  
-2.29 0.0425 
ALOX5AP arachidonate 5-lipoxygenase-activating protein -2.29 0.0330 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor 
type 1), member 1 
-2.25 0.0158 
LBH limb bud and heart development homolog (mouse) -2.25 0.0148 
PLAU plasminogen activator, urokinase -2.18 0.0192 
LAPTM5 lysosomal protein transmembrane 5 -2.17 0.0295 
LYZ lysozyme  -2.15 0.0443 
HMOX1 heme oxygenase (decycling) 1  -2.15 0.0105 
SMOC1 SPARC related modular calcium binding 1 -2.14 0.0098 
CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 -2.13 0.0270 
SRGN serglycin  -2.11 0.0273 
PLAUR plasminogen activator, urokinase receptor  -2.09 0.0384 
OGN osteoglycin -2.05 0.0341 
KIAA1217 KIAA1217  -2.04 0.0481 
CHI3L2 chitinase 3-like 2 -2.02 0.0452 
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Table III- 4. Complete list of differentially expressed genes (DEGs) 
between the BAVc (BAV4, BAV5) and TAV (TAV1-TAV3) groups (p<0.05 
with post-hoc Bonferroni correction), sorted by fold change. 
DEGs in BAVc versus TAV 
Gene 
symbol 
Gene annotation Fold 
change  
Adjusted 
p-value 
CCKAR cholecystokinin A receptor  14.97 5.73E-05 
RNASE3 ribonuclease, RNase A family, 3  9.98 0.0169 
FMN2 formin 2 8.79 0.0456 
FOSB FBJ murine osteosarcoma viral oncogene homolog B 7.75 0 
GSTT1 glutathione S-transferase theta 1  5.91 0 
C1QTNF8 C1q and tumor necrosis factor related protein 8  5.41 3.23E-07 
ABP1 amiloride binding protein 1 (amine oxidase (copper-containing))  4.95 2.76E-11 
CST1 cystatin SN  4.92 0.0489 
ESPNL espin-like 4.47 2.47E-04 
SSTR5 somatostatin receptor 5  4.39 0.0123 
MLC1 megalencephalic leukoencephalopathy with subcortical cysts 1 3.75 0.0033 
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 3.66 3.19E-08 
DKK1 dickkopf homolog 1 (Xenopus laevis)  3.38 0.0417 
C1orf51 chromosome 1 open reading frame 51  3.31 1.80E-05 
PAX8 paired box 8 3.21 3.22E-06 
MATN4 matrilin 4  3.13 0.0014 
NR1D1 nuclear receptor subfamily 1, group D, member 1 3.01 0 
POU6F2 POU class 6 homeobox 2  2.99 0.0319 
FOS FBJ murine osteosarcoma viral oncogene homolog  2.94 2.11E-12 
MTRNR2L9 MT-RNR2-like 9 (pseudogene)  2.93 0.0012 
C17orf97 chromosome 17 open reading frame 97 2.78 2.10E-04 
POLR2J2 polymerase (RNA) II (DNA directed) polypeptide J2  2.77 2.82E-12 
DPYSL4 dihydropyrimidinase-like 4  2.77 4.03E-04 
MUC20 mucin 20, cell surface associated  2.64 3.86E-04 
GSTM1 glutathione S-transferase mu 1  2.57 0.0021 
OCLN occludin  2.55 0.0195 
RPSAP58 ribosomal protein SA pseudogene 58  2.51 0.0224 
RASA4 RAS p21 protein activator 4 2.30 2.45E-06 
JUN jun proto-oncogene  2.28 5.53E-07 
DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11  2.23 3.85E-05 
CHRFAM7A CHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5-10) and 
FAM7A (family with sequence similarity 7A, exons A-E) fusion 
2.23 0.0365 
JAKMIP2 janus kinase and microtubule interacting protein 2  2.20 0.0405 
RASA4B RAS p21 protein activator 4B 2.18 3.16E-06 
UPK3BL uroplakin 3B-like  2.09 3.77E-05 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1  2.06 0.0011 
DBP D site of albumin promoter (albumin D-box) binding protein 2.06 1.27E-04 
COL13A1 collagen, type XIII, alpha 1  2.06 6.58E-04 
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Table III-4 continued 
DEGs in BAVc versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
SCG2 secretogranin II 2.05 1.88E-05 
PER1 period homolog 1 (Drosophila) 2.04 1.06E-05 
CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 2.02 0.0158 
GPX7 glutathione peroxidase 7  1.99 0.0015 
MASP1 mannan-binding lectin serine peptidase 1 (C4/C2 activating 
component of Ra-reactive factor)  
1.98 1.53E-05 
POLR2J3 polymerase (RNA) II (DNA directed) polypeptide J3  1.98 6.06E-06 
KIAA1683 KIAA1683  1.98 0.0028 
FNDC1 fibronectin type III domain containing 1 1.87 0.0033 
ACAN aggrecan  1.86 0.0059 
NTM neurotrimin  1.85 7.74E-04 
TMTC2 transmembrane and tetratricopeptide repeat containing 2  1.84 0.0168 
HLA-DRB5 major histocompatibility complex, class II, DR beta 5  1.82 0.0032 
HLF hepatic leukemia factor 1.82 0.0026 
HLA-B major histocompatibility complex, class I, B  1.81 0.0124 
COMP cartilage oligomeric matrix protein 1.80 0.0326 
C1QTNF3 C1q and tumor necrosis factor related protein 3 1.80 0.0059 
MIR3654 microRNA 3654  1.78 0.0308 
PCDHB5 protocadherin beta 5 1.75 0.0191 
ADAM12 ADAM metallopeptidase domain 12  1.72 0.0455 
TEF thyrotrophic embryonic factor  1.71 0.0075 
LRRC37A2 leucine rich repeat containing 37, member A2  1.71 0.0121 
SLC6A4 solute carrier family 6 (neurotransmitter transporter, serotonin), 
member 4  
1.71 0.0437 
GAP43 growth associated protein 43  1.69 0.0230 
SCO2 SCO cytochrome oxidase deficient homolog 2 (yeast)  1.68 0.0434 
NR1D2 nuclear receptor subfamily 1, group D, member 2  1.66 0.0283 
CCDC85B coiled-coil domain containing 85B 1.64 0.0222 
ANK3 ankyrin 3, node of Ranvier (ankyrin G) 1.63 0.0355 
HMCN1 hemicentin 1  1.62 0.0447 
RRP7A ribosomal RNA processing 7 homolog A (S. cerevisiae)  1.62 0.0251 
LTBP2 latent transforming growth factor beta binding protein 2  1.60 0.0209 
DEFA1 defensin, alpha 1  -22.30 0.0277 
TSPAN10 tetraspanin 10  -16.32 1.28E-04 
SIGLEC6 sialic acid binding Ig-like lectin 6  -10.74 0.0189 
GPC5 glypican 5  -8.96 0.0311 
MS4A2 membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment 
of IgE, high affinity I, receptor for; beta polypeptide)  
-8.44 3.43E-05 
ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 -8.30 0.0386 
DACH1 dachshund homolog 1 (Drosophila)  -8.16 0.0296 
CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1  -7.40 2.83E-06 
HLA-DQB2 major histocompatibility complex, class II, DQ beta 2 -6.87 8.62E-10 
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Table III-4 continued 
DEGs in BAVc versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
NOS1 nitric oxide synthase 1 (neuronal)  -6.85 0.0423 
CMA1 chymase 1, mast cell  -6.61 3.38E-07 
CTSE cathepsin E  -6.51 0.0096 
THNSL2 threonine synthase-like 2 (S. cerevisiae)  -5.90 0 
NKAIN2 Na+/K+ transporting ATPase interacting 2 -5.73 8.57E-04 
HDC histidine decarboxylase  -5.58 6.03E-06 
TPSD1 tryptase delta 1 -5.51 1.70E-05 
TRDN triadin -5.48 0.0085 
LTF lactotransferrin -5.30 0.0365 
CPA3 carboxypeptidase A3 (mast cell) -4.99 0 
ACTC1 actin, alpha, cardiac muscle 1  -4.96 9.64E-11 
DES desmin  -4.86 1.05E-12 
IGLL5 immunoglobulin lambda-like polypeptide 5  -4.82 0 
MTRNR2L8 MT-RNR2-like 8  -4.77 1.14E-04 
RP11-
1280I22.1 
Plasma cell-induced resident endoplasmic reticulum protein -4.60 2.46E-11 
CHL1 cell adhesion molecule with homology to L1CAM  -4.30 1.27E-04 
TPSAB1 tryptase alpha/beta 1  -4.20 0 
MMRN1 multimerin 1  -4.10 1.32E-10 
CTSG cathepsin G  -3.86 1.51E-05 
CD79A CD79a molecule, immunoglobulin-associated alpha  -3.79 2.73E-12 
RASSF6 Ras association (RalGDS/AF-6) domain family member 6  -3.70 0.0162 
CCDC163P coiled-coil domain containing 163, pseudogene  -3.70 0.0028 
COCH coagulation factor C homolog, cochlin (Limulus polyphemus) -3.69 1.28E-04 
FCRL5 Fc receptor-like 5  -3.42 1.14E-04 
ADIPOQ adiponectin, C1Q and collagen domain containing  -3.41 0.0099 
EGFLAM EGF-like, fibronectin type III and laminin G domains -3.29 0.0065 
SGCA sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) -3.29 8.19E-09 
IGJ immunoglobulin J polypeptide, linker protein for immunoglobulin alpha 
and mu polypeptides  
-3.27 0 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) -3.19 0.0224 
FCN3 ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen) -3.17 0.0193 
WNT7A wingless-type MMTV integration site family, member 7A  -3.11 0.0410 
GFRA1 GDNF family receptor alpha 1  -3.03 1.10E-11 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog -3.00 0.0019 
GPHA2 glycoprotein hormone alpha 2 -2.95 6.93E-05 
CHIT1 chitinase 1 (chitotriosidase)  -2.93 1.40E-06 
MYOC myocilin, trabecular meshwork inducible glucocorticoid response  -2.92 4.04E-05 
CXCL9 chemokine (C-X-C motif) ligand 9 -2.61 1.33E-07 
PI16 peptidase inhibitor 16  -2.57 4.00E-07 
PLP1 proteolipid protein 1  -2.42 0.0263 
PPP1R1B protein phosphatase 1, regulatory (inhibitor) subunit 1B  -2.38 5.42E-04 
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Table III-4 continued 
DEGs in BAVc versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
LPL lipoprotein lipase -2.37 1.81E-05 
AQP2 aquaporin 2 (collecting duct)  -2.34 2.50E-06 
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 -2.32 0.0039 
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa 
type IV collagenase) 
-2.30 4.66E-08 
PLIN4 perilipin 4  -2.26 0.0021 
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9  -2.25 0.0306 
GZMK granzyme K (granzyme 3; tryptase II) -2.23 0.0322 
PRRT4 proline-rich transmembrane protein 4  -2.21 0.0411 
NOS3 nitric oxide synthase 3 (endothelial cell)  -2.16 6.15E-06 
RGS5 regulator of G-protein signalling 5  -2.13 0.0191 
APLN apelin  -2.12 0.0330 
WNT9B wingless-type MMTV integration site family, member 9B  -2.11 0.0134 
VMO1 vitelline membrane outer layer 1 homolog (chicken) -2.11 0.0116 
SEMA3F sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3F  
-2.09 3.90E-05 
CHRDL1 chordin-like 1 -2.07 0.0015 
TIMD4 T-cell immunoglobulin and mucin domain containing 4  -2.07 0.0018 
C7 complement component 7  -2.07 2.54E-04 
CNTFR ciliary neurotrophic factor receptor  -2.05 0.0448 
HSPA12B heat shock 70kD protein 12B  -2.04 0.0019 
APOE apolipoprotein E  -2.02 9.64E-05 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide  -2.02 0.0276 
CCL19 chemokine (C-C motif) ligand 19 -2.01 1.80E-05 
PDPR pyruvate dehydrogenase phosphatase regulatory subunit -2.00 2.30E-04 
ZFAT zinc finger and AT hook domain containing -2.00 0.0011 
SCARA5 scavenger receptor class A, member 5 (putative)  -1.99 8.60E-05 
SLCO2A1 solute carrier organic anion transporter family, member 2A1  -1.97 9.27E-05 
PTHLH parathyroid hormone-like hormone -1.97 4.93E-04 
DERL3 Der1-like domain family, member 3  -1.96 0.0102 
ST6GALNAC1 ST6 euraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 1 
-1.96 0.0083 
GLRX glutaredoxin (thioltransferase)  -1.95 4.12E-05 
HYAL2 hyaluronoglucosaminidase 2  -1.93 8.21E-04 
ESAM endothelial cell adhesion molecule -1.92 0.0086 
ARHGEF15 Rho guanine nucleotide exchange factor (GEF) 15  -1.91 0.0014 
GPR116 G protein-coupled receptor 116  -1.89 6.66E-04 
LIFR leukemia inhibitory factor receptor alpha  -1.89 8.24E-04 
DDX39B DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B  -1.88 0.0011 
TIE1 tyrosine kinase with immunoglobulin-like and EGF-like domains 1  -1.88 0.0191 
SELE selectin E  -1.87 0.0054 
GOLGA8B golgin A8 family, member B  -1.87 0.0015 
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Table III-4 continued 
DEGs in BAVc versus TAV 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
NPR1 natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic 
peptide receptor A) 
-1.86 0.0033 
DYNC1LI2 dynein, cytoplasmic 1, light intermediate chain 2 -1.83 0.0150 
C4orf48 chromosome 4 open reading frame 48  -1.82 0.0294 
HS3ST1 heparan sulfate (glucosamine) 3-O-sulfotransferase 1  -1.82 0.0087 
ACP5 acid phosphatase 5, tartrate resistant -1.82 0.0030 
NPIPL2 nuclear pore complex interacting protein-like 2  -1.78 0.0134 
HBA2 hemoglobin, alpha 2  -1.78 0.0054 
ARNTL aryl hydrocarbon receptor nuclear translocator-like  -1.78 0.0462 
INMT indolethylamine N-methyltransferase -1.78 0.0099 
GSN gelsolin -1.77 0.0125 
GNA14 guanine nucleotide binding protein (G protein), alpha 14  -1.76 0.0116 
AIF1L allograft inflammatory factor 1-like  -1.75 0.0048 
PTGDS prostaglandin D2 synthase 21kDa (brain)  -1.75 0.0073 
TEK TEK tyrosine kinase, endothelial  -1.74 0.0011 
FAM107A family with sequence similarity 107, member A  -1.74 0.0116 
CRHBP corticotropin releasing hormone binding protein -1.74 0.0022 
HTRA3 HtrA serine peptidase 3 -1.73 0.0017 
A2M alpha-2-macroglobulin -1.72 0.0033 
VWF von Willebrand factor -1.72 0.0169 
JAM2 junctional adhesion molecule 2  -1.72 0.0347 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit)  -1.71 0.0158 
CRELD1 cysteine-rich with EGF-like domains 1  -1.71 0.0178 
CHI3L2 chitinase 3-like 2  -1.69 0.0104 
HBA1 hemoglobin, alpha 1  -1.67 0.0192 
ITGA6 integrin, alpha 6  -1.66 0.0264 
SYNPO2 synaptopodin 2  -1.65 0.0220 
CDH5 cadherin 5, type 2 (vascular endothelium)  -1.64 0.0270 
ZNF266 zinc finger protein 266  -1.64 0.0318 
RAMP3 receptor (G protein-coupled) activity modifying protein 3  -1.64 0.0417 
CXCR7 chemokine (C-X-C motif) receptor 7 -1.63 0.0280 
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 -1.62 0.0296 
PTPRB protein tyrosine phosphatase, receptor type, B -1.61 0.0324 
RPS12 ribosomal protein S12 -1.61 0.0357 
SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1  -1.60 0.0414 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 -1.59 0.0456 
ADAM33 ADAM metallopeptidase domain 33  -1.57 0.0432 
BMPER BMP binding endothelial regulator  -1.56 0.0467 
EMCN endomucin  -1.53 0.0406 
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Table III- 5. Complete list of differentially expressed genes (DEGs) 
between the BAVr (BAV1-BAV3) and BAVc (BAV4, BAV5) groups (p<0.05 
with post-hoc Bonferroni correction), sorted by fold change. 
DEGs in BAVr versus BAVc 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
IGFN1 immunoglobulin-like and fibronectin type III domain containing 1  22.06 0.0022 
ENTPD2 ectonucleoside triphosphate diphosphohydrolase 2  22.05 0.0132 
CBLN1 cerebellin 1 precursor  20.11 1.97E-04 
FAM123A family with sequence similarity 123A  13.73 0.0244 
TRDN triadin  13.04 2.15E-05 
OTOGL otogelin-like  12.90 0.0305 
VSTM2A V-set and transmembrane domain containing 2A  11.08 0.0132 
CTSE cathepsin E 10.99 1.94E-06 
SLC6A20 solute carrier family 6 (proline IMINO transporter), member 20 10.50 2.59E-04 
KISS1 KiSS-1 metastasis-suppressor  10.10 3.20E-04 
CNTFR ciliary neurotrophic factor receptor  9.69 2.16E-09 
NPPC natriuretic peptide C  9.09 6.47E-08 
NKAIN2 Na+/K+ transporting ATPase interacting 2  9.04 0.0250 
COL9A1 collagen, type IX, alpha 1  8.45 0.0498 
MYOC myocilin, trabecular meshwork inducible glucocorticoid response  7.86 6.90E-08 
DES desmin  7.47 8.82E-11 
CADM2 cell adhesion molecule 2  6.08 1.48E-04 
PLCH1 phospholipase C, eta 1  6.01 4.93E-05 
ADCYAP1R1 adenylate cyclase activating polypeptide 1 (pituitary) receptor type I  5.79 1.50E-04 
CHL1 cell adhesion molecule with homology to L1CAM  5.61 0.0443 
SCN7A sodium channel, voltage-gated, type VII, alpha  5.60 4.93E-05 
PPP1R1B protein phosphatase 1, regulatory (inhibitor) subunit 1B 5.55 3.19E-08 
ITLN1 intelectin 1 (galactofuranose binding) 5.52 0.0132 
SMTNL2 smoothelin-like 2  5.40 2.84E-06 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide  5.26 1.39E-08 
KIF1A kinesin family member 1A  5.20 5.40E-04 
COL6A6 collagen, type VI, alpha 6 5.16 7.21E-11 
OTC ornithine carbamoyltransferase 5.10 0.0075 
COCH coagulation factor C homolog, cochlin (Limulus polyphemus)  5.04 1.22E-04 
ACTC1 actin, alpha, cardiac muscle 1  4.99 1.66E-04 
HLA-DRB5 major histocompatibility complex, class II, DR beta 5  4.81 7.72E-08 
IGSF10 immunoglobulin superfamily, member 10  4.80 3.22E-08 
HMGCLL1 3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1 4.73 0.0358 
PRODH proline dehydrogenase (oxidase) 1  4.71 0.0019 
WNT9B wingless-type MMTV integration site family, member 9B  4.66 2.63E-04 
ST6GALNAC1 ST6 euraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 1  
4.42 3.94E-06 
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Table III-5 continued 
DEGs in BAVr versus BAVc 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
GFAP glial fibrillary acidic protein  4.41 1.41E-09 
NWD1 NACHT and WD repeat domain containing 1  4.12 0.0019 
PTGDS prostaglandin D2 synthase 21kDa (brain)  4.08 2.19E-07 
SPOCK3 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 3  
4.06 6.47E-06 
PRLR prolactin receptor  4.04 0.0019 
SCARA5 scavenger receptor class A, member 5 (putative)  3.97 2.55E-07 
CECR2 cat eye syndrome chromosome region, candidate 2 3.88 0.0116 
IL1RL1 interleukin 1 receptor-like 1  3.80 7.81E-04 
ALDH3A1 aldehyde dehydrogenase 3 family, member A1  3.77 0.0025 
TMEM132C transmembrane protein 132C  3.74 9.49E-05 
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 3.73 3.89E-05 
MED12L mediator complex subunit 12-like  3.69 6.94E-05 
LAMC3 laminin, gamma 3  3.60 5.93E-06 
SOX10 SRY (sex determining region Y)-box 10  3.60 0.0182 
COL4A3 collagen, type IV, alpha 3 (Goodpasture antigen) 3.57 4.54E-05 
PPP1R39 protein phosphatase 1, regulatory subunit 39 3.51 0.0047 
CLDN10 claudin 10  3.47 0.0378 
ERAP2 endoplasmic reticulum aminopeptidase 2  3.41 3.01E-06 
C2orf88 chromosome 2 open reading frame 88  3.37 0.0023 
PTPN20A protein tyrosine phosphatase, non-receptor type 20A  3.37 0.0376 
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9  3.36 0.0111 
PDE4B phosphodiesterase 4B, cAMP-specific  3.34 0.0302 
LCNL1 lipocalin-like 1 3.31 0.0256 
MYH14 myosin, heavy chain 14, non-muscle  3.27 8.48E-04 
THNSL2 threonine synthase-like 2 (S. cerevisiae)  3.22 0.0111 
CHRDL1 chordin-like 1 3.20 2.67E-04 
SFRP1 secreted frizzled-related protein 1 3.19 3.13E-04 
PLIN1 perilipin 1  3.08 0.0439 
ACTG2 actin, gamma 2, smooth muscle, enteric  3.06 8.48E-04 
MET met proto-oncogene (hepatocyte growth factor receptor) 3.05 0.0377 
LIFR leukemia inhibitory factor receptor alpha  3.05 1.08E-04 
MYH10 myosin, heavy chain 10, non-muscle 3.03 0.0016 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 3.00 0.0227 
CNTN1 contactin 1  2.99 0.0363 
CLDN11 claudin 11  2.99 0.0013 
TBX20 T-box 20  2.98 0.0012 
NDNF neuron-derived neurotrophic factor 2.88 0.0420 
AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 
2; bile acid binding protein) 
2.88 0.0024 
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Table III-5 continued 
DEGs in BAVr versus BAVc 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8 2.88 0.0069 
RIMS4 regulating synaptic membrane exocytosis 4 2.82 4.21E-04 
PLIN4 perilipin 4  2.81 0.0217 
ZEB1 zinc finger E-box binding homeobox 1  2.80 0.0345 
AIF1L allograft inflammatory factor 1-like 2.79 0.0025 
CPA3 carboxypeptidase A3 (mast cell) 2.79 0.0409 
KIF26A kinesin family member 26A  2.79 0.0378 
GFRA1 GDNF family receptor alpha 1 2.76 0.0032 
MAPT microtubule-associated protein tau  2.69 0.0039 
C7 complement component 7  2.69 3.89E-04 
DOK6 docking protein 6  2.66 0.0432 
PKHD1L1 polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1  2.62 0.0019 
EMILIN3 elastin microfibril interfacer 3 2.61 0.0056 
MATN2 matrilin 2  2.61 5.13E-04 
PIR pirin (iron-binding nuclear protein)  2.49 0.0441 
PI16 peptidase inhibitor 16 2.47 0.0286 
ANGPTL7 angiopoietin-like 7  2.44 0.0360 
PDZRN4 PDZ domain containing ring finger 4  2.42 0.0267 
PKP2 plakophilin 2 2.41 0.0402 
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 2.40 0.0154 
PTPRB protein tyrosine phosphatase, receptor type, B  2.35 0.0129 
SAMD5 sterile alpha motif domain containing 5  2.29 0.0500 
PLEKHA6 pleckstrin homology domain containing, family A member 6 2.27 0.0254 
TPSAB1 tryptase alpha/beta 1  2.27 0.0300 
BMPER BMP binding endothelial regulator 2.26 0.0069 
NSG1 Neuron-specific protein family member 1 2.25 0.0135 
LGI4 leucine-rich repeat LGI family, member 4  2.21 0.0484 
FAM107A family with sequence similarity 107, member A  2.20 0.0208 
NOS3 nitric oxide synthase 3 (endothelial cell)  2.20 0.0305 
DHCR24 24-dehydrocholesterol reductase  2.19 0.0233 
TNXB tenascin XB  2.17 0.0203 
LDLR low density lipoprotein receptor  2.17 0.0248 
SPTBN1 spectrin, beta, non-erythrocytic 1  2.14 0.0467 
HS3ST1 heparan sulfate (glucosamine) 3-O-sulfotransferase 1  2.13 0.0372 
MEIS2 Meis homeobox 2  2.10 0.0267 
SYNPO2 synaptopodin 2 2.04 0.0462 
NDRG2 NDRG family member 2  2.03 0.0332 
MMP13 matrix metallopeptidase 13 (collagenase 3)  -299.48 0 
CHGA chromogranin A (parathyroid secretory protein 1)  -51.58 0.0163 
GADL1 glutamate decarboxylase-like 1 -46.95 0.0206 
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Table III-5 continued 
DEGs in BAVr versus BAVc 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
IBSP integrin-binding sialoprotein -44.35 0 
FLT4 fms-related tyrosine kinase 4 -41.38 1.55E-11 
CCL7 chemokine (C-C motif) ligand 7  -34.84 0.0341 
MEPE matrix extracellular phosphoglycoprotein  -31.83 0.0425 
CBLN4 cerebellin 4 precursor -29.84 1.32E-04 
SP7 Sp7 transcription factor  -28.23 1.99E-05 
PRND prion protein 2 (dublet)  -23.89 1.08E-04 
IGLL5 immunoglobulin lambda-like polypeptide 5  -21.10 0 
GPIHBP1 glycosylphosphatidylinositol anchored high density lipoprotein binding 
protein 1 
-19.76 0.0203 
IGJ immunoglobulin J polypeptide, linker protein for immunoglobulin alpha 
and mu polypeptides  
-18.75 0 
TDO2 tryptophan 2,3-dioxygenase  -18.73 4.37E-04 
MMP1 matrix metallopeptidase 1 (interstitial collagenase)  -16.74 0.0022 
RP11-
1280I22.1 
Plasma cell-induced resident endoplasmic reticulum protein  -16.71 0.0014 
FOSB FBJ murine osteosarcoma viral oncogene homolog B -15.97 0 
AQP9 aquaporin 9  -15.68 0.0023 
MAT1A methionine adenosyltransferase I, alpha  -15.24 0.0279 
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa 
type IV collagenase) 
-14.51 0 
SPP1 secreted phosphoprotein 1  -14.04 0 
CXCL5 chemokine (C-X-C motif) ligand 5  -13.87 0.0016 
CCKAR cholecystokinin A receptor  -13.37 0.0172 
CXCL13 chemokine (C-X-C motif) ligand 13 -13.36 0.0185 
GSTT1 glutathione S-transferase theta 1  -12.58 0 
GJB2 gap junction protein, beta 2, 26kDa  -12.02 0.0069 
SIRPB1 signal-regulatory protein beta 1  -11.68 0.0038 
CYP26A1 cytochrome P450, family 26, subfamily A, polypeptide 1 -11.42 0.0097 
TNFRSF18 tumor necrosis factor receptor superfamily, member 18 -11.07 0.0173 
C10orf81 chromosome 10 open reading frame 81  -11.00 2.49E-10 
CD79A CD79a molecule, immunoglobulin-associated alpha  -10.81 1.51E-04 
FCRL5 Fc receptor-like 5 -9.87 0.0288 
CXorf36 chromosome X open reading frame 36  -9.24 3.64E-07 
DLL4 delta-like 4 (Drosophila) -9.18 3.93E-04 
DLX5 distal-less homeobox 5  -8.73 6.04E-05 
C1QTNF8 C1q and tumor necrosis factor related protein 8 -8.63 9.40E-04 
GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine 
esterase 1) 
-8.58 0.0089 
KCNK2 potassium channel, subfamily K, member 2  -8.46 2.77E-04 
S100A8 S100 calcium binding protein A8 -8.41 0.0104 
COL10A1 collagen, type X, alpha 1 -8.26 4.61E-10 
POU2AF1 POU class 2 associating factor 1 -8.25 5.45E-07 
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Table III-5 continued 
DEGs in BAVr versus BAVc 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
COL2A1 collagen, type II, alpha 1  -7.91 0.0012 
TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 -7.89 0.0349 
CCL3 chemokine (C-C motif) ligand 3  -7.72 1.58E-06 
ACAN aggrecan -7.69 0 
COL11A1 collagen, type XI, alpha 1  -7.49 2.74E-08 
LRRC15 leucine rich repeat containing 15  -7.30 3.30E-13 
SDC1 syndecan 1  -7.06 3.05E-07 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)  -7.04 1.24E-11 
FCN1 ficolin (collagen/fibrinogen domain containing) 1  -6.48 0.0123 
RNASE2 ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin)  -6.18 0.0077 
TMEM200A transmembrane protein 200A -6.09 2.00E-07 
SLAMF7 SLAM family member 7 -6.04 1.58E-06 
NELL2 NEL-like 2 (chicken) -5.94 1.44E-04 
BGLAP bone gamma-carboxyglutamate (gla) protein -5.74 2.93E-04 
TREM1 triggering receptor expressed on myeloid cells 1  -5.67 9.11E-06 
HBA1 hemoglobin, alpha 1  -5.59 8.82E-11 
GALNT3 putative sodium/glutamine symporter GlnT -5.55 0.0039 
KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15  -5.53 0.0172 
SIGLEC14 sialic acid binding Ig-like lectin 14 -5.46 7.79E-04 
SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), 
member 5 
-5.39 4.25E-05 
HBA2 hemoglobin, alpha 2  -5.35 3.55E-11 
TM4SF18 transmembrane 4 L six family member 18  -5.34 2.15E-04 
CCL14 chemokine (C-C motif) ligand 14  -5.27 0.0022 
IRF4 interferon regulatory factor 4  -5.27 2.67E-04 
CPXM1 carboxypeptidase X (M14 family), member 1 -5.17 0.0031 
ADAMTS16 ADAM metallopeptidase with thrombospondin type 1 motif, 16  -5.00 0.0336 
HBB hemoglobin, beta  -4.95 6.57E-10 
PTP4A3 protein tyrosine phosphatase type IVA, member 3 -4.93 5.79E-08 
DERL3 Der1-like domain family, member 3  -4.79 1.84E-04 
GNLY granulysin  -4.76 0.0420 
FOS FBJ murine osteosarcoma viral oncogene homolog  -4.68 5.56E-10 
CA12 carbonic anhydrase XII  -4.62 4.99E-07 
PLVAP plasmalemma vesicle associated protein  -4.48 3.93E-09 
ADRA2A adrenergic, alpha-2A-, receptor -4.39 1.92E-07 
PAX8 paired box 8  -4.26 1.17E-04 
SLC11A1 solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 1  
-4.25 5.34E-06 
SIGLEC5 sialic acid binding Ig-like lectin 5  -4.22 0.0065 
AOC2 amine oxidase, copper containing 2 (retina-specific) -4.08 0.0366 
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64)  -3.98 8.55E-05 
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Table III-5 continued 
DEGs in BAVr versus BAVc 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
FPR1 formyl peptide receptor 1  -3.88 3.82E-04 
ISM1 isthmin 1 homolog (zebrafish) -3.79 0.0011 
GPR84 G protein-coupled receptor 84  -3.75 0.0119 
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
-3.69 1.93E-04 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64)  -3.67 4.14E-06 
PIM2 pim-2 oncogene  -3.67 3.82E-04 
TNC tenascin C  -3.63 1.23E-04 
GPR68 G protein-coupled receptor 68  -3.60 0.0017 
SOCS3 suppressor of cytokine signalling 3 -3.55 3.28E-06 
CCL8 chemokine (C-C motif) ligand 8 -3.55 0.0035 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 -3.53 4.17E-06 
PDGFRL platelet-derived growth factor receptor-like -3.51 0.0022 
SLPI secretory leukocyte peptidase inhibitor -3.50 0.0077 
GPR88 G protein-coupled receptor 88 -3.45 0.0241 
ABP1 amiloride binding protein 1 (amine oxidase (copper-containing)) -3.39 0.0154 
RGS16 regulator of G-protein signalling 16  -3.39 0.0056 
IL21R interleukin 21 receptor -3.29 0.0307 
VCAM1 vascular cell adhesion molecule 1  -3.28 4.93E-05 
DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11  -3.25 8.84E-04 
DPYSL4 dihydropyrimidinase-like 4  -3.22 0.0225 
CCL21 chemokine (C-C motif) ligand 21 -3.21 0.0019 
SLAMF6 SLAM family member 6  -3.19 0.0164 
F3 coagulation factor III (thromboplastin, tissue factor)  -3.16 0.0190 
TSPAN11 tetraspanin 11 -3.14 7.69E-05 
STMN2 stathmin-like 2  -3.12 0.0017 
SCG2 secretogranin II  -3.12 1.50E-05 
KIAA1199 KIAA1199  -3.10 2.83E-04 
ST14 suppression of tumorigenicity 14 (colon carcinoma)  -3.09 0.0182 
TIMD4 T-cell immunoglobulin and mucin domain containing 4 -3.08 0.0311 
NDUFA4L2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2  -3.07 7.77E-05 
ADAM12 ADAM metallopeptidase domain 12  -3.03 9.05E-04 
CLEC5A C-type lectin domain family 5, member A -3.02 0.0371 
FCGR3B Fc fragment of IgG, low affinity IIIb, receptor (CD16b) -2.97 0.0480 
APOC1 apolipoprotein C-I  -2.96 0.0381 
IFI30 interferon, gamma-inducible protein 30 -2.93 3.99E-04 
S100A9 S100 calcium binding protein A9  -2.92 0.0180 
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1  -2.86 7.33E-05 
HIST2H2BF histone cluster 2, H2bf  -2.86 0.0500 
SLC16A3 solute carrier family 16, member 3 (monocarboxylic acid transporter 4)  -2.83 0.0048 
FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) -2.79 3.38E-04 
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Table III-5 continued 
DEGs in BAVr versus BAVc 
Gene 
symbol 
Gene annotation Fold 
change 
Adjusted 
p-value 
C4A complement component 4A (Rodgers blood group) -2.76 0.0075 
CD300C CD300c molecule  -2.76 0.0446 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1  
-2.71 2.61E-04 
CADM1 cell adhesion molecule 1  -2.70 0.0065 
C4B complement component 4B (Chido blood group)  -2.70 0.0101 
CCL18 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)  -2.68 6.98E-05 
KCNN4 potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 4 
-2.68 0.0074 
HAPLN3 hyaluronan and proteoglycan link protein 3  -2.65 8.48E-04 
PDPN podoplanin -2.61 0.0016 
THY1 Thy-1 cell surface antigen  -2.61 0.0048 
FNDC1 fibronectin type III domain containing 1  -2.60 0.0228 
CTHRC1 collagen triple helix repeat containing 1 -2.55 0.0168 
IGFBP2 insulin-like growth factor binding protein 2, 36kDa -2.50 0.0025 
RPSAP58 ribosomal protein SA pseudogene 58  -2.43 0.0291 
RGS2 regulator of G-protein signalling 2, 24kDa  -2.40 0.0254 
FCGBP Fc fragment of IgG binding protein  -2.37 0.0084 
SYT12 synaptotagmin XII -2.35 0.0110 
ASPN asporin  -2.33 0.0195 
POU2F2 POU class 2 homeobox 2 -2.32 0.0300 
C1orf162 chromosome 1 open reading frame 162 -2.31 0.0300 
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 1 
-2.30 0.0152 
FZD8 frizzled family receptor 8 -2.30 0.0235 
PLAUR plasminogen activator, urokinase receptor  -2.26 0.0169 
LILRB2 leukocyte immunoglobulin-like receptor, subfamily B (with TM and 
ITIM domains), member 2  
-2.26 0.0450 
IFITM10 interferon induced transmembrane protein 10 -2.26 0.0019 
JUNB jun B proto-oncogene -2.24 0.0173 
FAP fibroblast activation protein, alpha  -2.21 0.0111 
THBS2 thrombospondin 2  -2.19 0.0290 
CD93 CD93 molecule  -2.17 0.0497 
JUN jun proto-oncogene  -2.10 0.0407 
TP53I11 tumor protein p53 inducible protein 11  -2.09 0.0357 
C5AR1 complement component 5a receptor 1  -2.08 0.0218 
OGN osteoglycin -2.07 0.0500 
XBP1 X-box binding protein 1 -2.06 0.0233 
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Table III- 6. Selected genes-of-interest comparison between the 
subgroups.  
  
BAVr vs TAV 
fold change 
adjusted  
p-value 
BAVr vs BAVc 
fold change 
 adjusted  
p-value 
BAVc vs TAV 
fold change 
adjusted  
p-value 
ACAN# -4.56 5.37E-09 -7.69 0 1.86 0.0059 
ADAMTS9 -2.90 0.0490 - ns - ns 
BGLAP -6.32 5.22E-05 -5.74 2.93E-04 - ns 
BMP3 -20.01 0.0043 - ns - ns 
CHAD 2.52 0.0015 - ns - ns 
CHI3L1# -6.76 1.20E-10 -7.04 1.24E-11 - ns 
CHIT1 -7.79 9.26E-08 - ns -2.93 1.40E-06 
CLU 3.11 2.56E-04 - ns - ns 
COL11A1 -10.92 0 -7.49 2.74E-08 - ns 
COL2A1 -9.10 1.34E-04 -7.91 0.0012 - ns 
COL6A6# 3.47 1.24E-05 5.16 7.21E-11 - ns 
DLL4 -8.53 8.56E-05 -9.18 3.93E-04 - ns 
EMILIN3 2.19 0.0170 2.61 0.0056 - ns 
GATA4 2.33 0.0079 - ns - ns 
GFAP 3.57 5.38E-07 4.41 1.41E-09 - ns 
GREM1 -5.43 0.0074 - ns - ns 
GZMB -7.66 0.0068 -8.58 0.0089 - ns 
HAND2 2.08 0.0110 - ns - ns 
HMOX1 -2.15 0.0105 - ns - ns 
IBSP# -39.43 0 -44.35 0 - ns 
ITGAL -2.42 0.0195 - ns - ns 
ITGAX -3.63 3.16E-07 - ns -1.71 0.0158 
LAMC3# 3.38 6.39E-06 3.60 5.93E-06 - ns 
LBH -2.25 0.0148 - ns - ns 
MMP1 -11.69 0.0072 -16.74 0.0022 - ns 
MMP13# -186.53 0 -299.48 0 - ns 
MMP7# -29.87 5.54E-06 - ns -3.19 0.0224 
MMP9# -32.29 0 -14.51 0 -2.30 4.66E-08 
MYH10 3.41 0.0050 3.03 0.0016 - ns 
PLAUR -2.09 0.0384 -2.26 0.0169 - ns 
PTGDS 2.41 0.0112 4.08 2.19E-07 -1.75 0.0073 
SOX10 3.63 0.0110 3.60 0.0182 - ns 
SP7 -36.34 2.78E-07 -28.23 1.99E-05 - ns 
SPP1# -20.35 0 -14.04 0 - ns 
TNC -2.87 8.98E-05 -3.63 1.23E-04 - ns 
TNXB 2.61 0.0052 2.17 0.0203 - ns 
#genes used in RT-qPCR validation analysis; ns = not statistically significant. 
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Table III- 8. Validation cohort characteristics. 
 TAV BAVr BAVc 
Patients number, n 6 9 12 
RNA samples#, n 8 10 13 
Male gender (%) 6 (100) 8 (89) 11 (92) 
Mean age (SD) 69 (9) 54 (16) 65 (6) 
Background    
Caucasian 5 
0 
1 
0 
7 
1 
0 
1 
12 
0 
0 
0 
Mediterranean 
Middle Eastern 
Asian 
Leaflet calcification 
(patients, n) +++ (6) 
– (6) 
+ (3) +++ (12) 
BAV morphology 
(patients, n) n/a 
R-L fusion (6) 
R-N fusion (1) 
True BAV (2) 
R-L fusion (9) 
R-N fusion (1) 
True BAV (2) 
Predominant valve 
dysfunction 
(patients, n) 
Severe AS (6) Moderate or severe AR (6) 
Mild AR* (2) 
Mild AS* (1) 
Severe AS (12) 
*surgically unsuitable for either repair or preservation; #when residual sample 
was available, RNA was extracted from a different portion of the leaflet and 
used for validation analysis; AS, aortic stenosis; AR, aortic regurgitation; TAV, 
tricuspid aortic valve; BAVr, bicuspid aortic valve with leaflet redundancy and 
either no calcification or minimal calcification; BAVc, BAV with severe valve 
calcification; leaflet calcification: +++ for heavily calcified leaflets (>2/3 leaflet 
area), + for mild calcification (<1/3 leaflet area), and – for no calcification ; BAV 
morphology: R-L fusion, functionally bicuspid due to fusion of right and left 
coronary leaflets; R-N fusion, functionally bicuspid due to fusion of right and 
noncoronary leaflets; true BAV, anatomically bicuspid with 2 equal sized leaflets 
and the absence of raphe; n/a, not applicable. 
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Table III- 9. Gene lists comprising the different Venn diagram 
compartments (A-G) as depicted in Figure 5.6. 
Group No. genes Genes list 
A 71 ACE,ADAMTS9,ADCYAP1,ALOX5AP,AMPD1,AOAH,APOC2,ATP6V0D2,BMP3,CCL4, 
CD3E,CD52,CHAD,CHST1,CHST15,CHST9,CLU,CPEB1,CR1,EBF2,EMR1,EPB41L4B, 
EYA1,FAIM3,FCRL3,FMO3,GATA4,GBP3,GREM1,HAND2,HLA-DOB,HMOX1,IL1RN, 
ITGAL,KIAA1217,KIRREL3,KLK4,LAPTM5,LBH,LTB,LYZ,MATK,MFAP5,MS4A1, 
MYO1G,NFIA,NTRK2,NUP210,PLA2G2D,PLAU,PNOC,PPBP,RBP1,S100B,SCUBE1, 
SDS,SEMA6B,SLC14A1,SLC44A3,SLC6A1,SLC7A2,SMOC1,SMOC2,SPIB,SRGN, 
TCEAL2,TM4SF19,TMEM119,TMEM56,TREM2,TRHDE 
B 91 ACTG2,ADAMTS16,ADCYAP1R1,ALDH3A1,ANGPTL7,AOC2,ASPN,C2orf88,C4A,C4B, 
C5AR1,CBLN1,CCL8,CD300C,CD93,CECR2,CHGA,CLDN10,CNTN1,COL9A1,CPXM1, 
CTHRC1,CYP26A1,DOK6,ENTPD2,ERBB3,FAM123A,FAP,FCGBP,FCGR3A,FCGR3B, 
FCN1,FZD8,GADL1,GNLY,GPR84,GPR88,HAPLN3,HIST2H2BF,IFITM10,IGFBP2, 
IGFN1,ITLN1,JUNB,KIF26A,KISS1,LDLR,LGI4,LILRB2,MATN2,MEIS2,MEPE,MET, 
MYH14,NDNF,NDRG2,OTC,OTOGL,PDE4B,PDGFRL,PDPN,PIR,PKHD1L1,PLEKHA6,
PLIN1,POU2F2,PPP1R39,PRLR,PRODH,PTPN20A,RGS2,RNASE2,S100A8,SAMD5, 
SIGLEC14,SIGLEC5,SIRPB1,SLC16A3,SMTNL2,SOCS3,SPOCK1,SPTBN1,SYT12, 
TBX20,THBS2,THY1,TNFRSF18,TNFSF11,VSTM2A,XBP1,ZEB1 
C 113 ABCC8,ADAM33,ADAMTS1,ADIPOQ,ANK3,APOE,AQP2,ARHGEF15,ARNTL, 
C17orf97,C1QTNF3,C1orf51,C4orf48,CCDC163P,CCDC85B,CDH5,CDH6,CHRFAM7A,
COL13A1,COMP,CRELD1,CRHBP,CST1,CTSG,CXCR7,CYP4B1,DACH1,DBP, DDX- 
39B,DEFA1,DKK1,DYNC1LI2,EGFLAM,EMCN,ESAM,ESPNL,FCN3,FMN2, GAP43, 
GNA14,GOLGA8B,GPC5,GPR116,GPX7,GSN,GSTM1,HDC,HLA-B,  HLA-DQB1, 
HLADQB2,HMCN1,HSPA12B,HTRA3,HYAL2,INMT,ITGA6,JAKMIP2,JAM2, KIAA1683, 
KIT,LPL,LRRC37A2,LTBP2,LTF,MASP1,MATN4,MIR3654,MLC1,MS4A2, MTRNR2L9, 
NOS1,NPIPL2,NPR1,NR1D1,NR1D2,NTM,OCLN,PCDHB5,PDK4,PDPR, PER1,PLP1, 
POLR2J2,POLR2J3,POU6F2,PRRT4,PTHL,RAMP3,RASA4,RASA4B, RGS5,RNASE3, 
RPS12,RRP7A,SCO2,SELE,SEMA3F,SIGLEC6,SLC40A1,SLC6A4, SLCO2A1,SSTR5, 
TEF,TEK,TIE1,TMTC2,TPSD1,TSPAN10,UPK3BL,VWF,WNT7A, ZFAT,ZNF266 
D 114 ABCA8,ADRA2A,AKR1C2,APOC1,AQP9,BGLAP,C10orf81,C1orf162,CA12,CADM1, 
CADM2,CBLN4,CCL14,CCL18,CCL21,CCL3,CCL7,CHI3L1,CLDN11,CLEC5A, 
COL10A1,COL11A1,COL2A1,COL4A3,COL6A6,CPAMD8,CXCL13,CXCL5,CXorf36, 
DHCR24,DLL4,DLX5,EMILIN3,ENPP1,ERAP2,F3,FCGR1A,FCGR1B,FLT4,FPR1, 
GALNT3,GFAP,GJB2,GPIHBP1,GPR68,GZMB,HBB,HMGCLL1,IBSP,IFI30,IGSF10, 
IL1RL1,IL21R,IRF4,ISM1,KCNJ15,KCNK2,KCNN4,KIAA1199,KIF1A,LAMC3,LCNL1, 
LRRC15,MAPT,MAT1A,MED12L,MMP1,MMP13,MYH10,NDUFA4L2,NELL2,NPPC, 
NSG1,NWD1,OGN,PDZRN4,PIM2,PKP2,PLAUR,PLCH1,PLVAP,POU2AF1,PRND, 
PTP4A3,RGS16,RIMS4,S100A9,SCN7A,SDC1,SERPINA1,SERPINE1,SFRP1, 
SLAMF6,SLAMF7,SLC11A1,SLC2A5,SLC6A20,SLPI,SOX10,SP7,SPOCK3,SPP1, 
ST14,STMN2,TDO2,TM4SF18,TMEM132C,TMEM200A,TNC,TNXB,TP53I11,TREM1, 
TSPAN11,VCAM1 
E 20 A2M,ACP5,APLN,CCL19,CHI3L2,CHIT1,CMA1,CXCL9,GLRX,GPHA2,GZMK,HLF, 
ITGAX,MMP7,MMRN1,MTRNR2L8,MUC20,RASSF6,SGCA,VMO1 
F 41 ABCC9,ABP1,ACTC1,ADAM12,AIF1L,ALDH1A1,BMPER,C1QTNF8,C7,CCKAR,CHL1, 
CHRDL1,COCH,CPA3,DDX11,DES,DPYSL4,FAM107A,FNDC1,FOS,FOSB,GFRA1, 
GSTT1,HLA-DQA1,HS3ST1,JUN,LIFR,NKAIN2,NOS3,PAX8,PI16,PLIN4,PTPRB, 
RPSAP58,SCG2,ST6GALNAC1,SYNPO2,THNSL2,TPSAB1,TRDN,WNT9B 
G 19 ACAN,ATP1A2,CD79A,CNTFR,CTSE,DERL3,FCRL5,HBA1,HBA2,HLA-DRB5,IGJ, 
IGLL5,MMP9,MYOC,PPP1R1B,PTGDS,RP11-1280I22.1,SCARA5,TIMD4 
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